



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 1/00, C07H 21/04		A1	(11) International Publication Number: WO 98/54206
			(43) International Publication Date: 3 December 1998 (03.12.98)
(21) International Application Number: PCT/US98/10868		<p>Court, Carlsbad, CA 92009 (US). ENDRESS, Gregory, A. [US/US]; 9729 Clagett Farm Drive, Potomac, MD 20854 (US). YU, Guo-Liang [CN/US]; 13524 Straw Bale Lane, Darnestown, MD 20878 (US). NI, Jian [CN/US]; 5502 Manorfield Road, Rockville, MD 20853 (US). FENG, Ping [CN/US]; 4 Relda Court, Gaithersburg, MD 20878 (US).</p> <p>(74) Agents: BROOKES, A., Anders et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
(22) International Filing Date: 28 May 1998 (28.05.98)			
(30) Priority Data:			
60/044,039	30 May 1997 (30.05.97) US		
60/048,093	30 May 1997 (30.05.97) US		
60/048,190	30 May 1997 (30.05.97) US		
60/050,935	30 May 1997 (30.05.97) US		
60/048,101	30 May 1997 (30.05.97) US		
60/048,356	30 May 1997 (30.05.97) US		
60/056,250	29 August 1997 (29.08.97) US		
60/056,296	29 August 1997 (29.08.97) US		
60/056,293	29 August 1997 (29.08.97) US		
(71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). CARTER, Kenneth, C. [US/US]; 11601 Brandy Hall Lane, North Potomac, MD 20878 (US). DILLON, Patrick, J. [US/US]; 1055 Snipe			
(54) Title: 32 HUMAN SECRETED PROTEINS			
(57) Abstract			
<p>The present invention relates to 32 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

32 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and
5 their production.

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or
10 organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum
15 (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

20 Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or
25 secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include
30 the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using
35 secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig

analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard,
5 Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained
10 in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42° C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the
15 filters in 0.1x SSC at about 65°C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages
20 of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even
25 lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include
30 Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such
35 as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a

complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

5 The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and
10 double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability
15 or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

 The polypeptide of the present invention can be composed of amino acids joined
20 to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs,
25 as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be
30 branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a
35 nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine,

formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS -
5 STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990);
10 Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting
15 activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present
20 invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

25 Polynucleotides and Polypeptides of the Invention

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

This gene maps to chromosome 3 and therefore polynucleotides of the present invention can be used in linkage analysis as a marker for chromosome 3.

This gene is expressed in several fetal tissues including brain, liver and lung and
30 to a lesser extent in adult tissues, particularly skin.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, a variety of cancers, particularly of the brain, liver, and lung. Similarly,
35 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a

number of disorders of the above tissues or cells, particularly of the central nervous system, hepatic system, and hepatic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., brain and other tissue of the nervous system, liver, lung, and skin, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful as a target for a variety of blocking agents, as they are likely to be involved in the promotion of a variety of cancers.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

In specific embodiments, the polypeptides of the invention comprise the sequence: MSVPAFIDISEEDQAAELRAYLKSKGAEISEENSEGGLHVDLAQIEAC DVCLKEDDKDVESVMNSVVSLLLILEPDKQEALIESLCEKLVKFREGERPSLRQLQ LLSNLFHGMMDKNTVPVRYTVYCSLIKVAASCGAIQYIPTELDQVRKWISDWNLTTEKKHTLLRLLYEALVDCKKSDAASKVMVELLGSYTEDNASQARVDAHRCIVRALKDPNAFLFDHLLTLKPVKFLEGELIHDLLTIFVSAKLASYVKFYQNNKDFIDSL GLLHEQNMAKMRLITFMGMAVENKEISFDTMQQELQIGADDVEAFVIDAVRTKMVYCKIDQTRKVVVSHSTHRTFGKQQWQQLYDTLNAWKQNLNKVKNLSLS LSDT (SEQ ID NO:85), MSVPAFIDISEED (SEQ ID NO:86), QAAELRAYLKSKG AE (SEQ ID NO:87), ISEENSEGGLHVDLAQI (SEQ ID NO:88), IEACDVCLKED DKDVESV (SEQ ID NO:89), VARPSSLFRSAWSCEW (SEQ ID NO:90), LRLQLLS NLFHG (SEQ ID NO:91), KDVESVMNSVVSLLLIL (SEQ ID NO:92), DAASKVMVELLGSYTEDNASQARVDA (SEQ ID NO:93), and/or VEAFFVIDAVR (SEQ ID NO:94). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed in bone and to a lesser extent in brain, lung, T-cells, muscle, skin, testis, spleen and macrophages.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, bone cancer, osteoarthritis, and autoimmune diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a

number of disorders of the above tissues or cells, particularly of the immune system and skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, T-cells and other cells and tissue of the immune system, lung, muscle, 5 skin, and testis and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those 10 comprising a sequence shown in SEQ ID NO:49 as residues: Arg-31 to Ser-37, Met-50 to Val-56, Glu-80 to Trp-87, Thr-94 to His-99, Tyr-129 to Ser-135, Tyr-193 to Phe-199, Ser-274 to Gln-285, and/or Ala-293 to Lys-302.

FEATURES OF PROTEIN ENCODED BY GENE NO: 3

15 The translation product of this gene shares sequence homology with various kinases. The closest homolog is mouse TIF1 which is a mouse nuclear protein. TIF1 enhances RXR and RAR AF-2 in yeast and interacts in a ligand-dependent manner with several nuclear receptors in yeast and mammalian cells, as well as in vitro. Remarkably, these interactions require the amino acids constituting the AF-2 activating domain 20 conserved in all active NRs. Moreover, the oestrogen receptor (ER) AF-2 antagonist hydroxytamoxifen cannot promote ER-TIF1 interaction. We propose that TIF1, which contains several conserved domains found in transcriptional regulatory proteins, is a mediator of ligand-dependent AF-2. Interestingly, the TIF1 N-terminal moiety is fused to B-raf in the mouse oncoprotein T18.

25 This gene is expressed primarily in activated T-cells and to a lesser extent in various other tissues including testes and brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are 30 not limited to, autoimmune diseases, AIDS, leukemias, and various other cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be 35 routinely detected in certain tissues and cell types (e.g., T-cells and other cells and tissue of the immune system, testes and other reproductive tissue, and brain and other

tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:50 as residues: Ala-31 to Glu-36.

The tissue distribution and homology to TIF indicates that polynucleotides and polypeptides corresponding to this gene are useful for modulation of nuclear receptor and ligand interaction in various immune disorders.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 4

This gene maps to chromosome 11. Accordingly, polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 11. In specific embodiments, the polypeptides of the invention comprise the sequence:

15 MSEIYLRCQDEQQYARWMAGCRLASKGRTMADSSY (SEQ ID NO:95), LVAPRF
QRKFKAKQLTPRILEAHQNVAQLSLAEQLRFIQAWQSL (SEQ ID NO:96), VGD
VVKTWRFSNMRQWNVNWDIR (SEQ ID NO:97), EEIDCTEEEMMVFAALQYH
INKLSQS (SEQ ID NO:98), and/or EEIDCTEEEMMVFAALQYHINKLSQS (SEQ ID
NO:99). Polynucleotides encoding these polypeptides are also encompassed by the
20 invention.

This gene is expressed primarily in several white blood cell types including monocytes, T-cells, and neutrophils and to a lesser extent in a limited number of other tissues including umbilical vein and liver.

Therefore, polynucleotides and polypeptides of the invention are useful as
25 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, various diseases of the immune system including AIDS, immunodeficiency diseases, and autoimmune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes
30 for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., blood cells, liver, and vascular tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
35 another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily

fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:51 as residues: Ser-3 to Pro-9, Leu-17 to Leu-29, Asp-64 to Pro-69, Ile-105 to Gln-110, Thr-183 to Gln-200, Cys-239 to Arg-247, Ser-256 to Met-261, Gln-280 to Ala-296, Arg-310 to Thr-321, Lys-363 to Asp-368, Ser-395 to Trp-400, and/or Thr-443 to Asp-453.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for replacement therapy in a variety of immune system disorders.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 5

This gene is expressed primarily in brain and little or not at all in any other tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, mood disorders, schizophrenia and related diseases, bipolar disorder and unipolar depression. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:52 as residues: Met-1 to Gly-8, Pro-10 to Arg-17, Pro-45 to Ser-55, and/or Gly-63 to Tyr-74.

The tissue distribution of this gene primarily in brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Also given the brain-specific expression of this gene, the promoter region of this gene contains a brain-specific element that could be used for targeting expression of vector systems to the brain in gene replacement therapy.

FEATURES OF PROTEIN ENCODED BY GENE NO: 6

This gene maps to chromosome 1 and therefore, polynucleotides of the invention can be used in linkage analysis as a marker for chromosome 1.

5 This gene is expressed abundantly in rhabdomyosarcoma, is expressed to a high level and in different regions of the brain and pituitary gland and to a lesser extent in a variety of other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological disorders and muscular disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., smooth muscle, brain and other tissue of the nervous system, and pituitary, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The abundant expression of this gene in rhabdomyosarcoma indicates a role for the protein product either in the detection and/or treatment of skeletal muscle disorders including muscle degeneration, muscle wasting, and rhabdomyolysis. Furthermore expression in the brain indicates a role for the protein product of this gene in the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder.

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

30 The translation product of this gene shares sequence homology with the TDAG51 gene which is thought to be important in the mediation of apoptosis and cell death by coupling TCR stimulation to Fas expression. In specific embodiments, the polypeptides of the invention comprise the sequence: KELSFAKAVECVSTGR HIYFTLV (SEQ ID NO:100) and/or GWNAQITLGLVKFKNQQ (SEQ ID NO:101).

35 This gene is expressed in various human tissues including macrophages.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., macrophages and other blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:54 as residues: Met-1 to Pro-9, Gln-43 to Glu-49, and/or Phe-95 to Arg-102.

The tissue distribution and homology to TDAG51 gene indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of immune disorders, such as immunodeficiency, allergy, infection, inflammation, tissue/organ transplantation.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 8

This gene is expressed in breast tissue, and amniotic cells and to a lesser extent in smooth muscle, T-cells, and infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, fetal distress syndrome and embryonic wasting. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., mammary tissue, amniotic cells, smooth muscle, brain and other tissue of the nervous system, and T-cells and other cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

35

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

5 In specific embodiments, the polypeptides of the invention comprise the sequence: LVLGLSXLNNSYNFSF (SEQ ID NO:102), HVVIGSQAEEGQYSLNF (SEQ ID NO:103), HNCNNSVPGKEHPFDITVM (SEQ ID NO:104), FIKYVLSD KEKKVFGIV (SEQ ID NO:105), IPMQVLANVAYII (SEQ ID NO:106), IPMQVL ANVAYII (SEQ ID NO:107), DGKVAVNLA KLKLFR (SEQ ID NO:108), and/or
10 IREKNPDGFLSAA (SEQ ID NO:109). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is primarily expressed in the fetal liver, spleen and pituitary gland, and to a lesser extent in multiple tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as
15 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of
20 the above tissues or cells, particularly of the hepatic, immune and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., liver, spleen, and pituitary gland, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder,
25 relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:56 as residues: Ser-62 to Cys-71, Thr-78 to Leu-86, Ser-104 to Lys-109, Ser-130 to Ala-135, and/or Gln-168 to Asp-174.

30 The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of hepatic disorders, and disorders of the immune and hematopoietic systems, such as hepatic failure, hepatitis, alcoholic liver diseases, portal hypertension, toxic liver injury, liver transplantation, and neoplasm of the liver. The expression in the fetal liver spleen also
35 indicates its function in hematopoiesis, and therefore the gene may be useful in hematopoietic disorders including anemia, leukemia or cancer

radiotherapy/chemotherapy. The expression in the pituitary gland may indicate its use in endocrine disorders with systemic or specific manifestations.

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

- 5 The translation product of this gene shares sequence homology with a chicken DNA binding protein which is thought to be important in transcriptional regulation of gene expression. In specific embodiments, polypeptides of the invention comprise the sequence: MMFGGYETI (SEQ ID NO:110), YRDESSSELSVDSEVEFQLYSQIH (SEQ ID NO:111), YAQDLDDVIREEEHEEKNSGNSSESSSKPNQKKLIVLSDSEVI
- 10 QLSDGSEVITLSDDESIYRCKGKNVRVQAQENAHGLSSSLQSNELVDKKCKSDI EKPKSEERSGVIREVMIIIEVSSEEEESTISEGDNVESW (SEQ ID NO:112), MLLG CEVDDKDDILLNLVGCENSVTEGEDGINWSIS (SEQ ID NO:113), DKDIEAQI ANNRTTPGRWT (SEQ ID NO:114), QRYYSANKNIICRNCDKRGHLSKNCPLP RKV (SEQ ID NO:115), and/or RRCFLCSRRGHLLYSCPAPLCEYCPVPKMLDHS
- 15 CLFRHSWDKQCDRCHMLGHYTDACEIWRQYHLTTKPGPPKKPKTPSRPSAL AYC YHCAQKGHYGHECPEREVYDPSVSPFICYXDKYEIQEREKRLKQKIKV XKKNGVPEPSKLPYIKAANENPHHDIRKGRASWKS NRWPQ (SEQ ID NO:116). Polynucleotides encoding these polypeptides are also encompassed by the invention.
- 20 This gene is expressed in tonsils and bone marrow.
- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the immune, hematopoietic, and lymphatic systems.
- 25 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, hematopoietic, and lymph systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., tonsils, and
- 30 bone marrow, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to DNA binding protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders in the immune, hematopoietic, and lymph systems.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 11

This gene is expressed in dendritic and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cells types (e.g., dendritic cells, and T-cells and other cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for the treatment and diagnosis of immune system disorders, particularly those involving dendritic or T-cells such as inflammation.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 12

This gene is expressed in activated neutrophils, endothelial cells, T cells and to a lesser extent in brain and liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, AIDS, immune disorders and susceptibility to infectious disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and skin, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., neutrophils and other

blood cells, endothelial cells, T-cells and other cells and tissue of the immune system, brain and other tissue of the nervous system, and liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to
5 the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:59 as residues: Glu-41 to Val-46.

This gene product is useful for the diagnosis and/or treatment of a variety of disorders, including hematopoietic disorders, neurological disorders, liver disease, and
10 disorders involving angiogenesis.

FEATURES OF PROTEIN ENCODED BY GENE NO: 13

This gene is expressed in keratinocytes and to a lesser extent in endothelial cells and placenta.

15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, impaired wound healing. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential
20 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skin, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cells types (e.g., keratinocytes and other cells of the skin, endothelial cells, and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
25 spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:60 as residues: Pro-35 to Trp-42, Ala-53 to Asp-62, and/or Arg-103 to Pro-113.

30 The tissue distribution indicates that the protein products of this gene are useful for the treatment of wound healing deficiency and skin disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 14

This gene is expressed in kidney and to a lesser extent in embryonic tissues.

35 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, renal failure. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the kidney, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., kidney, embryonic and other rapidly developing (e.g., dividing) tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

This gene is expressed primarily in brain and to a lesser extent in liver. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, depression, manic depression and other mental diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., brain and other tissue of the nervous system, and liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for the treatment of central nervous system disorders such as depression and other mental illnesses.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

This gene is expressed in fetal brain and to a lesser extent in placenta, endothelial cells, fetal lung, and T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, restinosis, birth defects and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, and developmental process, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., placenta, endothelial cells, lung, and T-cells and other cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:63 as residues: Gln-36 to Lys-42, and/or Glu-89 to Arg-104.

The tissue distribution indicates that the protein products of this gene are useful for the development of agonists and/or antagonists for treatment of nervous system disorders and fetal development.

20

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

This gene is expressed in hemangiopericytoma and to a lesser extent in fetal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hemangiopericytomas and other cancers, as well as developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., vascular tissue, pericytic tissue, and developing tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include

35

those comprising a sequence shown in SEQ ID NO:64 as residues: Glu-43 to Pro-51, Gly-71 to Arg-82, Pro-96 to Arg-103, and/or Thr-130 to Gly-140.

The polynucleotides and polypeptides related to this gene are believed to be useful for the treatment and diagnosis of tumors, particularly hemangiopericytomas, and for the treatment of developmental disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 18

This gene is expressed in fetal liver and to a lesser extent in brain and T cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, fetal disorders, fetal development, and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic system, nervous system and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., liver, brain and other tissue of the nervous system, and T-cells and other cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for the identification of agonists and /or antagonists for treatment of mental illnesses such as schizophrenia and depression. The gene product may also be useful for monitoring fetal development during pregnancy.

FEATURES OF PROTEIN ENCODED BY GENE NO: 19

This gene is expressed in T cells and to a lesser extent in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, central nervous diseases and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of

disorders of the above tissues or cells, particularly of the central nervous system and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., T-cells and other cells and tissue of the immune system, and brain and other tissue of the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:66 as residues:

10 Lys-69 to Leu-74, Ser-92 to Phe-97, Asp-109 to Leu-117, Leu-142 to Ser-159, Thr-166 to Glu-183, Ala-191 to Glu-205, and/or Pro-213 to Glu-220.

The tissue distribution indicates that the protein products of this gene are useful for the development of drugs for treatment of disorders affecting the central nervous system and immune system.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 20

The translation product of this gene shares sequence homology with a *C. elegans* ORF that seems to be a transmembrane protein. (See GenBank Accession No. 790406.) This contig has two probable frameshifts between the +2 and +3 frames based on homology with the *C. elegans* gene. This frameshift can easily be resolved by sequencing the deposited clone. Moreover, this gene maps to chromosome 8, and therefore can be used as a marker in linkage analysis for chromosome 8.

20

This gene is expressed ubiquitously, including T cells and amygdala.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and endocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., T-cells and other cells and tissue of the immune system, amygdala, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25

30

35

The ubiquitous tissue distribution and homology to a *C. elegans* transmembrane-like protein indicates that the protein product of this gene plays a role important in both vertebrates and invertebrates and is useful for diagnosis or treatment of disorders related to this gene.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 21

This gene is expressed primarily in embryonic and testes and to a lesser extent in ovary, hepatoma, kidney, endothelial, and smooth muscle cells.

Therefore, polynucleotides and polypeptides of the invention are useful as
10 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic disorder, abnormal embryonic development and tumor. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell
15 type(s). For a number of disorders of the above tissues or cells, particularly of the embryonic or vascular tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., ovary and other reproductive tissue, kidney, endothelial cells, and smooth muscle cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
20 spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to NADH dehydrogenase indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis
25 and/or treating metabolic disorders, particularly involving embryonic and vascular tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 22

The translation product of this gene shares sequence homology with alpha 1C
30 adrenergic receptor which is thought to be important in neuronal signal transmission.

This gene is expressed primarily in breast lymphnode and to a lesser extent in uterine cancer and testis tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
35 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological disorders. Similarly, polypeptides and antibodies directed to

these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neurologic, breast lymphonode, uterine cancer, and testis, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., breast tissue, lymphoid tissue, uterine tissue, and testis and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to alpha 1C adrenergic receptor indicates that polynucleotides and polypeptides corresponding to this gene are useful for transmitting signals to neurons.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 23**

The translation product of this gene shares sequence homology with G-protein-coupled receptor which is thought to be important in mediating a wide variety of physiological function and belongs to a gene superfamily with members ranging from chemokine receptor to bradykinin receptor. This gene has also recently been cloned by another group, calling the gene platelet activating receptor homolog. (See GenBank Accession No. 2580588.) Preferred polypeptide fragments comprise the amino acid sequence: LSIIFLAFVSIDRCLQL (SEQ ID NO:117) and GSCFATWAFIQKNTNHRCSVSIY LINLLTADFLTLALPVKIVVDLGVAPWKLKIFHCQVTACLIYN (SEQ ID NO:118). Also preferred are polynucleotide fragments encoding these polypeptide fragments.

This gene is expressed primarily in immune cells, particularly lymphocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of lymphocytes and other immune cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., lymphocytes and other cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum,

plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID
5 NO:70 as residues: Asp-59 to Asn-65, Lys-72 to Trp-79, Tyr-110 to Val-121, and/or Ala-204 to Asn-215.

The tissue distribution and homology to G-protein coupled receptor indicates that polynucleotides and polypeptides corresponding to this gene are useful as chemokine receptor on lymphocytes that regulate immune response.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 24

The translation product of this gene shares sequence homology with protein disulfide isomerase which is thought to be important in protein folding and protein-protein interaction. This gene also shares homology to genes having thioredoxin
15 domains. (See Accession No. 1943817.) This gene also maps to chromosome 9, and therefore may be useful in linkage analysis as a marker for chromosome 9.

This gene is expressed primarily in tumor tissues and to a lesser extent in a wide variety of normal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as
20 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders due to inappropriate protein folding and protein-protein interaction. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s)
25 or cell type(s). For a number of disorders of the above tissues or cells, particularly of the tumorigenic process, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the
30 standard gene expression level; i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred epitopes include those comprising a sequence shown in SEQ ID NO:71 as residues: Glu-78 to Asn-83, Asp-91 to Gln-100, Glu-122 to Ser-128, Arg-137 to Pro-143, Asp-157 to Asn-162, Glu-168 to Asn-174, Ser-199 to Gly-206, Pro-213 to Ala-218, Glu-251 to Thr-257, Ser-353 to His-361, Gly-363 to Ala-375, Pro-382 to Phe-387, and/or Arg-401 to Leu-406.
35

The tissue distribution and homology to protein disulfide isomerase indicates that polynucleotides and polypeptides corresponding to this gene are useful for regulating protein folding and protein-protein interaction in tumor tissues.

5 **FEATURES OF PROTEIN ENCODED BY GENE NO: 25**

This gene is expressed primarily in leukocytes involved in immune defense, including T cells, macrophages, neutrophils and to a lesser extent in synovium, adrenal gland tumor, adipose, and placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as
10 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, defects or disorders in leukocytes. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of
15 the above tissues or cells, particularly of the immune and defense systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., leukocytes and other cells and tissues of the immune system, synovium, adrenal gland, adipose and placenta, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
20 another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for regulating leukocyte function and may be used
25 for diagnosis and treatment of disorders in immune and defense systems.

FEATURES OF PROTEIN ENCODED BY GENE NO: 26

This gene is expressed in a variety of tissues and cell types, including colon cancer, breast cancer, neutrophils, T cells, spinal cord, fibroblasts, and vascular
30 endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer, disorder and abnormalities in leukocytes and other tissues.
35 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell

type(s). For a number of disorders of the above tissues or cells, particularly those cells involved in tumorigenesis and immune defense systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., colon, breast tissue, neutrophils, T-cells and other blood cells, spinal cord and other tissue of the nervous system, endothelial cells, vascular tissue, and fibroblasts, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancer or immune system disorders.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 27**

The translation product of this gene shares sequence homology with a mouse pancreatic polypeptide. (See GenBankAccession No. 200464.) Thus, it is likely that this gene has activity similar to the mouse pancreatic polypeptide. Preferred polypeptide fragments comprise the amino acids sequence: APLETMQNKPRAPQKRALPFPEL ELRDYASVLTRYSLGLRNKEPSLGHRWGTQKLGRSPC (SEQ ID NO:119). Also preferred are polynucleotide fragments encoding this polypeptide fragment.

This gene is expressed primarily in neutrophils and to a lesser extent in induced endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders in neutrophils or leukocyte adhesion. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., neutrophils and other blood cells, and endothelial cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for regulation of neutrophils or leukocyte adhesion to endothelial cells. It may be used to diagnose or treat disorders associated with neutrophils and vascular endothelial cells.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 28

This gene is expressed primarily in prostate BPH.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, benign hypertrophy of the prostate. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male urogenital system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., prostate, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10
15
20

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of benign hypertrophy of the prostate or prostate cancer.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 29

The translation product of this gene shares sequence homology with C16C10.7, a *C. elegans* gene similar to zinc finger protein, a protein involved in DNA binding. Thus, this protein is expected to share certain biological activities with C16C10.7 including DNA binding activities.

30

This gene is expressed primarily in activated T-cells and to a lesser extent in fetal brain, TNF-induced amniotic cells and epididymus.

35

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes

for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and central nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., T-cells and other cells and tissue of the immune
5 system, brain and other tissue of the nervous system, amniotic cells, and epididymus and other reproductive tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an
10 individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for the diagnosis and treatment of immune and/or neurodegenerative disorders and promotion of survival and differentiation of neurons.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 30**

This gene is expressed primarily in T-cells and to a lesser extent in bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immunological disorders including autoimmune disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system,
25 expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues and cell types (e.g., T-cells and other cells and tissue of the immune system, and bone marrow, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene
30 expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. It is believed that this gene maps to chromosome 4: Transcript map: WI-11395, Chr.4, D4S395-D4S414; Whitehead map: WI-11395, Chr.4, 498.0 cR; dbSTS entries: G21269.

The tissue distribution indicates that the protein products of this gene are useful
35 for diagnosis and treatment of immunologically mediated disorders as they are thought

to play a role in the proliferation, survival, differentiation, and/or activation of a variety of hematopoietic cells, including early progenitors or hematopoietic stem cells.

FEATURES OF PROTEIN ENCODED BY GENE NO: 31

5 This gene is expressed primarily in human skin.

 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, wound healing and skin cancers. Similarly, polypeptides and antibodies
10 directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the integumentary system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., skin and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,
15 urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

 The tissue distribution indicates that the protein products of this gene are useful
20 for diagnosis and treatment of skin cancers and wound healing.

FEATURES OF PROTEIN ENCODED BY GENE NO: 32

 The translation product of this gene shares sequence homology with human Tear Prealbumin (GenBank accession no. gil307518) and rat Oderant-binding protein
25 (GenBank accession no. gil207551), both of which are thought to be important in molecule binding and transport.

 This gene is expressed primarily in endometrial tumor.

 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
30 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers of the endometrium, skin and haemopoietic system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the haemopoietic
35 system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues (e.g., cells and tissue of the immune system, and

5 endometrium and other tissue of the reproductive system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 The tissue distribution and homology to the molecule binding and transport gene family indicates that the protein products of this gene are useful for the diagnosis and treatment of cancers of the endometrium and haemopoietic system as well as for the treatment of autoimmune disorders such as inflammation.

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HSVBZ80	209075 05/22/97	Uni-ZAP XR	11	1169	64	1060	162	162	48	1	38	39	145
2	HTAAU21	209075 05/22/97	Uni-ZAP XR	12	1310	1	1310	283	283	49	1	18	19	311
3	HTLEK16	209075 05/22/97	Uni-ZAP XR	13	1139	19	1111		251	50	1	21	22	46
4	HUSIR91	209075 05/22/97	pSportl	14	2271	743	2271	59	59	51	1	23	24	466
4	HUSIR91	209075 05/22/97	pSportl	43	2581	1035	2164	1148	1148	80	1	27	28	207
5	HADMC21	209075 05/22/97	pBluescript	15	626	60	479	91	91	52	1	51	52	82
6	HAGFM45	209075 05/22/97	Uni-ZAP XR	16	2118	1170	2058	1248	1248	53	1	16	17	62
7	HAIBE65	209075 05/22/97	Uni-ZAP XR	17	1076	396	993	528	528	54	1	31	32	123
8	HAQBH57	209075 05/22/97	Uni-ZAP XR	18	1379	420	1306	618	618	55	1	25	26	179
9	HATCX80	209075 05/22/97	Uni-ZAP XR	19	1337	47	1337	199	199	56	1	18	19	286
10	HCFLQ84	209075 05/22/97	pSportl	20	1390	237	1390	410	410	57	1	20	21	33
11	HCFLS78	209075 05/22/97	pSportl	21	1431	178	981	420	420	58	1	21	22	23

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
12	HTADI12	209075 05/22/97	Uni-ZAP XR	22	2539	69	2539	104	104	59	1	27	28	46
13	HEMCM42	209075 05/22/97	Uni-ZAP XR	23	1041	48	1007	58	58	60	1	29	30	113
14	HEONP72	209075 05/22/97	pSport1	24	1962	1	1947	181	181	61	1	19	20	31
15	HFCDW34	209075 05/22/97	Uni-ZAP XR	25	1228	321	1228	525	525	62	1	24	25	80
16	HTTEU91	209075 05/22/97	Uni-ZAP XR	26	1340	325	1340	15	15	63	1	18	19	103
17	HHGBF89	209075 05/22/97	Lambda ZAP II	27	806	31	806	77	77	64	1	19	20	145
17	HHGBF89	209075 05/22/97	Lambda ZAP II	45	796	31	796	77	77	82	1	25	26	145
18	HKIYQ65	209075 05/22/97	pBluescript	28	696	1	684	98	98	65	1	17	18	30
19	HKMLN27	209075 05/22/97	pBluescript	29	1007	71	963	129	129	66	1	23	24	259
20	HKIAC30	209022 05/08/97	Uni-ZAP XR	30	2017	126	2007	161	161	67	1			22
21	HKIXB95	209022 05/08/97	pBluescript	31	699	196	699	230	230	68	1	22	23	26
22	HLMY86	209022 05/08/97	Lambda ZAP II	32	1264	1	1264		342	69	1	16	17	28
23	HLYAZ61	209022 05/08/97	pSport1	33	997	74	997	205	205	70	1	20	21	215

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
24	HMQDT36	209022 05/08/97	Uni-ZAP XR	34	1914	37	1897	192	192	71	1	32	33	406
25	HNEDF25	209022 05/08/97	Uni-ZAP XR	35	1020	11	1020	211	211	72	1			8
26	HNFET17	209022 05/08/97	Uni-ZAP XR	36	781	31	781	100	100	73	1			33
27	HNHCR46	209022 05/08/97	Uni-ZAP XR	37	966	507	948		576	74	1	29	30	56
28	HPWAS91	209022 05/08/97	Uni-ZAP XR	38	416	1	416	95	95	75	1	24	25	25
29	HWTAW41	209022 05/08/97	Uni-ZAP XR	39	1114	804	1114	843	843	76	1			14
30	HBMUT52	209022 05/08/97	Uni-ZAP XR	40	602	142	602	204	204	77	1	26	27	32
31	HERAG83	209022 05/08/97	Uni-ZAP XR	41	970	1	970	110	110	78	1	22	23	22
32	HETFI51	209022 05/08/97	Uni-ZAP XR	42	1002	1	1002	43	43	79	1	21	22	172
32	HETFI51	209022 05/08/97	Uni-ZAP XR	47	981	1	981	23	23	84	1	17	18	30

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may

be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification ,
5 such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified by the
10 one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

15 Signal Sequences

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The
20 method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, supra.) However, the two methods do not always
25 produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the
30 methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty.
35 Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in

some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Polynucleotide and Polypeptide Variants

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are:

Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words,

to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the

subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988

(1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

5 Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over
10 the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-
15 type.

 Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form
20 will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

25 Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al.,
30 Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

 The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino
35 acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these

positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

Polynucleotide and Polypeptide Fragments

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or

the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Epitopes & Antibodies

In the present invention, "epitopes" refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983).)

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including

monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., *Cell* 37:767-778 (1984); Sutcliffe, J. G. et al., *Science* 219:660-666 (1983).)

Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., *supra*; Wilson et al., *supra*; Chow, M. et al., *Proc. Natl. Acad. Sci. USA* 82:910-914; and Bittle, F. J. et al., *J. Gen. Virol.* 66:2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')₂ fragments) which are capable of specifically binding to protein. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., *J. Nucl. Med.* 24:316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

Fusion Proteins

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the

polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., *Nature* 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., *J. Biochem.* 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., *J. Molecular Recognition* 8:52-58 (1995); K. Johanson et al., *J. Biol. Chem.* 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., *Cell* 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

5 The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

10 The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

15 The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding
20 portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

 As indicated, the expression vectors will preferably include at least one
25 selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect
30 cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

 Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A,
35 pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptre99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1

and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.

Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers,

since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

5 Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

10 Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-
15 sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides
20 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for
25 marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the
30 physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per
35 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural
5 alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic
10 polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic
15 marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the
20 region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off
25 of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One
30 goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

35 The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In

this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

5 A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene
10 expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium ($^{99\text{m}}\text{Tc}$), and fluorescent labels, such as fluorescein and rhodamine, and
15 biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit
20 detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with
25 an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I , ^{112}In , $^{99\text{m}}\text{Tc}$), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety
30 needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{m}}\text{Tc}$. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of
35 Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Biological Activities

The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

Immune Activity

A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the

proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders
5 may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotide or polypeptide of the present invention may be useful in
10 treating or detecting deficiencies or disorders of hematopoietic cells. A polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to:
15 blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polypeptide or polynucleotide of the present invention could also
20 be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet
25 disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

A polynucleotide or polypeptide of the present invention may also be useful in
30 treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the
35 present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, 5 Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

10 Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to 15 treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polypeptide or polynucleotide of the present invention that inhibits 20 an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory 25 response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel 30 disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

A polypeptide or polynucleotide can be used to treat or detect hyperproliferative 35 disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect

interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Infectious Disease

A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes

Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Pasteurellaceae Infections (e.g., Actinobacillus, Haemophilus, Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, 5 Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide 10 of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide 15 of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

20 A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal 25 disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vascular (including vascular endothelium), nervous, hematopoietic, and 30 skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or 35 polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue

regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

15 **Chemotaxis**

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit

(antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying
5 agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Other Activities

10 A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color,
15 skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to change
20 a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

25 A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

35 Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of

positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous
5 nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of
10 contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide
15 sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide
sequence which is at least 95% identical to a sequence of at least about 500 contiguous
20 nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a
nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ
ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the
First Amino Acid of the Signal Peptide and ending with the nucleotide at about the
25 position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in
Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising
a nucleotide sequence which is at least 95% identical to the complete nucleotide
sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under
30 stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which
35 comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type

Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous
5 nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete
10 open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising
15 a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

20 A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone
25 identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95%
30 identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of
35 comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino
5 acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at
10 least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence
15 at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the
20 ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and
25 contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with
30 the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with
35 the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide
5 comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

10 Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

15 Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid
20 sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human
25 cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an
30 individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of
35 illustration and are not intended as limiting.

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

5 Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For
10 example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited Plasmid</u>
	Lambda Zap	pBluescript (pBS)
	Uni-Zap XR	pBluescript (pBS)
15	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
	pCMVSPORT 3.0	pCMVSPORT 3.0
20	pCR [®] 2.1	pCR [®] 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 25 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. 30 The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

35 Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain

DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., *Focus* 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into *E. coli* strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., *Nuc. Acids Res.* 16:9677-9686 (1988) and Mead, D. et al., *Bio/Technology* 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ³²P-γ-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μ l of reaction mixture with 0.5 μ g of the above cDNA template. A convenient reaction mixture is 1.5-5 mM $MgCl_2$, 0.01% (w/v) gelatin, 20 μ M each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligation step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is

used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

5

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

10

Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

15

20

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

25

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on

30

35

either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

5 **Example 5: Bacterial Expression of a Polypeptide**

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as
10 BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site
15 (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses
20 the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml).
25 The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

30 Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from
35 QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high

affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

5 Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

10 The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

15 In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a
20 neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

25 DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or
30 Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

- 5 Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50
10 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

- The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by
15 centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

- The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C
20 overnight to allow further GuHCl extraction.

- Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing
25 for 12 hours prior to further purification steps.

- To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive
30 Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 μ g of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus

Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five μ g of a plasmid containing the polynucleotide is co-transfected with 1.0 μ g of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One μ g of BaculoGold™ virus DNA and 5 μ g of the plasmid are mixed in a sterile well of a microtiter plate containing 50 μ l of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 μ l Lipofectin plus 90 μ l Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life

Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.)

- 5 After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 μ l of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested
10 and then they are stored at 4° C.

- To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is
15 removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 μ Ci of 35 S-methionine and 5 μ Ci 35 S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE
20 followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

- 25 The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by
30 donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from

Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden),
5 pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

10 Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the
15 encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is
20 the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the
25 production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the
30 CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

35 Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μ g of the expression plasmid pC6 is cotransfected with 0.5 μ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 9: Protein Fusions

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the

polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

```
GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGCC
CAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAACC
CAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGGT
GGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACG
GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC
AGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTG
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAACCCCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT
GTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCT
GACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGGA
GAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTGG
ACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCA
```

GGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGC
ACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGC
GACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

5 **Example 10: Production of an Antibody from a Polypeptide**

 The antibodies of the present invention can be prepared by a variety of methods.
(See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of
the present invention is administered to an animal to induce the production of sera
containing polyclonal antibodies. In a preferred method, a preparation of the secreted
10 protein is prepared and purified to render it substantially free of natural contaminants.
Such a preparation is then introduced into an animal in order to produce polyclonal
antisera of greater specific activity.

 In the most preferred method, the antibodies of the present invention are
monoclonal antibodies (or protein binding fragments thereof). Such monoclonal
15 antibodies can be prepared using hybridoma technology. (Köhler et al., Nature
256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J.
Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell
Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures
involve immunizing an animal (preferably a mouse) with polypeptide or, more
20 preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in
any suitable tissue culture medium; however, it is preferable to culture cells in Earle's
modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at
about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about
1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

25 The splenocytes of such mice are extracted and fused with a suitable myeloma
cell line. Any suitable myeloma cell line may be employed in accordance with the
present invention; however, it is preferable to employ the parent myeloma cell line
(SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are
selectively maintained in HAT medium, and then cloned by limiting dilution as
30 described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells
obtained through such a selection are then assayed to identify clones which secrete
antibodies capable of binding the polypeptide.

 Alternatively, additional antibodies capable of binding to the polypeptide can be
produced in a two-step procedure using anti-idiotypic antibodies. Such a method
35 makes use of the fact that antibodies are themselves antigens, and therefore, it is
possible to obtain an antibody which binds to a second antibody. In accordance with

this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide.

- 5 Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such
10 fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use
15 "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496;
20 Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

25 **Example 11: Production Of Secreted Protein For High-Throughput Screening Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution
30 (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The
35 PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

- 5 The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. 10 Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

- 15 Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, 20 adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

- While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl_2 (anhyd); 0.00130 mg/L $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$; 0.050 mg/L of $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$; 0.417 mg/L of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$; 311.80 25 mg/L of KCl; 28.64 mg/L of MgCl_2 ; 48.84 mg/L of MgSO_4 ; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO_3 ; 62.50 mg/L of $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$; 71.02 mg/L of Na_2HPO_4 ; .4320 mg/L of $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic 30 Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine- H_2O ; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL- H_2O ; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 35 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL- H_2O ; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-

Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H₂O; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

5	<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u>		<u>Jak3</u>	<u>STATS</u>	<u>GAS(elements) or ISRE</u>
			<u>Jak1</u>	<u>Jak2</u>			
	<u>IFN family</u>						
	IFN-a/B	+	+	-	-	1,2,3	ISRE
10	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	IL-10	+	?	?	-	1,3	
	<u>gp130 family</u>						
15	IL-6 (Pleiotrohic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	IL-11(Pleiotrohic)	?	+	?	?	1,3	
	OnM(Pleiotrohic)	?	+	+	?	1,3	
	LIF(Pleiotrohic)	?	+	+	?	1,3	
	CNTF(Pleiotrohic)	-/+	+	+	?	1,3	
20	G-CSF(Pleiotrohic)	?	+	?	?	1,3	
	IL-12(Pleiotrohic)	+	-	+	+	1,3	
	<u>g-C family</u>						
25	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
30	IL-15	?	+	?	+	5	GAS
	<u>gp140 family</u>						
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
35	IL-5 (myeloid)	-	-	+	-	5	GAS
	GM-CSF (myeloid)	-	-	+	-	5	GAS
	<u>Growth hormone family</u>						
40	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
	EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
45	<u>Receptor Tyrosine Kinases</u>						
	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	
	CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCG
AAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAATG
ATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCC
CTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGC
CCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGC
CTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTT
TGCAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using Sall and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies)

with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

- During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final
5 concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in Example 11.

- 10 On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

- 15 Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100,000 cells per well).

- After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12
20 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

- The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples
25 from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophane covers) and stored at -20°C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4°C and serve as a source of material for repeating the assay on a specific well if desired.

- 30 As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells.

- 5 Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

- 10 To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

- 15 Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 1 mM MgCl_2 , and 675 uM CaCl_2 . Incubate at 37°C for 45 min.

- 20 Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

- 25 These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

- 30 Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes,
5 EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or
10 differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

15 The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

20 Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

25 To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker)
30 containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

35 Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine

growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS
5 (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5
10 cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold
15 induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

Example 16: High-Throughput Screening Assay for T-cell Activity

NF- κ B (Nuclear Factor κ B) is a transcription factor activated by a wide variety
20 of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF- κ B regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- κ B appears to shield cells from apoptosis), B and T-cell development, anti-viral and
25 antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- κ B is retained in the cytoplasm with I- κ B (Inhibitor κ B). However, upon stimulation, I- κ B is phosphorylated and degraded, causing NF- κ B to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- κ B include IL-2, IL-6, GM-CSF, ICAM-1 and
30 class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF- κ B promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF- κ B would be useful in treating

diseases. For example, inhibitors of NF- κ B could be used to treat those diseases related to the acute or chronic activation of NF- κ B, such as rheumatoid arthritis.

To construct a vector containing the NF- κ B promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF- κ B binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:
5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:
5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)
Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCCA
TCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACT
AATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTATTC
CAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:
3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF- κ B/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF- κ B/SV40/SEAP cassette is removed from the above NF- κ B/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF- κ B/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF- κ B/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 μ l of 2.5x dilution buffer into Optiplates containing 35 μ l of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 μ l Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 μ l Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6

23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-3, used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-3 is made in 10% pluronic acid DMSO. To load the cells with fluo-3, 50 ul of 12 ug/ml fluo-3 is added to each well. The plate is incubated at 37°C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

5 For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-3 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10⁶ cells/ml, and dispensed into a microplate, 100
10 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-3. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the
15 following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca⁺⁺ concentration.

20

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase
25 RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

30 Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members
35 of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a

biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

- 5 The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂₊ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the
- 10 components gently and preincubate the reaction mix at 30°C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

- Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction
- 15 mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as
- 20 above.

- Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of
- 25 tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity

- As a potential alternative and/or compliment to the assay of protein tyrosine
- 30 kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase,
- 35 Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other

phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then
5 rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C
10 until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts
15 filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and
20 Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

25

Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from
30 these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

35 PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies).

The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

5 PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

10 Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

15 Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and
20 chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated
25 disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

30 A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

35 For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10.

The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 23: Formulating a Polypeptide

The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 µg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1 µg/kg/hour to about 50 µg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally,

intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules.

- 10 Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008;
- 20 U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

- For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

- Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 24: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form.

- 5 Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

- 10 For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

- 15 Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

- For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 20 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy

- 25 One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is 30 turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long
5 terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set
10 forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to
15 transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is
20 then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media,
25 containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is
30 required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

- 5 The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT: Human Genome Sciences, Inc., et al.
(ii) TITLE OF INVENTION: 32 Human Secreted Proteins
(iii) NUMBER OF SEQUENCES: 120
- 10 (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Human Genome Sciences, Inc.
(B) STREET: 9410 Key West Avenue
(C) CITY: Rockville
(D) STATE: Maryland
15 (E) COUNTRY: USA
(F) ZIP: 20850
- 20 (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: Diskette, 3.50 inch, 1.4Mb storage
(B) COMPUTER: HP Vectra 486/33
(C) OPERATING SYSTEM: MSDOS version 6.2
25 (D) SOFTWARE: ASCII Text
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:
30 (B) FILING DATE: May 27, 1998
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
- 35 (A) APPLICATION NUMBER:
(B) FILING DATE:
- 40 (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: A. Anders Brookes
(B) REGISTRATION NUMBER: 36,373
45 (C) REFERENCE/DOCKET NUMBER: PZ006PCT
- (vi) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: (301) 309-8504
50 (B) TELEFAX: (301) 309-8439

(2) INFORMATION FOR SEQ ID NO: 1:

55

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 733 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

10 GGGATCCGGA GCCCAAATCT TCTGACAAAA CTCACACATG CCCACCGTGC CCAGCACCTG 60
AATTCGAGGG TGCACCGTCA GTCTTCCTCT TCCCCC AAA ACCCAAGGAC ACCCTCATGA 120
TCTCCCGGAC TCCTGAGGTC ACATGCGTGG TGGTGGACGT AAGCCACGAA GACCCTGAGG 180
15 TCAAGTTCAA CTGGTACGTG GACGGCGTGG AGGTGCATAA TGCCAAGACA AAGCCGCGGG 240
AGGAGCAGTA CAACAGCACG TACCGTGTGG TCAGCGTCCT CACCGTCCTG CACCAGGACT 300
GGCTGAATGG CAAGGAGTAC AAGTGCAAGG TCTCCAACAA AGCCCTCCCA ACCCCCATCG 360
20 AGAAAACCAT CTCCAAAGCC AAAGGGCAGC CCCGAGAACC ACAGGTGTAC ACCCTGCCCC 420
CATCCCGGGA TGAGCTGACC AAGAACCAGG TCAGCCTGAC CTGCCTGGTC AAAGGCTTCT 480
25 ATCCAAGCGA CATCGCGGTG GAGTGGGAGA GCAATGGGCA GCCGAGAAC AACTACAAGA 540
CCACGCCTCC CGTGCTGGAC TCCGACGGCT CCTTCTTCCT CTACAGCAAG CTCACCGTGG 600
ACAAGAGCAG GTGGCAGCAG GGAACGTCT TCTCATGCTC CGTGATGCAT GAGGCTCTGC 660
30 ACAACCACTA CACGCAGAAG AGCCTCTCCC TGTCTCCGGG TAAATGAGTG CGACGGCCGC 720
GACTCTAGAG GAT 733

35

(2) INFORMATION FOR SEQ ID NO: 2:

40

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Trp Ser Xaa Trp Ser
1 5

50

(2) INFORMATION FOR SEQ ID NO: 3:

55

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 86 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

60 GCGCCTCGAG ATTTCCCCGA AATCTAGATT TCCCCGAAAT GATTTCCCG AAATGATTTC
5 CCGGAAATAT CTGCCATCTC AATTAG 86

10 (2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

20 GCGGCAAGCT TTTTGCAAAG CCTAGGC 27

25 (2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 271 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

35 CTCGAGATTT CCGGAAATC TAGATTTCCC CGAAATGATT TCCCCGAAAT GATTTCCCG 60
AAATATCTGC CATCTCAATT AGTCAGCAAC CATAGTCCCG CCCCTAACTC CGCCCATCCC 120
GCCCCTAACT CCGCCAGTT CCGCCCATTC TCCGCCCCAT GGCTGACTAA TTTT TTTTAT 180
40 TTATGCAGAG GCGAGGCCG CCTCGGCTC TGAGCTATTC CAGAAGTAGT GAGGAGGCTT 240
TTTGGAGGC CTAGGCTTTT GCAAAAAGCT T 271

45

(2) INFORMATION FOR SEQ ID NO: 6:

- 50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
55 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

60 GCGCTCGAGG GATGACAGCG ATAGAACCCC GG 32

(2) INFORMATION FOR SEQ ID NO: 7:

5

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

15

GCGAAGCTTC GCGACTCCCC GGATCGCCT C

31

20

(2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

30

GGGGACTTTC CC

12

35

(2) INFORMATION FOR SEQ ID NO: 9:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 73 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

45

GCGGCCTCGA GGGGACTTTC CCGGGGACTT TCCGGGGACT TTCCGGGACT TTCCATCCTG

60

CCATCTCAAT TAG

73

50

(2) INFORMATION FOR SEQ ID NO: 10:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 256 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

60

CTCGAGGGGA CTTTCCCGG GACTTTCCGG GGACTTTCCG GGACTTTCCA TCTGCCATCT 60
 CAATTAGTCA GCAACCATAG TCCCGCCCCT AACTCCGCCC ATCCCGCCCC TAACTCCGCC 120
 5 CAGTTCCGCC CATTCTCCGC CCCATGGCTG ACTAATTTTT TTTATTTATG CAGAGGCCGA 180
 GGGCGCCTCG GCCTCTGAGC TATTCCAGAA GTAGTGAGGA GGCTTTTTTG GAGGCCTAGG 240
 CTTTTCGAAA AAGCTT 256
 10

(2) INFORMATION FOR SEQ ID NO: 11:

15

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1169 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear
 20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GGGGCGCAAA TAGGGTCAGT GGGCGGCTTG GCGKTGTTTCG TTGCGGTACC AGGTCCGGT 60
 25 GAGGGGTTTCG GGGGTCTCTGG GCAGGCACAA TGGCGTCTCG AGCAGGCCCG CGAGCGGCCG 120
 RCACCGACGC AGCGAGCTTT CAGCACCGGG AGCGCGTCGC CATGCACTAC CAGATGAGTG 180
 30 TGACCTCAA GTATGAAATC AAGAAGCTGA TCTACGTACA TCTGGTCATA TGGCTGCTGC 240
 TGGTTGCTAA GATGAGCGTG GGACACCTGA GGCTCTGTGC ACATGATCAG GTGGCCATGC 300
 CCTATCAGTG GGAATACCCG TATTTGCTGA GCATTTTGCC CTCTCTCTTG GGCCTTCTCT 360
 35 CCTTCCCCG CAACAACATT AGCTACCTGG TGCTCTCCAT GATCAGCATG GGAATCTTTT 420
 CCATCGCTCC ACTCATTTAT GGCAGCATGG AGATGTTCCC TGCTGCACAG CCTTCTACCG 480
 40 CCATGGCAAG GCCTACCGTT TCCTCTTTGG TTTTCTGCCC GTTCCATCA TGTACCTGGT 540
 GTTGGTGTTC GCAGTGCAAG TGCATGCCTG GCAGTGTAC TACAGCAAGA AGCTCCTAGA 600
 CTCTTGGTTC ACCAGCACAC AGGAGAAGAA GCATAAATGA AGCCTCTTTG GGGTGAAGCC 660
 45 TGGACATCCC ATCGAATGAA AGGACACTAG TACAGCGGTT CCAAAATCCC TTCTGGTGAT 720
 TTTAGCAGCT GTGATGTTGG TACCTGGTGC AGACCCAGGC CAAAGTTCTG GAAAGCTCCT 780
 50 TTTGCCATCT GCTGAGGTGG CAAACTATA ATTTATTCCT GGTGGGCTAG AACTGGGTGA 840
 CCAACAGCTA TGAAACAAAT TTCAGCTGTT TGAAGTTGAA CTTTGAGGTT TTTCTTTAAG 900
 AATGAGCTTC GTCCCTGCCT CTACTCGGTC ATTCTCCCCA TTTCCATCCA TTACCCCTTA 960
 55 GCCATTGAGA CTAAAGGAAA TAGGGAATAA ATCAAATTAC TTCATCTCTA GGTACGGGT 1020
 CAGGAAACAT TTGGGCAGCT GCTCCCTTGG CAGCTGTGGT CTCTCTGCA AAGCATTTTA 1080
 60 ATTAAAAACC TCAATAAAGA TGCCCTGCCC ACAAAAAAAA AAAAAAAA AATTCCGGGG 1140

GGGGCCCGG NAACCAATTN GCCCCTANA

1169

5

(2) INFORMATION FOR SEQ ID NO: 12:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1310 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

AATTCGGCAC	GAGGCAGCGT	CGCGCGGCCC	AGTTCCTTTT	TCCGGTCGGC	GTGGTCTTGC	60
GAGTGGAGTG	TCCGCTGTGC	CCGGGCCTGC	ACCATGAGCG	TCCCGGCCTT	CATCGACATC	120
AGTGAAGAAG	ATCAGGCTGC	TGAGCTTCGT	GCTTATCTGA	AATCTAAAGG	AGCTGAGATT	180
TCAGAAGAGA	ACTCGGAAGG	TGGACTTCAT	GTTGATTTAG	CTCAAATTAT	TGAAGCCTGT	240
GATGTGTGTC	TGAAGGAGGA	TGATAAAGAT	GTTGAAAGTG	TGATGAACAG	TGTGGTATCC	300
CTACTCTTGA	TCCTGGAACC	AGACAAGCAA	GAAGCTTTGA	TTGAAAGCCT	ATGTGAAAAG	360
CTGGTCAAAT	TTGCGGAAGG	TGAACGCCCG	TCTCTGAGAC	TGCAGTTGTT	AAGCAACCTT	420
TTCCACGGGA	TGATAAGAA	TACTCCTGTA	AGATACACAG	TGTATGCAG	CCTTATTAAA	480
GTGGCAGCAT	CTTGTGGGGC	CATCCAGTAC	ATCCCAACTG	AGCTGGATCA	AGTTAGAAAA	540
TGGATTTCTG	ACTGGAATCT	CACCACTGAA	AAAAAGCACA	CCCTTTTAAG	ACTACTTTAT	600
GAGGCACCTG	TGGATTGTAA	GAAGAGTGAT	GCTGCTTCAA	AAGTCATGGT	GGAATTGCTC	660
GGAAGTTACA	CAGAGGACAA	TGCTTCCCAG	GCTCGAGTTG	ATGCCACAG	GTGTATTGTA	720
CGAGCATTGA	AAGATCCAAA	TGCATTTCTT	TTTGACCACC	TTCCTACTTT	AAAACCAGTC	780
AAGTTTTTGG	AAGGCGAGCT	TATTCATGAT	CTTTTAACCA	TTTTTGTGAG	TGCTAAATTG	840
GCATCATATG	TCAAGTTTTA	TCAGAATAAT	AAAGACTTCA	TTGATTCACT	TGGCCTGTTA	900
CATGAACAGA	ATATGGCAAA	AATGAGACTA	CTTACTTTTA	TGGGAATGGC	AGTAGAAAAT	960
AAGGAAATTT	CTTTTGACAC	AATGCAGCAA	GAACCTCAGA	TGGAGCTGA	TGATGTTGAA	1020
GCATTTGTTA	TTGACGCCGT	AAGAACTAAA	ATGGTCTACT	GCAAAATTGA	TCAGACCCAG	1080
AGAAAAGTAG	TTGTCAGTCA	TAGCACACAT	CGGACATTTG	GAAAACAGCA	GTGGCAACAA	1140
CTGTATGACA	CACTTAATGC	CTGGAAACAA	AATCTGAACA	AAGTGAAAAA	CAGCCTTTTG	1200
AGTCTTTCTG	ATACCTGAGT	TTTTATGCTT	ATAATTTTTG	TTCCTTGAAA	AAAAAGCCCT	1260
AAATCATAGT	AAAACATTAT	AAACTAAAAA	AAAAAAAAAA	AAAAAAAAAA		1310

60

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1139 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

AGGGCANACT TACAGAGATA TCATATGAGA TCACCCCTCG CATTCTGTGC TGGCGCCAGA 60
CCCTCGAGCG GTGCCGAGC GCASCCAGGT GTGCTTGTGC CTGGGCCAGC TGGAGAGGTC 120
CATTGCCTGG GANGAAGTCT GTCAACAAAG TGACATGTCT AGTCTGCCGG AAGGGTGACA 180
ATGATGAGTT TCTTCTGCTT TGTGATGGGT GTRACCGTGG CTGCCACATT TACTGCCATC 240
GTCCCAAGAT GGAGGCTGTC CCAGAAGGAG ATTGGTTCCTG TACTGTCTGT TTGGCTCAGC 300
AGGTGGAGGG AGAATTCAC TACAAGCCTG GTTTCCTCAA GCGTGGCCAG AAGCGGAAAA 360
GTGGTTATTC GCTGAACCTC TCAGAGGGTG ATGGCCGCGG ACGCCGGGTA CTGTTGAGGG 420
GCCGAGAAAG CCCAGCAGCA GGGCCTCGGT ACTCGGAAGA AGGGCTCTCC CCCTCCAAGC 480
GGCGGCGACT CTCTATGCGG AACCACCACA GTGATCTCAC ATTTTGCGAG ATTATCCTGA 540
TGGAGATGGA GTCCCATGAT GCAGCCTGGC CTTTCCTAGA GCCTGTGAAC CCACGTTTGG 600
TGAGTGGGTA CCGGCGCATC ATCAAAAATC CTATGGATTT TTCCACCATG CGGGAGCGGC 660
TGCTCAGGGG AGGGTACACC AGCTCAGAGG AGTTTGCGGC TGATGCCCTC CTGGTATTTG 720
ACAACTGCCA GACTTTCAAC GAGGATGACT CTGAAGTAGG CAAGGCTGGG CACATCATGC 780
GCCGCTTCTT CGAGAGCCGC TGGGAGGAGT TTTATCAGGG AAAACAGGCC AATCTGTGAG 840
GCAAGGGAGG TGGGAGTCA CCTTGTGGCA TCTCCCCCA CCTTCCAAAC AAAAACCTGC 900
CATTTTCACC TGCTGATGCT GCCCTGGGTC CAGACTCAAG TCAGATACAA CCCTGATTTT 960
TGACCTTACC CTGGCAGTG CCCCATATCC TCTTATTCCT ACATCCCTTT CTCCCTTCCC 1020
TCCTCTTGCT CCTCAAGTAA GAGGTGCAGA GATGAGGTCC TTCTGGACTA AAAGCCAAAA 1080
AAAGAAAGAA AAAAATAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAN 1139

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2271 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

5	GTTCGGGGG ATGCCAGCTC ACTTCTCGGA CAGCGCCCAG ACTGAGGCCT GCTACCACAT	60
	GCTGAGCCGG CCCAGCCGC CACCCGACCC CCTCCTGCTC CAGCGTCTGC CACGGCCCAG	120
	CTCCCTGTCA GACAAGACCC AGCTCCACAG CAGGTGGCTG GACTCGTCGC GGTGTCTCAT	180
10	GCAGCAGGC ATCAAGGCCG GGGACGCACT CTGGCTGCGC TTCAAGTACT ACAGCTTCTT	240
	CGATTTCGAT CCAAGACAG ACCCCGTGCG GCTGACACAG CTGTATGAGC AGGCCCGGTG	300
15	GGACCTGCTG CTGGAGGAGA TTGACTGCAC CGAGGAGGAG ATGATGGTGT TTGCCGCCCT	360
	GCAGTACCAC ATCAACAAGC TGTCCAGAG CGGGGAGGTG GGGGAGCCGG CTGGCACAGA	420
	CCCAGGGCTG GACGACCTGG ATGTGGCCCT GAGCAACCTG GAGGTGAAGC TGGAGGGGTC	480
20	GGCGCCACA GATGTCTGG ACAGCCTCAC CACCATCCCA GAGCTCAAGG ACCATCTCCG	540
	AATCTTTCGG CCGCGAAGC TGACCTGAA GGGCTACCGC CAACACTGGG TGGTGTTCAA	600
25	GGAGACCACA CTGTCTACT ACAAGAGCCA GGACGAGGCC CCTGGGGACC CCATTACGCA	660
	GCTCAACCTC AAGGGCTGTG AGGTGGTTCC CGATGTTAAC GTCTCCGGCC AGAAGTTCTG	720
	CATTAACTC CTAGTGCCCT CCCCTGAGGG CATGAGTGAG ATCTACCTGC GGTGCCAGGA	780
30	TGAGCAGCAG TATGCCCGCT GGATGGCTGG CTGCCGCTG GCCTCCAAAG GCCGCACCAT	840
	GGCCGACAGC AGCTACACCA GCGAGGTGCA GGCCATCCTG GCCTTCCTCA GCCTGCAGCG	900
35	CACGGGCAGT GGGGGCCCG GCAACCACCC CCACGGCCCT GATGCCTCTG CCGAGGCGCT	960
	CAACCCCTAC GGCCTCGTTG CCCCCGTTT CCAGCGAAAG TTCAAGGCCA AGCAGCTCAC	1020
	CCCACGGATC CTGGAAGCCC ACCAGAATGT GGCCAGTTG TCGCTGGCAG AGGCCAGCT	1080
40	GCGCTTCATC CAGGCCTGGC AGTCCCTGCC CGACTTCGGC ATCTCCTATG TCATGGTCAG	1140
	GTTCAGGGC AGCAGGAAAG ACGAGATCCT GGGCATCGCC AACAACGAC TGATCCGCAT	1200
45	CGACTTGCCC GTGGCGACG TGGTCAAGAC CTGGCGTTTC AGCAACATGC GCCAGTGAA	1260
	TGTCAACTGG GACATCCGGC AGGTGGCCAT CGAGTTTGAT GAACACATCA ATGTGGCCTT	1320
	CAGCTCGCTG TCTGCCAGCT GCCGAATTGT ACACGAGTAT ATCGGGGCT ACATTTCCT	1380
50	GTCGACGCGG GAGCGGGCCC GTGGGGAGGA GCTGGATGAA GACCTCTTCC TGCAGCTCAC	1440
	CGGGGGCCAT GAGGCCTTCT GAGGGCTGTC TGATTGCCCC TGCCCTGCTC ACCACCCTGT	1500
55	CACAGCCACT CCAAGCCCC CACCCACAGG GGCTCACTGC CCCACACCCG CTCCAGGCAG	1560
	GCACCCAGCT GGGCATTTCA CTGCTGTCA CTGACTTTGT GCAGGCCAAG GACCTGGCAG	1620
60	GGCCAGACGC TGTACCATCA CCCAGGCCAG GGATGGGGT GGGGTCCTT GAGCTCATGT	1680

	GGTGCCCCCT TTCCTGTCT GAGTGGCTGA GGCTGATACC CCTGACCTAT CTGCAGTCCC	1740
	CCAGCACACA AGGAAGACCA GATGTAGCTA CAGGATGATG AAACATGGTT TCAAACGAGT	1800
5	TCTTTCTTGT TACTTTTTAA AATTTCTTTT TTATAAATTA ATATTTTATT GTTGGATCCT	1860
	CCTCCTTTCT CTGGAGCTGT GCTTGGGGCT ACTCTGACAC TCTGTCTCTT CATCACCAGC	1920
10	CAAGGAAAGG GGCTTTCTG ATAAAGACAA GAGTTGGTTA GAGAAAGGA CACCTAAGTC	1980
	AGTCTAGGGT TGGAAGCTAG GAGAGAGGTG AGGGCAGAAG GGCACAGCTT TCAGGAACAA	2040
	GGAATAGGGG CTGGGGTKGT KGTCTCACG GGTAGGCGTA CCTGCAGGGC CTCCTTGAAG	2100
15	TACTTGGGAA GGAGGAAGCC ATCAGTATTC CCTGGAGTCA GAATCACCCC ATTGGCAGAG	2160
	CGGAAGAAGG GTATTCCATC TGCTGACAGA GCCAGAGATG TGACTCATGC OCTCCCCGAA	2220
20	GGCAAAGTCA GCTCCTGCTT TGTCCAGACT CACCTGCCAG AGCCAGGGGT C	2271

25 (2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 626 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

35	ACAACAAACA TCGAAATCG ANTATGTGCC CCGAAAAGTC GGAACGCAGG CAATCAGTCC	60
	GCACGMGCGC AAGTTCAACA TGAAGATGAT ATGAGGCCGG GCGGGGGGC AGGGACCCCC	120
	GGCGGCCCGG GCAGGGGAAG GGGCCTGGCC GCCACCTGCT CACTCTCCAG TCCTTCCCAC	180
40	CTCCTCCCTA CCCTTCTACA CACGTTCTCT TTCTCCCTCC CGCCTCCGTC CCCTGCTGCC	240
	CCCCGCCAGC CCTCACCACC TGCCCTCCTT CTACCAGGAC CTCAGAAGCC CAGACCTGGG	300
45	GACCCACCT ACACAGGGGC ATTGACAGAC TGGAGTTGAA AGCCGACGAA CCGACACGCG	360
	GCAGAGTCAA TAATTCAATA AAAAAGTTAC GAACTTCTC TGTAAGTTGG GTTTCAATAA	420
	TTATGGATTT TTATGAAAAC TTGAAATAAT AAAAAGAGAA AAAAATATT TCCTATAGCT	480
50	AGTCGGAATG CAAACTTTTG ACGTCTGAT TGCTCCAGG CCTCTTTCC AACTCAGTTT	540
	CTGTGTTTTC CTCTTCTCC TCCTCCTCTT CTCTCCTT TCTTTCTCTT NCCCCATGGG	600
55	GGAGGGGTTC ATTCAGGGAA AACAGG	626

60 (2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2118 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

10	TTTTCCAGCC ATGTCATAA TTGTGAATTC CTACCAACTA TTGACAGAAT ACAGAGTTGA	60
	TTTTTTAATA AAAAGTTATA TATAATTATC CCTTTAATTA AAGGGAGCAA AGGGGCGTTC	120
	CACATGGACA GAGGCTTGGA CCGAGGCGCTG GTCACAGCAG CGAGCATCCA GGGTTTGCAG	180
15	GGACGATGTT ACAGACTCTG TTTTCTGCCT GCGGTTTCAC TTGTGTCTGC TCCTAGCCTG	240
	TGCTCTGCCA GCAGCACAGA CATCTGCTCC ATCAGACCTC TTCCATTTTG CACAGGGAGT	300
20	GCAGGAGGTG AATGTTCACT TTCTGTCTC CAGTGTCACT GTTCTGTTTC CACGGGATGG	360
	AAAGCGCATG GGCCTGTGTC CATTGTAGAT TTCCTTCTAG ATTCTGTGT ACACACACTT	420
	GATTGTCTG GATGAATGTC TTTTTTAATA CTCGAAAAT TTCATCATCT AAGAAAATGA	480
25	TTCCATACAA ATAAGTACG ACACAAGTGA CCCAGGACAT ATGCCTGCCA AAGGGATGTG	540
	TTAGAAGGCT GCCTTCTCAT GCGCATGTG ACTTGGATCT TGTGGTGAGG ACGGCCCCAT	600
30	CTTTCTTGCC ACAGATTGAG GCCACTTTTG AGCAAGGGAG ATCCTGGAGT TAAGACAGGT	660
	GTTGGGGGCA GCCTGTATTT TACCCTAGGG GCAGGTCTGC ATGGTGACCC CACATYGCAC	720
	TGGTAAACCA TTTGAGTCCC ACTCTTCATC CTGGAAGTGG GAACTGGAGT CCCACCCACA	780
35	GTGCATTCAG AAAGCATGCT GTGTGGGGGC TGCTTCTCAG GAGGCCAGGC CCTTCTGAGC	840
	GGAACCGTCC TGGAGAGAGC CTGCCCTCGT TTCCAGGCTG CAGCCGTAAC GCACCTTCTC	900
40	CCAGGCTGAG GGGGGGTGTT CTGGGGTGTG TGCCCTCTGT CGGCCCTGCT TCCTGCCAGG	960
	ACGTGGCCTC TTCGATCCT TTTCTCTCAG AACTGGAGG TCTCTTCTGC CATTGTGCTG	1020
	GTCCCATCCC AAGAATTGTA GGACAGAGAC CACACTGGGT CGCGGACAC AAAGTCCATC	1080
45	CAGGACCCAG GCCGAGAGG GAGCAGGAAG AGATGCTGAT AGTTTGATCT AGAAACCAGC	1140
	AGCTACTGGC TCAAATTCAG GTTCTGGCGT CAAATAGCGA CATTTCCAGT TTCTCTTAAA	1200
50	AACCGTGTTC GGTTCAGTT GGGATAGGCT TGTTTTGTCT GTGAAAATG TTTCTAGTTT	1260
	TTTTTCTTTC ATTTTCTCT CATTCCATTT CTGCCCTAAC TTTAGTTTGT TCACAGGGAG	1320
	GCAAAGCTGA CATGAACCTT TTGTCGTGGG ACTTCAGGCC ACATTGGCTT GAAGGCATTC	1380
55	GTTTCCCTCT GGGGTGGGGA CAGGCCCTCA TGGCAGGCTT GTCCCGTGG CTCTGAGCGA	1440
	GGCCTCTTCC TGCTGGGCTC CCAGACTCCT GCATCCAGGC CCCACCTTC TCGGCTTCTG	1500
60	GTTTTTCTTT CTTTTGGTA GAACACAACA TCTACCATTC AGTTAAACCT TCCTTATCTC	1560

CTCTYTGGC ATCCATTMTT CCAAAGAAGA GTCGAGTCCT CTGAGGTCTG TGCTTGAAAR 1620
 CCGTCCGAAG GCATTCTTGT TAGCTTTGCT TTTCTCCCA TATCCAAGG CGAAGCGCTG 1680
 5 AGATTCCTCC ATCTAAAAA CCCTCGACCC GAAACCTCA CCAGATAAAC TACAGTTTGT 1740
 TTAGGAGGCC CTGACCTTCA TGGTGTCTTT GAAGCCCAAC CACTCGGTTT CCTTCGGATT 1800
 10 TTCTCTCCCTT TGTTCGGGGT TTGGTTTGGC TCCTCTGTGT GTGTCCGTAT CTGTTCGGT 1860
 GTCTCGAGG TTGAGCTTCA CTCCACTGCG GCAGAGGCAG CGTGCACT CGGATTGCT 1920
 ACGTTCTAT ATATCTTGAA GCTAAATGTA TATATGAGTA GTTTGCCATG AGATAACACA 1980
 15 GTGTAAACAG TAGACACCCA GAAATCGTGA CTTCTGTGTT CTCTCCATT T GAGTATTTTG 2040
 TAATTTTTTT GAAATATTTG TGGACATAAA TAAACCAAG CTACACTACA AAAAAAAAAA 2100
 20 AAAAAAATG GAGACTAG 2118

25 (2) INFORMATION FOR SEQ ID NO: 17:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1076 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 30 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

35 GCCCAAGGAG CTCAGCTTCG CCCGCATCAA GGCCGTTGAG TGCGTGGAGA GCACCGGGCG 60
 CCACATCTAC TTCACGCTGG TGACCGAAGG GWGCGGCGAG ATCGACTTCC GCTGCCCCCT 120
 GGAAGATCCC GGCTGGAACG CCCAGATCAC CCTAGGCCTG GTCAAGTTCA AGAACCAGCA 180
 40 GGCCATCCAG ACAGTGGGG CCCGCGAGAG CCTCGGGACC GGGACCTCG TGTCTAAAC 240
 CACCGGGCGC ACCATCTTTC CTTTCATGCTA CCCACCACCT CAGTGTGAG GTCAAGGCAG 300
 45 CTTGTTTGT CCCTCTGGCT TGTGGGGGCA CGGCTGTSYT CCATGTGGCA AGGTGGAAGG 360
 CATGGACGTG TGGAGGAGGC GCTGGAGCTG AAGGAATGGA CGAGCCCTGG GAGGAGGCA 420
 GAAGGCTACG CAGGGCTGAG GATGAAGATG CAGCCCCTGG ATGGTCCCAG ACTCTCAGGA 480
 50 CATGCCCAGC TCAGGGGCTT CGAGCCACAG GCCTGGCCTC ATATGGCATG AGGGGAGCT 540
 GGCATAGGAG CCCCCTCCCT GCTGTGGTCC TGCCCTCTGT CCTGCAGACT GCTCTTAGCC 600
 55 CCCTGGCTTT GTGCCAGGCC TGGAGGAGGG CAGTCCCCCA TGGGTGCGG AGCCAACGCC 660
 TCAGGAATCA GGAGGCCAGC CTGGTACCAA AAGGAGTACC CAGGGCCTGG TACCCAGGCC 720
 CACTCCAGAA TGGCCTCTGG ACTCACCTTG AGAAGGGGGA GCTGCTGGGC CTAAAGCCCA 780
 60 CTCCTGGGGG TCTCTGCTG CTTAGGTCCT TTTGGGACCC CCACCCATCC AGGCCCTTTC 840

5 TTTGCACACT TCTTCCCCCA CCTCTAYGCA TCTTCCCCCC ACTGCGGTGT TCGGCCTGAA 900
 GGTGGTGGGG GTGAGGGGGG GTTTGGCCAT TAGCATTTCA TGTCTTTCCC CAAATGAAGA 960
 TGCCTTGCAA AGGGCAGTNA ACCACAAAAA AAAAAAAAAA AAAACNTGG GGGGGGGGCC 1020
 CCGTTAACCA TTTTGGCCTN ATAGGGGGGN GGTMTTAA AATTAATTGG GCCCGG 1076

10

(2) INFORMATION FOR SEQ ID NO: 18:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1379 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

GGCACGAGCA CCTCCACACA CCTCCCTGAA CTTCATCTG ATCGACTTCA ACTTGCTGAT 60
 25 GGTGACCACC ATCGTTCCTG GCCGCCGCTT CATTTGGTCC ATCGTGAAGG AGGCCTCTCA 120
 GAGGGGAAG GTCTCCCTCT TTCGCTCCAT CCTGCTGTTT CTCACTCGCT TCACCGTTCT 180
 CACGGCAACA GGCTGGAGTC TGTGCCGATC CCTCATCCAC CTCTTCAGGA CCTACTCCTT 240
 30 CCTGAACCTC CTGTTCTCTT GCTATCCGTT TGGGATGTAC ATTCCGTTCC TGCARCTGAA 300
 TTKCGAMCTY CGSAAGACAA GCCTCTTCAA CCACATGGCC TCCATGGGGC CCCGGGAGGC 360
 35 GGTCACTGGC CTGGCAAAGA GCCGGGACTA CCTCCTGACA CTGCGGGAGA CGTGAAGCA 420
 GCACASAAGA CAGCTGTATG GCCCGGACGC CATGCCACC CATGCCTGCT GCCTGTCGCC 480
 CAGCCTCATC CGCAGTGAGG TGGAGTTCTT CAAGATGGAC TTCAACTGGC GCATGAAGGA 540
 40 AGTGCTCGTS AGCTCCATGC TGAGCGCCTA CTATGTGGCC TTTGTGCCGT TYTGGTTCGT 600
 GAAGAACACA CATTACTATG ACAAGCGCTG GTCCTGTGNA ACTCTTCCTG CTGGTGTCCA 660
 45 TCAGCACCTC CGTGATCCTC ATGCAGCACC TGCTGCNTGC CAGCTACTGT GACCTGCTGC 720
 ACAAGGCCGC CGCCCATCTG GGCTGTTGGC AGAAGGTGGA CCCAGCGCTG TGCTCCAACG 780
 TGCTGCAGCA CCCGTGGACT GAAGAATGCA TGTGGCCGCA GGGCGTGCTG GTGAAGCACA 840
 50 GCAAGAACGT CTACAAAGCC GTAGGCCAMW ACAAMGTGGC TATCCCCTCT GACGTCTCCC 900
 ACTTCCGCTT CCAKTTCTTT TTCAGCAAAC CCTGCGGAT CCTCAACATC CTCTGCTGC 960
 55 TGGAGGGGCG TGTCATTGTC TATCAGCTGT ACTCCCTAAT GTCCTCTGAA AAGTGGCACC 1020
 AGACCATCTC GCTGGCCCTC ATCCTCTTCA GCAACTACTA TGCTTCTTTC AAGCTGCTCC 1080
 GGGACCGCTT GGTATTGGGC AAGGCCTACT CATACTCTGC TAGCCCCCAG AGAGACCTGG 1140
 60

ACCACCGTTT CTCCTGAGCC CTGGGGTCAC CTCAGGGACA GCGTCCAGGC TTCAGCAAGG 1200
GCTCCCTGGC AAGGGGCTGT TGGGTAGAAG TGGTGGTGGG GGGGACAAAA GACAAAAAAA 1260
5 TCCACCAGAG CTTTGTATTT TTGTTACGTA CTGTTTCTTT GATAATGAT GTGATAAGGA 1320
AAAAAGTCCT ATTTTATATAC TCCCAANMAA AAAAAAANA NAAAAAGCGG CCGAAAGCT 1379

10

(2) INFORMATION FOR SEQ ID NO: 19:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1337 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

CTGGTGTGG GCCTGAGCCN CCTCAACAAC TCCTACAAC TCACTTTCCA CGTGGTGATC 60
GGCTCTCAGG CGGAAGAAGG CCAGTACAGC CTGAACCTCC ACAAAGCAA CAATTCAGTG 120
25 CCAGGAAAGG AGCATCCATT CGACATCAGC GTGATGATCC GGGAGAAGAA CCCCAGTGGC 180
TTCCTGTGG CAGCGGAGAT GCGGCTTTTC AAGCTCTACA TGGTCATGTC CGCCTGCTTC 240
30 CTGGCCGCTG GCATCTTCTG GGTGTCCATC CTCTGCAGGA ACACGTACAG CGTCTTCAAG 300
ATCCACTGGC TCATGGCGGC CTGGCCCTTC ACCAAGAGCA TCTCTCTCCT CTTCACAGC 360
ATCAACTACT ACTTCATCAA CAGCCAGGGG CCACCCCATC GAAGGCCTTG CCGKCATGTA 420
35 CTACATCGCA CACCTGCTGA AGGGCGCCCT CCTCTTCATC ACCATCGCCC TGATTTGGCTC 480
AGGCTGGGCT TCATCAAGTA CGTCTGTGCG GATAAGGAGA AGAAGGTCTT TGGGATCGTG 540
40 ATCCCATGCG AGGTCTGGC CAACGTGGCC TACATCATCA TCGAGTCCCG CGAGGAAGGC 600
GCCACGAAGT ACGTGTCTG GAAGGAGATT TTGTTCTGCG TGGACCTCAT CTGCTGTGGT 660
GCCATCCTGT TCCCGTAGT CTGGTCCATC CGGCATCTCC AGGATGCGTC TGGCACAGAC 720
45 GGAAGGTGG CAGTGAACCT GGCCAAGCTG AAGCTGTTCG GGCATTACTA TGTATGGTC 780
ATCTGCTACG TCTACTTCAC CCGCATCATC GCCATCCTGC TGCAGGTGGC TGTGCCCTTT 840
50 CAGTGGCAGT GGCTGTACMA GCTCTTGGTG GARGGCTCCA CCCTGGCCTT CTTCGTGCTC 900
ACGGGCTACA AGTTCAGCC CACAGGGAAC AACCCGTACC TGCAGCTGCC CCAGGAGGAC 960
GAGGAGGATG TTCAGATGGA GCAAGTAATG ACGGACTCTG GGTTCGGGA AGGCCTCTCC 1020
55 AAAGTCAACA AACAGCCAG CGGGCGGGAA CTGTTATGAT CACCTCCACA TCTCAGACCA 1080
AAGGGTCGTC CTCCCCAGC ATTTCTCACT CCTGCCCTTC TTCCACAGCG TATGTGGGGA 1140
60 GGTGGAGGGG TCCATGTGGA CCAGGCGCCC AGCTCCCGGG ACSCCGGTT CCGGACAAGC 1200

CCATTGTGAA GAAGAGTCCC TTCCTCCCC CAAATATTGG GCAGCCCTGT CCTTACCCCG 1260
 GGACCACCCC TCCCTTCCAG CTATGTGTAC AATAATGACC AATCTGTTTG GCTAAAAAAA 1320
 5 AAAAAAAAAA AACTCGA 1337

10

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

15

- (A) LENGTH: 1390 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

GCCGTTTGG TTCCCGGTTG GTGCTTCCTG TTCGCAGCTG CGGCACCTCA AGGTTACTGA 60
 CTTTTATGA TGTITGGTGG CTATGAGACT ATAGAWGCR TSGRRGATGA TYTTTATCGA 120
 25 GATGAGTCAT CTAGTGAAC TAGTGTGAT AGTGAGGTGG AATTTCAACT CTATAGCCAA 180
 ATTCAATTATG CCCAAGATCT TGATGATGTC ATCAGGGAGG AAGAGCATGA AGAAAAGAAC 240
 TCTGGGAATT CGGAATCTTC GAGTAGTAAA CCAAATCAGA AGAAGCTAAT CGTCCTTTCA 300
 30 GATAGTGAGG TCATCCAGCT GTCAGATGGG TCAGAGGTCA TCACTTTGTC TGATGAAGAC 360
 AGTATTTATA GATGTAAAGG AAAGAATGTT AGAGTTCAAG CACAAGAAAA TGCCCATGGT 420
 35 CTTTCTTCTT CTCTTCAATC TAATGAGCTG GTTGATAAGA AATGCAAGAG TGATATTGAG 480
 AAGCCTAAAT CTGAAGAGAG ATCAGGTGTA ATCCGAGAGG TCATGATTAT AGAGGTCAGT 540
 TCAAGTGAAG AGGAAGAGAG CACCAATTTC GAAGGTGATA ATGTGGAAAG CTGGATGCTA 600
 40 CTGGGATGTG AAGTAGATGA TAAAGATGAT GATATCCTTC TCAACCTTGT GGGATGTGAA 660
 AACTCTGTTA CTGAAGGAGA AGATGGTATA AACTGGTCCA TCAGTGACAA AGACATTGAG 720
 45 GCCCAGATAG CTAATAACCG AACACCTGGA AGATGGACCC AGCGGTACTA TTCAGCCAAC 780
 AAAAACATTA TCTGTAGAAA TTGTGACAAA CGTGGTCATT TATCAAAAAA CTGCCCCCTA 840
 CCACGAAAAG TTCGTCGCTG CTTCCTGTGC TCCAGGAGAG GACATCTCCT GTATTCCTGT 900
 50 CCAGCCCCC TTTGCGAATA CTGTCCGTGT CCTAAGATGT TGGACCACTC ATGTCTTTTC 960
 AGACATTCCT GGGATAACA GTGTGACCGA TGTATATGC TAGGCCACTA TACAGATGCT 1020
 55 TGCACAGAAA TCTGGAGGCA GTATCACCTA ACGACCAAAC CTGGACCACC CAAAAGCCG 1080
 AAGACCCCTT CAAGACCATC AGCCTTAGCA TATTGCTATC ACTGCGCGCA AAAAGGCCAT 1140
 TATGGACACG AATGTCCAGA AAGAGAAGTG TATGACCCGT CTCCAGTATC TCCATTATC 1200
 60

TGCTACTATG RTGACAAATA TGAAATTCAG GAGAGAGAAA AGAGACTAAA ACAAAAAATA 1260
 AAAGTANTCA AGAAAAATGG GGTATCCCA GAGCCATCCA AGCTACCTTA TATAAAAGCA 1320
 5 GCAAATGAGA ACCCCCACCA TGATATAAGG AAGGGCCGTG CCTCATGGAA AAGCAACAGG 1380
 TGGCCTCAAG 1390

10

(2) INFORMATION FOR SEQ ID NO: 21:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1431 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

GCCTGCAGTC GACACTAGTG GATCCAAAGA ATTCCGCCCTG TGCAGTAGG CGCTTGGGCA 60
 CTCAGTCTCC CTGGCGAGCG ACGGGCAGAA ATCTCGAACC AGTGGAGCGC ACTCGTAACC 120
 25 TGGATCCCGA AAGTCCGCA AGGCAGTACC GTTTCCTCAG CGCGGACTG CTGCAGTAAG 180
 AATGTCTTTT CCACCTCATT TGAATCGCCC TCCCATGGGA ATCCCAGCAC TCCCACCAGG 240
 30 GATCCCACCC CCGCAGTTTC CAGGATTTCC TCCACCTGTA CCTCCAGGGA CCCCAATGAT 300
 TCCTGTACCA ATGAGCATTA TGGCTCCTGC TCCAACCTGC TTAGTACCCA CTGTGTCTAT 360
 GGTGGAAAG CATTTGGGCG CAAGAAAGGA TCATCCAGGC TTAAAGGCTA AAGAAAATGA 420
 35 TGAAAATTGT GGTCTACTA CCACTGTTTT TGTTGGCAAC ATTTCCGAGA AAGCTTCAGA 480
 CATGCTTATA AGACAACTCT TAGCTAAATG TGGTTTGGTT TTGAGCTGGA AGAGAGTACA 540
 40 AGGTGCTTCC GGAAAGCTTC AAGCCTTCGG ATTCTGTGAG TACAAGGAGC CAGAATCTAC 600
 CCTCCGTGCA CTCAGATTAT TACATGACCT GCAAATTGGA GAGAAAAAGC TACTCGTTAA 660
 AGTTGATGCA AAGACAAAGG CACAGCTGGA TGAATGGAAA GCAAAGAAGA AAGCTTCTAA 720
 45 TGGGAATGCA AGGCCAGAAA CTGTCACTAA TGACGATGAA GAAGCCTTGG ATGAAGAAAC 780
 AAAGAGGAGA GATCAGATGA TTAAAGGGC TATTGAAGTT TTAATTCTGT AATACTCCAG 840
 50 TGAGCTAAAT GCCCCCTCAC AGGAATCTGA TTCTACCCC AGGAAGAAGA AGAAGGAAAA 900
 GAAGGAGGAC ATTTTCCGCA GATTTCAGT GGGCCCACTG ATCCCTTATC CACTCATCAC 960
 TAAGGAGGAT ATAAATGCTA TAGAAATGGA AGAAGACAAA AGAGACCTGA TATCTCGAGA 1020
 55 GATCAGCAAA TTCAGAGACA CACATAAGAA ACTGGAAGAA GAGAAAGGCA AAAAGGAAAA 1080
 AGAAAGACAG GAAATTGAGA AAGAACGGAG AGAAAGAGAG AGGGAGCGTG AAAGGGAACG 1140
 60 AGAAAGGCGA GAACGGGAAC GAGAAAGGGA AAGAGAACGT GAACGAGAAA AGGAGAAAGA 1200

ACGGGAGCGG GAACGAGAAC GGGATAGGGA CCGTGACCGG AAAAAAGAGA GAGACCGAGA 1260
 5 TCGGGATCGA GAGAGAGATC GTGACCGGGA TAGAGAAAGG AGCTCAGATC GTAATAAGGA 1320
 TCGCATTCTA TCAAGAGAAA AAAGCAGAGA TCGTGAAAGG GAACGAGAGC GGGAAAGAGA 1380
 GAGAGAGAGA GAACGAGAGC GAGAACGAGA ACGGGAGCGA GAGAGAGAAG C 1431
 10

(2) INFORMATION FOR SEQ ID NO: 22:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2539 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear
 20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

GGGTGCAGGA GTGCCACCCC CAGGGCCCTG TCAACCTCTC TTTTCTCCTC CATGGCTGTC 60
 25 TGCTTGCCTA TCTGTCTCTG AGAATCCTCG GGGCGGTCAG GGGATGTCAG GAGGGGAAGG 120
 AGCCGCCCTC CCTATCTTGC TGCTCCTCTT GGCACCTCAGG GGCACCTTCC ATGGAGCCAG 180
 ACCGGGTGGA GGGGCTTCTG GGATTGTGGT TCTGCTGCTG CCAGAGCAGG AACCCCCAGT 240
 30 CTAGGACTTG GGCATTTTAA CAGGGAGAAA GTAGTGGCTT CCCTTTTCTC TCTCTCTCC 300
 TTTTTCCTT TAAGCCACA GATTCAGGTC ATGCCAAAAG CTCTCTGGTT GTAACCTGGA 360
 35 GACATGTGGA GGGGAATGGC GATGGGATTA TAGGACTCTC CCCATCTCGG GCCCTGACCC 420
 TGACCCCTGC CACCAACCCA AAGACAGCTG GTGGGTTTCC CCTTGAGAGAM AATCCTGCGT 480
 TTGCCTGGGC CGGCCCTGGC TGCCCTCAGC TTTCGCTGAT CTGCCCGGCC TGGAGCCTCC 540
 40 CATCACCCCG CTTCTGTGTG GGCCTCAGGC ACTGGTTACC AGAAGGGGGT CTGGGTCTGC 600
 TCAGGAATCA TGTTTTGTAG CACCTCCTGT TGGAGGGGTG GAGGGATGTT CCCCTGAGCC 660
 45 AGGCTGAGAC TAGAACCCCA TCTTCCCTGA GCCAGGCTGA GACTAGAACC CCATCTTCCC 720
 CACCACGCCA CCCCTGTGST KGCTACAGGA GCACAGTAGT GAAGGCCTGA GCTCCAGGTT 780
 TGAAAGACCC AACTGGAGCG TGGGGCGGCG AGGCAGGGGT TAGTGAAAGG AACTTCCAG 840
 50 GGTTAGGACA GAGCATTTAG CCTTCTGGAA GAACCCCTGC CTGGGGTGGG ACTGTGCAGG 900
 CCAGAGAAGG TGGCATGGGC CTGAACCCAC CTGGACTGAC TTCTGCACTG AAGCCACAGA 960
 55 TGGAGGGTAG GCTGGTGGGT GGGGGTGGTT CGTTCTCTAG CCGGGGCAGA CACCCAGCTG 1020
 GCTGGGTCTT TCCTCAGCCT TGCTCCTCC TGTCCCAAC CCTTCTCTT CCTCCTGCTT 1080
 60 GCGGACTGCT GGTCCCTCT CCTTCCCTCC TTCCAGCTGT TTCTAGTTAC CACCTACCCC 1140

TGGGCCGTGG ACTGATCAGA CCAGCATTTCA AAATAAAAGT TTGTTCCAAG TTGACAGTGT 1200
GGTGCTCCCT GCCCAGCCCC TCCAGGTGGA GGTGCTGCCA CGGGAACGCA GTTGCTCTGC 1260
5 CTGCCCTGGG CCCCTGGCGA CANTGGGAGC AGGGCAGTGC TGTGAGGAGC CCAGCTTTCC 1320
CAGTCAGGCA GGCATGGCTT CCGTGTTCAG GCTCCCTCAC CAGCTGGTGA CACGGGACAA 1380
10 GCTTACAAAC CTTCTCTGAA CCTCAGTTTT CTCATTTACA AGAGGCAAAG CATCCATCAC 1440
CTTGTGTGGA TTCARAGAAT GTRAGGCCCT GGGGTGTCCT ACACAAGGGA AAGGCTTGCT 1500
CAGTGAGCGG TCTGCACACC GTTAGCCACC CTGCCACCTC TGTGCCCTGG GCAGGCTCCA 1560
15 AAGGAAAGCT CTGGCTGGGA CTGCCRGGAG TCTCACACGC TCCTGTGAC ATTCCCAGCA 1620
GCYCCCCCTG AGGTCGATGT TGTCTCTGTT TTTCTTTTTC TTTTGTGAGA CGGAGTCTCG 1680
CTGTGTTGCC AGGCTGGAGT GCAGTGGTGT GATCTCTGCT CACTGCAACC TCCGCTGCC 1740
20 AGTTTCAAGT GATCTCTGC CTCAGCCTTC TGAGTAGCTG GGACTACAGG TGCACGCCAC 1800
CACGCCCAGC TAACTTTTTG TATTWAGTA GAGACAGGGT TTCGCCATGT CGGCCAGGGT 1860
25 GGTCTTGATC TCCTGACCTC ATGATCCACC CGCTCAGCC TCCCAAAGTG CTGGGATTAC 1920
AGGTATGAGC CACCGCACCG GGCCTGTTCT ATTTTCTAG TTAAGGGAAC TGAAGCTCAG 1980
ARAGGTGTCA CCAGCARGTG TTCATTCCCA TGCCAGCCTT GCCCCCGGC TTTTCCCAGG 2040
30 CAGGCTCCTG CGTGCCCACT GGCTCCAGCC TGGTCTCTG TCTCTGGCT GCTTCACTCC 2100
TGCTCTTTGT CCGACTCTG GCCCTGCTTA CAGGGGCCAC TACCTGCTGG TGCTCCATA 2160
35 ACAAGCGTCT GCGTTGAGA CCCCTGGCAT GGCAGGGGCT TTGGGGTCTG GTTCCACAA 2220
GGCTTAGCCA TGGCAGAACC TCGTTTATT TTAACCTTTT GCCCTACAA ACAACAGCA 2280
GTACTTGCCA GAACATTCT TGGGATTAG GAGCTCGGC GACTGCCTTG GCCTCTGGCC 2340
40 GCACCCAGGA GGTGGGGTT GGATCTGTGT AGTTGCCAGG CCCACACCTG CCAGCAGGG 2400
GCTGACTGGA TCCATGCTTT ACTGTGTTTA ATGGGGGTAA CAGGGGTCCC TACAGCCCTC 2460
45 CCAGYTAAAM ATTTGGAACA AAACACCAGC CCTTTGTAG TGGATGCAGA ATAAAATTGT 2520
TAATCCAATC AAAAAAAAAA 2539

50

(2) INFORMATION FOR SEQ ID NO: 23:

55

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1041 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

	TCGACCCACG CGTCCGCCCA CGCGTCCGCC CACGCGTCCG GGCGCAGGAC GTGCACTATG	60
5	GCTCGGGGCT CGCTGCGCCG GTTGCTGCGG CTCTCTCGTG TGGGGCTCTG GCTGGCGTTG	120
	CTGCGCTCCG TGGCCGGGA GCAAGCGCCA GGCACCGCCC CCTGCTCCCG CGGCAGCTCC	180
	TGGAGCGCGG ACCTGGACAA GTGCATGGAC TGC CGCTCTT GCAGGGCGG ACCGCACAGC	240
10	GACTTCTGCC TGGGCTGCGC TGCAGCACCT CCTGCCCCCT TCCGGCTGCT TTGGCCCATC	300
	CTTGGGGGCG CTCTGAGCCT GACCTTCGTG CTGGGGCTGC TTTCTGGCTT TTTGGTCTGG	360
15	AGACGATGCC GCAGAGAGAG AAGTTCACCA CCCCATAGA GGAGACCGGC GGAGAGGGCT	420
	GCCCAGCTGT GCGCTGATC CAGTGACAAT GTGCCCCCTG CCAGCCGGGG CTCGCCCACT	480
	CATCATTCAT TCATCCATT TAGAGCCAGT CTCTGCCTCC CAGACGCGGC GGGAGCAAGC	540
20	TCCTCCAACC ACAAGGGGGG TGGGGGGCGG TGAATCACCT CYGAGGCCCTG GGCCCAAGGT	600
	TCAGGGGAAC TTCCAAGGTG TCTGGTTGCC CTGCCTCTGG CTCCAGAACA GAAAGGGAGC	660
25	CTCACGCTGG CTCACACAAA ACAGCTGACA CTGACTAAGG AACTGCAGCA TTTGCACAGG	720
	GGAGGGGGGT GCCCTCCTTC CTAGAGGCCC TGGGGGCCAG GCTGACTTGG GGGGCAGACT	780
	TGACACTAGG CCCCACTCAC TCAGATGTCC TGAAATTCCA CCACGGGGGT CACCCCTGGG	840
30	GGTTAGGGAC CTATTTTAA CACTAGGGGG CTGGCCCACT AGGAGGGCTG GCCCTAAGAT	900
	ACAGACCCCC CCAACTCCCC AAAGCGGGA GGAGATATTT ATTTTGGGA GAGTTTGGAG	960
35	GGGAGGGAGA ATTTATTAAT AAAAGAATCT TTAAC TTAA AAAAAAAAAA AAAAAAGGC	1020
	GGCGCTCTA GAGGATCCCT C	1041

40

(2) INFORMATION FOR SEQ ID NO: 24:

45

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1962 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

55

60

ACCCACGCGT CCGGTACAAA ACACAGTTTT ATCTATGAA AATTTTGAGA TTATTAGAAA	60
CATTAGATTT AGGGTGCAT ATTA AAACT ATATCCATTT TGCCTTATTA TTTAGTGTCT	120
CACTCAGGAT ATAACAACT ATAATAGAAA ATGTAGACTT CAGAATCAGG TATATTGAG	180
ATGGTTTGTA TACTGGTTCT GACACTTGIT AGCTATTCAT CTTTGGTAAA TTCCCATTA	240
CCCTTTGTC ACCTATWGT GGGATCAGT GCATAGTGTG TGTWAAGCAT TTAATACCTG	300

	GCAAGTGTTC AGCAAATTTT TTGTTCTATA TATTTATTAT TTGATTATTG GCCCTGAGGA	360
	GTAGGTGTTT GTTTGTTTGT TTGTTTGTIT AGTTTTATT CTCTCTCCT CAGGAACACA	420
5	AATGAAACTT GGATATTGTT ATGGTGCTTT TNATAATATA TTTATTATTT TCAGCAATTN	480
	ATTCTTGTTA AAACAATTTT TTATGACAAG TTAATCATCT TCAATGGTGA GAAGAAATCT	540
10	AGCTCAGAAT AATATATTTT TAGTGTITGT ATCTCTGGAT ACTCATTTTG CTCATTGCCA	600
	CGTAAAGTAA AAAAATACAT AAATTAGCTT ATTCCAATGT AATATCTTCA GGATAGTCAT	660
	GGGCAAGGAA TTAATCACAT TAAGAGATAA CTGCAACTAA GCACTATTTG AGGTGACTTC	720
15	TGTGGAAAAA AAATTAATYC TTTACCATTG CAGCGTCTG CCTAGGTCC AAATGTTACC	780
	AAATCACTC TAGAATCTTT TCTTGCCTGG AAGAAAAGGA AAAGACAAGA AAAGATTGAT	840
20	AAACTTGAAC AAGATATGGA AAGAAGGAAA GCTGACTTCA AAGCAGGGAA AGCACTAGTG	900
	ATCAGTGGTC GTGAAGTGT TGAATTTGCT CCTGAACTGG TCAATGATGA TGATGAGGAA	960
	GCAGATGATA CCCGCTACAC CCAGGGAACA GGTGGTGATG AGGTTGATGA TTCAGTGAGT	1020
25	GTAAATGACA TAGATTTAAG CCTGTACATC CCAAGAGATG TAGATGAAAC AGGTATTACT	1080
	GTAGCCAGTC TTGAAAGATT CAGCACATAT ACTTCAGATA AAGATGAAAA CAAATTAAGT	1140
30	GAAGCTTCTG GAGGTAGGGC TGAAAATGGT GAAAGAAGTG ACTTGGAAGA GGACAACGAG	1200
	AGGGAGGGAA CGGAAAATGG AGCCATTGAT GCTGTTCTTG TTGATGAAAA TCTTTTCACT	1260
	GGAGAGGATT TGGATGAAC AGAAGAAGAA TTAAATACAC TTGATTTAGA AGAATGACAC	1320
35	CAACACATC GCTGAAAAA TTAAGTCAGC TCAGCACGAG TTGAAATGA CTACATTAAT	1380
	TTCTTTCCAC CTAGAATCAA CAGGATGTTT ATTTCTATG CTGATTCTGG AGGAGTTAAC	1440
40	CTCCTGCAAA AAAGGCATCT TGTCCCTACA TCTTCTCTTC TGACTTTGGC TACATCTCAT	1500
	AGTAAGTTCA GAGTAGTTCA TGATAAATTG AAAATATAAT GGTCAATGCA GAAATGATT	1560
	GATGTTGTAA CTGTCCACCC AAGTAAGAAG TGTATCTGCC TTTCCATCTT TTGGTTTTC	1620
45	TTTGGGCATG TGCTATTACC AGAAACAACA AACTTATATT TAAAATACCC TTCATTTGAC	1680
	ACAGTTTTTA ATGAGTGATT TAATTTCTC TGTATTTGTA TGTTTAGAAG ACTGCCTAAA	1740
50	ACATGAGCAC TGTAATTCAT AAAGGAAACG CGTATGCAGA TTCAGTATTG TGTATCTTTG	1800
	GACAATTAGA TGGACATTTA AAATGGAAC TCTTTTATCT GACAGGATCA GCTACAATGC	1860
	CCTGTGTTAA ATTGTTTAAA AGTTTCCCTT TTCTTTTTTG CCAATAAAGT TGTAATAAAA	1920
55	GACCATCATA CATTAAAATC CAAAAAAAAA AAAAAAAAAA AA	1962

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1228 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

10 GGCTGCCCAG GCCCGCACT GGAAGAGCCT CCAGCAGCAA GATGTGACCG YTG TGCCGAT 60
GAGCCCCAGC AGCCACTCCC CAGAGGGGAG GCCTCCACCT CTGCTGCCTG GGGGTCCAGT 120
GTGTAAGGCA GCTGCATCTG CACCGAGCTC CCTCCTGGAC CAGCGTGCC TCTGCCCCGC 180
15 ACCCTCTGTC CGCACCGCTG TTGCCCTGAC AACGCCGAT ATCACATTGG TTCTGCCCCC 240
TGACATCATC CAACAGGAAG CGTCACCCTG AGGGAGGAGA CAGAAGCCTG GGCCAGGTGA 300
20 ACAGTGGTAT AGCAGCCACT CCAGCCTCTG CTGCAGCAGC CACCTGGAT GTGGCTGTTC 360
GGAGAGGCCT GTCCCACGGA GCCCAGAGGC TGCTGTGCGT GCCCTGGGA CAGCTGGACC 420
25 GGCCTCCAGA CCTCGCCCAT GACGGGAGGA GTCTGTGGCT GAACATCAGG GGCAAGGAGG 480
CGGCTGCCCT ATCCATGTTC CATGTCTCCA CGCCACTGCC AGTGATGACC GGTGGTTTCC 540
TGAGCTGCAT CTTGGGCTTG GTGCTGCCCC TGGCCTATGN TTCCAGCCTG ACCTGGTGCT 600
30 GGTGGCGCTG GGGCCTGCCA NTGCCTGCAG GGGCCCCACG CTGCACTCCT GGCTGCAATG 660
CTTCGGGGGC TGGCAGGGG CCGAGTCTG GCCCTCCTGG AGGAGAACTC CACACCCAG 720
CTAGCAGGGA TCCTGGCCCG GGTGCTGAAT GGAGAGGCAC CTCCTAGCCT AGGCCCTTCC 780
35 TCTGTGGCCT CCCCAGAGGA CGTCCAGGCC CTGATGTACC TGAGAGGGCA GCTGGAGCCT 840
CAGTGGAAGA TGTTCAGTG CCATCCTCAC CTGGTGGCTT GAAATCGCC AAGGTGGAG 900
40 CATTTACACC GCAGAAATGA CACCGCACGC CAGOGCCCCG CGGCCGCGAT CCGACCCCA 960
AGCCACGGC TCCCTCGACT CTGGGGCAGC GAACCCCGCC CACTCCCAAT CCCCAGCCCC 1020
CGCCTCTCC CACCCGTGCT TCCCCGCTC CACCCCTCAC CTCACCTCGC CCCSGCCCCA 1080
45 CCCATCGCGC CCGGCCCGT CCCATCGAGG CCCATGCAAC CCACGCTCGG TYCCGTTCGG 1140
GCCCTGCGC TCKCGTKNS TTCGCTCCCC GCCCTGCGC CGTTAGTAAA CATCGCTCAA 1200
50 ACGAAAAAAA AAAAAAAAAA AAATCTGA 1228

55 (2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

- 60 (A) LENGTH: 1340 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

5	AATTCGGCAG AGAGATGGCC GCGCCCGTGG ATCTAGAGCT GAAGAAGGCC TTCACAGAGC	60
	TTCAAGCCAA AGTTATTGAC ACTCAACAGA AGGTGAAGCT CGCAGACATA CAGATTGAAC	120
	AGCTAAACAG AACGAAAAAG CATGCACATC TTACAGATAC AGAGATCATG ACTTTGGTAG	180
10	ATGAGACTAA CATGTATGAA GGTGTAGGAA GAATGTTTAT TCTTCAGTCC AAGGAAGCAA	240
	TTCACAGTCA GCTGTTAGAG AAGCAGAAAA TAGCAGAAGA AAAAATTAAA GAACTAGAAC	300
15	AGAAAAAGTC CTACCTGGAG CGACGTTAAA GGAAGCTGAG GACAACATCC GGGAGATGCT	360
	GATGGCACGA AGGGCCCACT AGGGAGCCTC TCTGGGAAGC TCTTCCTCCT GCCCCTCCCA	420
	TTCTTGGTGG GGGCAGAGGA GTGTCTGCAG GGAAACAGCT TCTCCTCTGC CCCGATGGAT	480
20	GCTTTATTTG GATGGCCTGG CAACATCACA TTTTCTGCAT CACCCTGAGC CCCATTTGCT	540
	TCCCAGCCCT GGAGTTTTTA CCCGGCTTTG CTGCCACCTC TGCCCAGGAC ACKCTTCCCT	600
25	CTCGGGATGT GTGATGAACT CCCAGGAGAG GGAAGATGGG AGCCAGGGCA AGATAGGAAG	660
	CTCTGCCTGA GCTTTCCACT AGGCACGCCA GCCAGACCAA TAAAAAGCGT CTGTCCCACT	720
	CTGCTAAGCC TGGTTTTCTT GAGCAGAGGG ATGGAACAGA GGGTGAGAGA GGCAGTGGCC	780
30	GTCTCCACCT CAGCTCCTGC TCCCTCTGCA TCAGAGCCCT TCCTTTCTTG GGGGATGGGC	840
	CTTGCCNTCT TCTCTTTTCC CTTCCTGTAC CTTTGAATAA CGCTCAGCTT CCGGGCCTGC	900
35	ATGCAGTAGA CAGAAGAGGA AGAAAGAACA GATGTTTACA GCTGAATCTC AGTGAACAGA	960
	ATAGCAGTCC CTGGATGGCA GTCTGCCTAA AGATTCTTTT CCTGCCTTC TCCCATACAT	1020
	TCCAAAAGGA AGTTCAACAG TAAGCAGCAC CTCCAAGACT GTCTCCTTTY GGCCARTATC	1080
40	ATAAGATGGA CGCCATAATC CTGAGGCCTC CTAGAGGCTG AGGGGGCAAC GGTGTGATCC	1140
	AGCTGGCTCA TCCAGCCAG GTGGGCCAAT TATTCAATTT TCAAGAATTT TGTGCAAGC	1200
45	CAGTTGTCAA ACACAGCCAT TATAATTATG TAAATTTGCA AATTATGTTA AAAACAAGGA	1260
	CAATAAATAT TCAAAATGCA TCCCTAAWWA AAAAAAAAAA AANGGGNGGC CGCNCTAGGG	1320
50	GATCCAAGCT TACGTACGCG	1340

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 806 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

5	ACCTTCTTCC ATGTTTAGTC CCTTGGGCTC TGCTACCTC CTGCTGGAGG TGAGAGCATC	60
	CTGTGTGCAA CCAGAGATGC CTTCTGGCTT TCAGACCTGC CTGCTTTTCA CCCTCAGCCC	120
	TTTCTCACTC AGCAAAATTG TGGGGGTCCC TAGTCAGCAG CTCCTTGGGC AGCTCTCTGA	180
10	GCAAGGTGGT CTCTGTGGTC ATGAAGGAGA GCCGGCTAGG ACAGTGCCGG AACTCAGCT	240
	GCCTCTCCCC TTCAACTCAG CTGGCCCCC GCACCTGAAG TGCACAGGAG CCGGGAAGAG	300
15	AGTCTGGAGC CCACCCCGGA GGCAGCACA GGAGGTGTCT CTGCAGCTGG TGTCTGCCA	360
	CCCCTGCAGG CAGCACACGT CCGGGCATT CTCCTTAGCC ACAGACAGAA CAGCCAGTGC	420
	CAGAGTCTGC TGTGTTTCCC CTTAAGCAC ACTCATTCAC CACACCCGAG GAGGCCAGAG	480
20	GTGCAGGAG CATGGGCTGT CGCTTCCCT TTAAGCACAC TCATTACCA CACCCGAGGA	540
	GGCCAGAAGT GCAGGAGCA TGGGCTGGT GCACCTCCGC AGGAGAGAAG GCTGAGCCAC	600
25	CGCCGTCCCG GGAGCCCGC TCCAGGCT CTCGTTTCC CTTACCTCCC TAAGACTTTT	660
	CTGTCACTCT CTGGCCATTG AAAGGCTTCT GTTCTTAAA GTGCTGTAC ACTCTCTTT	720
	CCCAGGATGC AGCAAGCCAA AACAGTACCA CTGCACGTCA GCCTGGGTGA CAGAGTGAGA	780
30	CCCTATCTTA AAAAAAAAAA AAAAAA	806

35 (2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

	(A) LENGTH: 696 base pairs
40	(B) TYPE: nucleic acid
	(C) STRANDEDNESS: double
	(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

45	GAGTTCCNA CGCGTGGCG NCCGTTTtag AAATTAGTGG ATCCCCCGG GCTGGCAGGG	60
	AATTCCGCAC GAGCACAGAG GAAAGCGGT GCCCGCATG GCCATCCTGA TGTGCTGGC	120
50	GGGATCCCCA TGCACTTGT CTTCTCCAC TGATACTGGC AGCTCGGCTC CTGGACCCAA	180
	GATCCCTTGA GTGGAATTCT GCAGTGCAAG AGCCCTTCGT GGGAGCTGTC CCATGTTTCC	240
	ATGGTCCCCA GTCTCCCTC CACTTGGTGG GGTCAACCAAC TACTCACCAG AAGGGGGCTT	300
55	ACCAAGAAAG CCTTAAAAAG CTGTTGACTT ATCTGCGCTT GTTCCAACCTC TTATGCCCCC	360
	AACCTGCCCT ACCACCACCA CGCGCTCAGC CTGATGTGTT TACATGGTAC TGTATGTATG	420
60	GGAGAGCAGA CTGCACCTC CAGCAACAAC AGATGAAAGC CAGTGAGCCT ACTAACCGTG	480

CCATCTTGCA AACTACACTT TAAAAAAAC TCATTGCTTT GTATTGTAGT AACCAATATG 540
TGCAGTATAC GTTGAATGTA TATGAACATA CTTTCCTATT TCTGTTCTTT GAAAATGTCA 600
5 GAAATATTTT TTTCTTTCTC ATTTTATGTT GAACTAAAAA GGATTAAAAA AAAAATCTCC 660
AGAMAAAAAA AAAAAAATAA AAATTACTGC GGTCCG 696

10

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:
15 (A) LENGTH: 1007 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

AATTCGGCAC GAGGAAAAAA TACCATTGTG GTATGATACC CAATTGGAT CTCAATTTGG 60
ATAGAGATTT GGTGCTTCCA GATGTRAGTT ATCAGGTGGA ATCCAGTGAG GAGGATCAGT 120
25 CTCAGACTAT GGATCCTCAA GGACAACTC TGCTGCTTTT TCTCTTTGTG GATTTCACA 180
GTGCATTTCC AGTCCAGCAA ATGGAAATCT GGGGAGTCTA TACTTTGCTC ACAACTCATC 240
30 TCAATGCCAT CCTGTGGAG AGCCACAGTG TAGTGCAAGG TTCCATCCAA TTCACTGTGG 300
ACAAGGTCTT GGAGCAACAT CACCAGGCTG CCAAGGCTCA GCAGAAACTA CAGGCCTCAC 360
TCTCAGTGGC TGTGAACTCC ATCATGAGTA TTCTGACTGG AAGCACTAGG AGCAGCTTCC 420
35 GAAAGATGTG TCTCCAGACC CTTCAAGCAG CTGACACACA AGAGTTCAGG ACCAAACTGC 480
ACAAAGTATT TCGTGAGATC ACCCAACACC AATTTCITCA CCACTGCTCA TGTGAGGTGA 540
40 AGCAGCTAAC CCTAGAAAAA AAGGACTCAG CCCAGGGCAC TGAGGACGCA CCTGATAACA 600
GCAGCCTGGA GCTCCTAGCA GATACCAGCG GGCAAGCAGA AAACAAGAGG CTCAAGAGGG 660
GCAGCCCCCG CATAGAGGAG ATGCGAGCTC TGCGCTCTGC CAGGGCCCCG AGCCCGTCAG 720
45 AGGCCGCCCC GGGCGCCCCG GAAGCCACCG CGGCCCCCT CACTCCTAGA GGAAGGGAGC 780
ACCGCGAGGC TCACGGCAGG GCCCTGGCGC CGGCAGGGC GAGCCTCGGA AGCCGCCTGG 840
50 AGGACGTGCT GTGGCTGCAG GAGGTCTCCA ACCTGTCAGA GTGGCTGAGT CCCAGCCCTG 900
GGCCCTGAGC CGGGTCCCCT TNCGAAGCG CCCACCGATC CGGARGCTGC GGGCAGCCGT 960
TATCCCGTGG TTTAATAAAG TGCCGCGCGC TCACCAAAAA AAAAAAA 1007
55

60

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2017 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

10	AATTCGGCAC GAGCGGATCC GTTGGGCTG CAGCTCTGCA GTCGGGCCGT TCCTTCGCCG	60
	CCGCCAGGGG TAGCGGTGTA GCTGCGCAGC TCGCGCGCGC TACCGCACCC AGGTTCCGCC	120
	CGTAGCGTCT GGCAGCCCGG CGCCATCTTC ATCGAGCGCC ATGGCCGAG CCTGCGGGCC	180
15	GGGAGCGGCG GGTACTGCTT GCTCCTCGGC TTGCATTTGT TTCTGCTGAC CGCGGGCCCT	240
	GCCTGGGCTG GAACGACCCT GACAGAATGT TGCTGCGGGA TGTAAAAGCT CTTACCCTCC	300
20	ACTATGACCG CTATACCACC TCCGCGAGCT GGATCCCATC CCACAGTTGA AATGTGTTGG	360
	AGGCACAGCT GGTGTGATT CTTATACCCC AAAAGTCATA CAGTGTGAGA ACAAAGGCTG	420
	GGATGGGTAT GATGTACAGT GGAATGTAA GACGGACTTA GATATTGCAT ACAAATTTGG	480
25	AAAACTGTG GTGAGCTGTG AAGGCTATGA GTCCTCTGAA GACCAGTATG TACTAAGAGG	540
	TTCTTGTTGC TTGGAGTATA ATTTAGATTA TACAGAACTT GGCTGCAGA AACTGAAGGA	600
30	GTCTGGAAAG CAGCACGGCT TTGCCTCTTT CTCTGATTAT TATTATAAGT GGTCTCGGC	660
	GGATTCTGT AACATGAGTG GATTGATTAC CATCGTGGTA CTCCTTGGGA TCGCCTTTGT	720
	AGTCTATAAG CTGTTCTGA GTGACGGGCA GTATTCTCCT CCACCGTACT CTGAGTATCC	780
35	TCCATTTTCC CACCGTTACC AGAGATTCAC CAACTCAGCA GGACCTCCTC CCCCAGGCTT	840
	TAAGTCTGAG TTCACAGGAC CACAGAATAC TGGCCATGGT GCAACTTCTG GTTTTGGCAG	900
40	TGCTTTTACA GGACAACAAG GATATGAAAA TTCAGGACCA GGGTTCCTGA CAGGCTTGGG	960
	AACTGGTGA AACTAGGAT ATTTGTTTGG CAGCAATAGA GCGGCAACAC CCTTCTCAGA	1020
	CTCGTGGTAC TACCGTCTCT ATCCTCCCTC CTACCTGGC ACGTGAATA GGGCTTACTC	1080
45	ACCCCTTCAT GGAGGCTCGG GCAGCTATTC GGTATGTTCA AACTCAGACA CGAAAACCAG	1140
	AACTGCATCA GGATATGGTG GTACCAGGAG ACGATAAAGT AGAAAGTTGG AGTCAAACAC	1200
50	TGGATGCAGA AATTTTGGAT TTTCATCAC TTTCTCTTTA GAAAAAAGT ACTACCTGTT	1260
	AACAATGGG AAAAGGGGAT ATTCAAAAGT TCTGTGGTGT TATGTCCAGT GTAGCTTTT	1320
	GTATTCTATT ATTTGAGGCT AAAAGTTGAT GTGTGACAAA ATACTTATGT GTTGATGTC	1380
55	AGTGTAACAT GCAGATGTAT ATTCAGTTT TTGAAAGTGA TCATTACTGT GGAATGCTAA	1440
	AAATACATTA ATTTCTAAAA CCTGTGATGC CCTAAGAAGC ATTAAGAATG AAGGTGTTGT	1500
60	ACTAATAGAA ACTAAGTACA GAAAATTTCA GTTTTAGGTG GTTGTAGCTG ATGAGTTATT	1560

ACCTCATAGA GACTATAATA TTCTATTTGG TATTATATTA TTTGATGTTT GCTGTTCTTC 1620
AAACATTTAA ATCAAGCTTT GGAATAATTA TGCTAATTTG TGAGTTCTGA TCACTTTTGA 1680
5 GCTCTGAAGC TTTGAATCAT TCAGTGGTGG AGATGGCCTT CTGGTAACTG AATATTACCT 1740
TCTGTAGGAA AAGGTGGAAA ATAAGCATCT AGAAGGTGTG TGTGAATGAC TCTGTGCTGG 1800
CAAAAATGCT TGAAACCTCT ATATTCTTTT CGTTCATAAG AGGTAAAGGT CAAATTTTTC 1860
10 AACAAAAGTC TTTTAATAAC AAAAGCATGC AGTTCTCTGT GAAATCTCAA ATATTGTGTG 1920
AATAGTCTGT TTCAATCTTA AAAAGAATCA ATAAAAACAA ACAAGGGAAA AAAAAAAAAA 1980
15 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAA 2017

20 (2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 699 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

30 GNGTTTTTTC CAGCCAGGAA GTGACCGNTA CTGCAGCACG AGANAGATTG GTTGGGTTGG 60
TTGRAAATGA CYCTGAACAT TTATTTCCAT TGCAATTTCT GTGGCTGAGG AGACTTAAAC 120
TTTACAAGTA TTATCCTTTT AAGATCATTT TAATTTTAGT TGAGTGCAGA GGGCTTTTAT 180
35 AACAAACGTG CAGAAATTTT GGAGGGCTGT GATTTTTCCTA GTATTAAACA TGCATGCATT 240
AATCTTGCAG TTTATTTTCT CATTTGTGTAT GTATATATCG CTTTCTCTCG CAGCACGATT 300
40 TCTCTTTTGA TAAWKCCCTT TAGGGCACAA CTAGTTATCA GTAACGAAT GTATCTTAAT 360
CATTATGGCT GCTTCTGTTT TTTCATTAAAC AAAGGTTATT CATATGTTAG CATATAGTTT 420
CTTTGCACCC ACTATTTATG TCTGAATCAT TTGTCACAAG AGAGTGTGTG CTGATGAGAT 480
45 TGTAAGTTTG TGTGTTTAAA CTTTTTTTTG AGCGAGGGAA GAAAAAGCTG TATGCATTTT 540
ATTGCTGTCT ACAGGTTTCT TTCAGATTAT GTTCATGGGT TTGTGTGTAT ACAATATGAA 600
50 GAATGATCTG AAGTAATGT GCTGTATTTA TGTTTATTC AAGTCTTTG ATTAAATAAA 660
AAGGAAAACC AGAAAAAAAA AAAAAAAAAA AAAAAA 699

55

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1264 base pairs

60

(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

GGCACGAGGG CACTGTTTCC TCAGTCCATG GCTGAGTACA TCACCGGTGT TTTCTCTCTT 60
ATTCTCTCCA TCAAGCCTAA AAGGAATCTC TATTGGAGAT ACTGCCATTA GTGTTCTTTT 120
10 TATAGGTGAG GAACTGAGGC ATAKAGGGTT CCCAGTTGA ACCAACTGAT AAATAGTAGA 180
ACTTGGATTT TAATTCAGTC TTGATGCCAG GGATAAGGCT CTTACTTTCT ACCTTAGGCT 240
15 ATTCTTAGGA AACGAGGAG AGTGTGAAG GGCAGAGAA AGGGATCCAG TTCCTTTCTG 300
TCCCGCATCC TAGTCCCTGA GAAGCAAAGA ARAATGTGTG GCTTCTTTTG CTTTGCTTTT 360
GTGTGCATCC CACACATCTC CAGGGGAMCT GGGCTCTTGA TCTTGGSCTC TTCCCTTTTA 420
20 ACTGTTAAGT GGGAGCARGT AAGGGGGTAC AGTAGGGCTG GCCTGGAGTT AGAGGCTTGG 480
ATGCCTTAGC TCCTCTGTCT GCACTCCAGA ACTGCCTGAC TTCATTTCTG ATGTTGTCCT 540
25 TTGTTTGTAC AATTGATCCA TGTCACGTC CGTCTCTTCT TCCTTCTTGA TACTTACACT 600
GCTTCTTTCT GTTGGTTTCC AGTGTTTAAC ACTGTATACA ACAGTGACGA CAACGTGTTT 660
GTGGGGGCCC CCACGGGCG CCGGAAGACT ATTTGTGCAG AGTTTGCCAT CCTGCGAATG 720
30 CTGCTGCAGA GCTCGGAGGG GCGCTGTGYS TWCWTCACCM CCATGGAGGC CCTGGCCAGA 780
RCAGGTATGA CGTGGCGCTG TGTCATGTGA ATTTCCCAAG AAGCATTTC TCTGTGATTC 840
35 CGTATGAAGG CTTTCTAAGC CCTGAAATTT GCAGGGTCAT TTCTCAGTT TGTGTATTAA 900
AGAAAAGCTG CCCAGCCAA GCGTGGTGGC TCAAGCCTGT AATCCAGCA CTTTGGGAGG 960
CCGAGGCGGG CAGATCTCCG GAGATCAGGA GTTCGAGACC AGCCTGGCCA ACATGGTGRA 1020
40 ACCCTGTCTC TACTAAAWT ACAGAAATTA GCTGGNGTG GTGGTGTGCG CCTGTAATCC 1080
CAGCTACTTG GAAGGCTGAG GCAGGAGAAT CGCTTGAACC CGGGAGGCGG AGGTTGCAGT 1140
45 GAGCCAAGTT CGCACCCTG CACTCCAGCC TGGGCAACAA GAGCGAGACT TCATCTCAA 1200
AAAAAAAAA AAAAAGCTGA GGGGGGGCCC GGTACCCAAT TCGCCCTATA GTGATCGTAT 1260
TACA 1264
50

55 (2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 997 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
60 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

5	ATTGGAAGTT GTTTTGCAAC CTGGGCTTTT ATACAGAAGA ATACGAATCA CAGGTGTGTG	60
	AGCATCTACT TAATTAATTT GCTTACAGCC GATTTCTGCG TTAGTCTGGC ATTACCAGTG	120
	AAAATTGTTG TTGACTTGGG TGTGGCACCT TGGAAGCTGA AGATATTCCA CTGCCAAGTA	180
10	ACAGCCTGCC TCATCTATAT CAATATGTAT TTATCAATTA TCTTCTTAGC ATTTGTGAGC	240
	ATTGACCGCT GTCTTCAGCT GACACACAGC TGCAAGATCT ACCGAATACA AGAACCCGGA	300
	TTTGCCAAAA TGATATCAAC CGTTGTGTGG CTAATGGTCC TTCTTATAAT GGTGCCAAAT	360
15	ATGATGATTC CCATCAAAGA CATCAAGGAA AAGTCAAATG TGGGTGTGTAT GGAGTTTAAA	420
	AAGGAATTTG GAAGAAATG GCATTTGCTG ACAAATTTCA TATGTGTAGC AATATTTTTA	480
20	AATTTCTCAG CCATCATTTT AATATCCAAT TGCCTGTAA TTCGACAGCT CTACAGAAAC	540
	AAAGATAATG AAAATTACCC AAATGTGAAA AAGGCTCTCA TCAACATACT TTTAGTGACC	600
	ACGGGCTACA TCATATGCTT TGTTCCTTAC CACATTGTCC GAATCCCGTA TACCCTCAGC	660
25	CAGACAGAAG TCATAACTGA TTGCTCAACC AGGATTTTAC TCTTCAAAGC CAAAGAGGCT	720
	ACACTGCTCC TGGCTGTGTC GAACCTGTGC TTTGATCCTA TCCTGTACTA TCACCTCTCA	780
30	AAAGCATTCG GCTCAAAGGT CACTGAGACT TTTGCCTCMC CTAAAGAGAC CAAGGTYAGA	840
	AAGAAAAATT AAGANGTGA AATAATGGCT AAAAGACAGG NTTTTTGTGG TACCAATTCT	900
	GGGCTTTATG GGACNTAAA GTTATTATAG CTTGGAAGGT AAAAAAAAAA AAAGGGNGGG	960
35	CGCTCTAGAG GTTCCCGAG GGGCCAGCTT AGGGTGC	997

40

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

- | | |
|----|-----------------------------|
| 45 | (A) LENGTH: 1914 base pairs |
| | (B) TYPE: nucleic acid |
| | (C) STRANDEDNESS: double |
| | (D) TOPOLOGY: linear |

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

50	GTGTGAGAGG CCTCTCTGGA AGTGTCCCG GGTGTTCGCC GCTGGAGCCC GGGTCGAGAG	60
	GACGAGGTGC CGCTGCCTGG AGAATCCTCC GCTGCCGTGC GCTCCCGGAG CCCAGCCCTT	120
55	TCCTAACCCA ACCCAACCTA GCCCAGTCCC AGCCGCCAGC GCCTGTCCCT GTCACGGACC	180
	CCAGCGTTAC CATGCATCCT GCCGTCTTCC TATCCTTACC CGACCTCAGA TGCTCCCTTC	240
60	TGCTCCTGGT AACTTGGGTT TTTACTCCTG TAACAACTGA AATAACAAGT CTTGATACAG	300

	AGAATATAGA TGAAATTTTA AACAAATGCTG ATGTTGCTTT AGTAAATTTT TATGCTGACT	360
	GGTGTCTGTTT CAGTCAGATG TTGCATCCAA TTTTGTGAGGA AGCTTCOGAT GTCATTAAAGG	420
5	AAGAATTTCC AAATGAAAAT CAAGTAGTGT TTGCCAGAGT TGATTGTGAT CAGCACTCTG	480
	ACATAGCCCA GAGATACAGG ATAAGCAAAT ACCCAACCCT CAAATTGTTT CGTAATGGGA	540
10	TGATGATGAA GAGAGAATAC AGGGGTCAGC GATCAGTGAA AGCATTGGCA GATTACATCA	600
	GGCAACAAAA AAGTGACCCC ATTCAAGAAA TTCGGGACTT AGCAGAAATC ACCACTCTTG	660
	ATCGCAGCAA AAGAAATATC ATTGGATATT TTGAGCAAAA GGACTCGGAC AACTATAGAG	720
15	TTTTTGAACG AGTAGCGAAT ATTTTGCATG ATGACTGTGC CTTTCTTTCT GCATTTGGGG	780
	ATGTTTCAAA ACCGGAAAGA TATAGTGGCG ACAACATAAT CTACAAACCA CCAGGGCATT	840
20	CTGCTCCGGA TATGGTGTAC TTGGGAGCTA TGACAAATTT TGATGTGACT TACAATTGGA	900
	TTCAAGATAA ATGTGTTCCT CTTGTCCGAG AAATAACATT TGAAAATGGA GAGGAATTGA	960
	CAGAAGAAGG ACTGCCTTTT CTCATACTCT TTCACATGAA AGAAGATACA GAAAGTTTAG	1020
25	AAATATTCCA GAATGAAGTA GCTCGGCAAT TAATAAGTGA AAAAGGTACA ATAAACTTTT	1080
	TACATGCCGA TTGTGACAAA TTTAGACATC CTCTTCTGCA CATAAGAAA ACTCCAGCAG	1140
30	ATTGTCTCTT AATCGCTATT GACAGCTTTA GGCATATGTA TGTGTTTGGA GACTTCAAAG	1200
	ATGTATTAAAT TCCTGGAAAA CTCAAGCAAT TCGTATTTGA CTTACATTCT GGAAACTGC	1260
	ACAGAGAAAT CCATCATGGA CCTGACCCAA CTGATACAGC CCCAGGAGAG CAAGCCCAAG	1320
35	ATGTAGCAAG CAGTCCACCT GAGAGCTCCT TCCAGAAACT AGCACCAGT GAATATAGGT	1380
	ATACTCTATT GAGGGATCGA GATGAGCTTT AAAAACTGA AAAACAGTTT GTAAGCCTTT	1440
40	CAACAGCAGC ATCAACCTAC GTGGTGGAAA TAGTAAACCT ATATTTTCAT AATTCTATGT	1500
	GTATTTTTAT TTTGAATAAA CAGAAAGAAA TTTTGGGTTT TTAATTTTTT TCTCCCGAC	1560
	TCAAAATGCA TTGTCATTTA ATATAGTAGC CTCTTAAAAA AAAAAAAAC CTGCTAGGAT	1620
45	TTAAAAATAA AAATCAGAGG CCTATCTCCA CTTTAAATCT GTCCTGTAAA AGTTTTATAA	1680
	ATCAAATGAA AGGTGACATT GCCAGAACT TACCATTAAC TTGCACTACT AGGGTAGGGA	1740
50	GGACTTAGGG ATGTTTCCTG TGTCGTATGT GCTTTTCITT CTTTCATATG ATCAATTCTG	1800
	TTGGTATTTT CAGTATCTCA TTTCTCAAAG CTAAGAGAT ATACATTCTG GATACTTGGG	1860
55	AGGGGAATAA ATTAAAGTTT TCACACTGNA AAAAAAAAAA AAAAAAAAC TCGA	1914

(2) INFORMATION FOR SEQ ID NO: 35:

60

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1020 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

CCNFTNNFTT TTTTTTTTTG CAAGACAAAA TATACTTTAT TGTGACAGCA AATGCACATA 60
 10 GTGCTGTAGG TAAGGCATGC TACTAGGAAT CTGCATATAA TCAAAAGCCA GTATGGAAAT 120
 GAATGGAAAT GAATGCTGTT GTTCTCAGAT TGAGTCCATG GTGGAGAAAG GATAGTTTGT 180
 15 GTCCACTTAT TTCAAATGCA GTATCATACC TACTTAATCA GTTACCTATG CTTCTAACCA 240
 ACAGCCCACT GGCAAATAGG AGGAACTTAA CTGTACTCAG AAGTCACCTT TAATATCAAC 300
 GACAGAAATA TTTCACTAAT TCAACTGAGG CAAATTTCTT TTCTAGACAA AGGACCTAGA 360
 20 AATGAGCAT GCAAAACATC CATCCATTCA TTCATTCAAA TAATTAGCCA ATTTTACCGT 420
 CATTTAATTC CACCAGAAGC AAATACTAGA ATATCTAGAA GTAGTTTGGG TAAAGAAACA 480
 25 TTTACATTTT AATATTGTGT AATGTCATAA ATTTGGGGCT AAAATAACAC CAGGTCAAAT 540
 TTGATCCCTT TGTATGTGAG GGTACAAAGT ACAGTTTTCG TTTCAACAGC TGAACCTCTG 600
 AGAGAAGAGC TGAAAAAAT GCTAAATAAG AGATCTAGGC CTTTGATGGA AACTATTAGG 660
 30 CTCTACAGAC TTGTCAAAAA ATCAATGCAA AACTGAGGGG GAAAGGCTGA AATGCTTTGT 720
 AAAGCAGTAT TTTTAGACAA GTTGCTTCAT TTCCCCCTT TCTAAAACAG ATGCAGATTA 780
 35 AATGTTTTTT TGCATGAATG CACATTGACA TTCTGTTCAA CTGTTTTCTA AATGCAACAC 840
 TGCGGGTTTC AACAGTATGC TTTCAATTAA ACAAAGAATA TTATATGCAT GTTCAATTTA 900
 GTTTAAGAGA TGAAAAAATA CTTTACTACT ATGAAAATTG CTTATCAAAT ACTCTCCTCT 960
 40 TTTATAAGGT GTTTTARGC AACACAGGAC CGGTNGAACC GANCAAAATT ATAATTATAC 1020

45

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

50

- (A) LENGTH: 781 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

55 AACTCCTGAC CTCAAGTGCT CCACCTGCGT TGGCTTCCCA AAGTGCTGGG ATACAGGAGT 60
 RAGCCACTGC GCCTGGCTGA TCCCAGCACT TTMAAATGA TGCCGCTCAA AGCOGTGACT 120
 60 TGGCCTACTT TGAACAGCAA ACTTGTGTCT GCTGTGTGCA ACCTGAAGGC CTCTCAAATG 180

	CCAGCTTCAA GCAGGGTGTG AATTGGCCAG TGTGAGATCT CAGGAGTCCT GTGTTGAGAG	240
	TGTGGCTTTC AGCTGCGGGG AGCTGCACTT GGTGGGAAA GCCAGGCAGG TCACCCTCAC	300
5	AGCCAGATAA TGTGGAGGTC AGAACCCAAG GAAGGGAGTG AGACCTCCAC TCCCAGTGGG	360
	GGACCTGGCC ACCCATCCTT GGGGACCTGA GAAAGCGTAC TTCACCTTGG GGTGAAGGCT	420
10	GGGTGGGGCC AGAGGGACCA GTGCCCTCCT CAGTGCTTAG GGGCAGAGCC ACCTGCAGCA	480
	ATGGTATCTG CATATTAGCC CCTCTCCACC TTCTTTCTCC CGCTGAATCA TTTCCCTCAA	540
	AGCCCAAGAG CTGTCACCTG TTCTTTCTCC CTGGGAAGAA TGGGTGGACT CTGCCTGGTG	600
15	ATAGACTGAA GCCAGAACAG TGCCACACCC TCGCCTTAAT TCCTTGCTAG GTGTTCTCAG	660
	ATTTATGAGA CTCTTAGTC AAATATGAGG GAGGTGGAT GTGGTGGCTT GTGCCTGTAA	720
20	TCCCAGCATT TTGGGAAGCC GAGGTGGGAG GATCCCTTGA AGCCAGGAGT TTGAGACAAG	780
	C	781

25

(2) INFORMATION FOR SEQ ID NO: 37:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 966 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

30

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

35

	GGCAGCAGGA AGCAGCTGGG GGCTGATCAG GGGGAGCAG CAGCCCTCCG ATTGCAGGGC	60
	TGCCTATTTG AGTGGCAGCT CCTCTTGAAA CAATGCAGAA CAAGCCCAGG GCCCCACAGA	120
40	AAAGGGCACT GCCCTTCCCA GAACCTGAGC TCGGGACTA CGCATCTGTT CTCACCAGAT	180
	ACAGCTTGGG GCTGAGGAAC AAAGAGCCTT CCCTGGGCCA CAGGTGGGGG ACCCAGAAGC	240
45	TGGGCAGGAG CCCCTGTCTT GAAGGGTCCC AGGGCCACAC CACAGATGCT GCTGACGTGC	300
	AGAACCACTC TAAAGAAGAA CAGAGAGACG CAGGAGCACA GAGGARGTGC GGCCAGGGGA	360
	GGCACACCTG GCGGTACAGG NGAGGGGCGC AGGACACTTC GAGGCTGACA GGAGACCCAC	420
50	GTGGTGGGGA AAGGAGCCCC CCAAAGTGTC AGAGCATGAA GCAGCAGGAA GGAGCTCCCT	480
	CGGGCCACTG CTGGGATCAG TGGTGCCATG GAGCAAGCGA GGTGTGTTGG CCTGAAAGCC	540
55	GGAAGCGTGC CCAAATCTTT SCATCACCAT GTAGGCAGTC ACCTCGCTCC TCAGCACTCG	600
	GGGCAGGACA GAAGCTTGCT GTCTGCTCAC CAGACATCCT GTGCTGCCCT ACAGACACCT	660
	TGCTCGCCAG CCATCCCCAC TCACCTCTGA CCGGGACCCA ATTCTCTGGC CAAACCCAGG	720
60	CTCTAGCACC GTCTTGGTGT GCTTGAGAAA CATCTAGTTT AAGTCAAAAT CCAATGTCTT	780

TTTAATATAT AGACTATATG TACCTATGGA CTAGAGGTGA ATATATATAC ATCATATCAA 840
 5 ATTCAAGTGA CCCAGTATTT CGGAGAAACC CACTATGTCC CCAGCCTGCA TGGGAAGCTG 900
 GGGATTCTGG CATGAACTGC ACCTTATCTT CCTCGAGGGG GGGCCGGTAC CAAITGCCNA 960
 TAGTGG 966

10

(2) INFORMATION FOR SEQ ID NO: 38:

15

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 416 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

GAATTCGGCA CGAGTAATA GGAGCCCTCG TACCTCTTGT GTTCCTTACA AACATTCTCA 60
 25 TCAGTAGCTC TACCGGTGA CTGGGTGGTT TGARATGGCT GGTATACACA GGGCTTTCTT 120
 GGTGTCTGT CTCTGGGGCT TARTTTGTG TGTGGTTGGA GGGCCCTGGT GAGATTGGAA 180
 GTACCAGAGA GTGCTGTGTC AGGGGCAGAG GGGCCTGTG CTGGAGCTGG AGGGTGCCTG 240
 30 CCTTTGTGTC TGA CTCTCARTC TCCTGTCTGC CTTGCCCCCT CAGGGTCTCG CCAGCCCAGC 300
 CTCTGTGGGA ATCTAAAAGG ARTGGATGTG GACGKTGAC CAAGCACATC TCAGCTTTTA 360
 35 ATACCTGGGC TATTTATAGA CCTTTGGGGG GAATNGCTTG TGAACAACA AGGGTT 416

40

(2) INFORMATION FOR SEQ ID NO: 39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1114 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

50 TGTGTATTTG GGGGACTGA AGGGTACGTG GGGCGAAACA AAACCGGCCA TGGCAGCAGC 60
 GGAGGAGGAG GACGGGGGCC CCGAAGCCAA AATCGCGAGC GGGCGGGGC GGGCGGACC 120
 TTCGAATGTA ATATATGTTT GGAGACTGCT CGGGAAGCTG TGGTCAGTGT GTGTGGCCAC 180
 55 CTGTACTGTT GGCCATGTCT TCATCAGTGG CTGGAGACAC GGCCAGAAGC GCAAGAGTGT 240
 CCAGTATGTA AAGCTGGGAT CAGCAGAGAG AAGGTTGTCC CGCTTTATGG GCGAGGGAGC 300
 60 CAGAAGCCCC AGGATCCCAG ATTAAAAACT CCACCCCGCC CCCAGGGCCA GAGACCAGCT 360

	CCGAGAGCA GAGGGGATT CCAGCCATTT GGTGATACCG GGGGCTTCCA CTTCTCATTT	420
5	GGTGTGGTG CTTTTCCTT TGGCTTTTC ACCACCGTCT TCAATGCCCA TGAGCCTTTC	480
	CGCCGGGTA CAGGTGTGA TCTGGACAG GGTCACCCAG CCTCCAGCTG GCAGGATTCC	540
	CTCTCCTGT TTCTGCCAT CTTCTCTTT TTTTGGCTGC TCAGTATTG AGCTATGTCT	600
10	GCTTCCTGCC CACCTCCAGC CAGAGAAGAA TCAGTATTGA GGTCCCTGC TGACCCTTCC	660
	GTA CTCTGG ACCCCCTTGA CCCCTCTATT TCTGTGGCT AAGGCCAGCC CTGGACATTG	720
15	TCCAGGAAGG CCTGGGGAGG AGGAGTGAAG TCTGTGCATA GATGGGAGAG CCTTCGTCTC	780
	AGAGGCTCAC TCAGTAACGT TGTTTAATTC TCTGCCCTGG GGAAGGAGGA TGGATTGAGA	840
	GAATGTCTTT CTCCTCTCCT AAGTCTTTGC TTTCCCTGAT TTCTTGATTT GATCTTCAAA	900
20	GGTGGGCAA GTTCCCTCTG ACTCTTCCCC CACTCCCCAT CTTACTGATT TAATTTAATT	960
	TTTCACTCCC CAGAGTCTAA TATGGATTCT GACTCTTAAG TGCTTCGGCC CCCTCACTAC	1020
25	CTCCTTTAAT ACAAATTCAA TAAAAAGGT GAAATATAAA AAAAAAAAAA AAAAAACYCG	1080
	GGGGGGGCC CGGTCCCCAT TCCCTTGGG GGGT	1114

30

(2) INFORMATION FOR SEQ ID NO: 40:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 602 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

35

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

40

	GGGTCGACCC ACGCGTCCGT CCCAGGCCAC AAGACATTTT CTGCTCGGAA CCTTGTTTAC	60
	TAATTGTCTC TGTGGACAT TTTGTTTCCC GTGCCTTGGG TGTCAAGTTG CAGCTGATAT	120
45	GAATGAATGC TGTCTGTGTG GAACAAGCGT CGCAATGAGG ACTCTCTACA GGACCCGATA	180
	TGGCATCCCT GGATCTATTT GTGATGACTA TATGGCAACT CTTTGCTGTC CTCATTGTAC	240
50	TCTTTGCCAA ATCAAGAGAG ATATCAACAG AAGGAGAGCC ATGCGTACTT TCTAAAAACT	300
	GATGGTGAAA AGCTCTTACC GAAGCAACAA AATTCAGCAG ACACCTCTTC AGCTTGAGTT	360
	CTTCACCATC TTTTGCAACT GAAATATGAT GGATATGCTT AAGTACAACT GATGGCATGA	420
55	AAAAAATCAA ATTTTGTATT TATTATAAAT GAATGTTGTC CCTGAACTTA GCTAAATGGT	480
	GCAACTTAGT TTCTCCTTGC TTTTCATTAT TCGAATTTC TGGCTTATAA ACTTTTATAA	540
60	TTACATTTGA AATATAAACC AAATGAAATA TTTTACTGAA AAAAAAAAAA AAAAAANCCC	600

CA

602

5

(2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERISTICS:

10

- (A) LENGTH: 970 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

GGCAGAGCTT AGGAGAACAG CTCCTTTTGG ATCCCTNTCA AAGGTGATAC CATTTGGCTCC	60
CAGCTTAGAG TAAGAAGCTC TGAGAAGTTG AATGAAGGGT GAGATAGAGA TGCTGAACCC	120
ATTCTTSCAG CTTCTTCTAG TGTGTITATT TCCAGAATGG CCAACACCCC TACATTGATA	180
CATAAACACA TTCCAAGGCC TTGTGTAATA CAAAGTTCAC CGTCCTCCTG GAATAGGAGC	240
CCTGGGTTCCT AGTTCTCACT CTGCCACTGG GGGAAAATCC AATTAAAGTC TGGTTTAGTC	300
AGCTTGGGTC ACCATAGACT GGGTGGCTTA AACAGCAGAC ATTTATTTCT GGTAGTTTCT	360
GGAGGCTACA AATCTAAGAG CAAGTGCCA GCATGGTCAC ATTCTGGTGA GGGSCCTCTT	420
CCTGGCTTGT AGACGGCTGC YTTCTCACCG TGTGCTCACA TAGCCTTTTG TGTGTGTGTG	480
TGTGTGTGTG TGCCTKCTG CAAGCTTCK GATGTCTCTT CTTAGAAGGA CACCAACCCC	540
ATCATGAGAG CCTACTCTC ATGACTTAGC CTAACCCTAA TTACCCTCCA AAGGCCCAT	600
CTCCAAATGC CATCACATTG GAGGGTAGAG CTTCAACATA GGGATTTTGG GGGACACAAA	660
CATTAGTCC ATAACAAAGG CTGTAGTCCT TARTTTCCTT GTCTGTGAAA TGAGAGTGT	720
GAGATTCTTT CTAGCCTTTA TCATTATATA TTCTGTGAGA TGTAGATTG CATTATTTTC	780
GAGTTCGAGT TATATGAAAT GTTTCCTCT ACATTTTCTT GGGCAACTGA GAACTGAATA	840
GGGCTAGGTT TAAATAGAGT TAGGCAGTTA GGCTTATTCT TTTATTTAAT AAGCATTTT	900
GGAGCATCTA CGGTGTTCCA GGAAGTGAAC TGTGTAAAC ATTGGAGCTG TAACAGAGAA	960
CAAAAGAGAC	970

50

(2) INFORMATION FOR SEQ ID NO: 42:

55

(i) SEQUENCE CHARACTERISTICS:

60

- (A) LENGTH: 1002 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

	GAATTCGGCA CGAGCCGAGG TCGGCAGCAC AGAGCTCTGG AGATGAAGAC CCTGTTCCCTG	60
5	GGTGTACACG TCGGCTGGC CGCTGCCCTG TCCTTMACCC TGGRGGAGGA GGATATCACA	120
	GGGACCTGGT ACGTGAAGGC CATGGTGGTC GATAAGACTT TCCGGAGACA GGAGGCCAG	180
10	AAGGTGTCCC CAGTGAAGGT GACAGCCCTG GCGGTGGGA AGTTGGAAGC CACGTTACCC	240
	TTCATGAGGG AGGATCGGTG CATCCAGAAG AAAATCCTGR TGCGGAAGAC GGAGGAGCCT	300
	GGCAAATACA GCGCCTGTGA GCGCCTCCCC CAYTCCCACC CCCACCTCC CCCACGCCA	360
15	ACCCCACTGC ACCAGCCTCC ACAGGTAGAG AGTGCCCGAG CTGCCCTTTT GCCAGGGCCC	420
	CAGCTCTGCC CACCTCCAAG GAGGGGCTGG CCTCTCCTTC CTGGGGGGCT GGTGGCCCTG	480
20	ACATCAGACA CCGGTGTGA CAGGCTTGTC CGCAGTCGAG ATGGACCAGA TCACGCCTGC	540
	CCTCTGGGAG GCGCTAGCCA TTGACACATT GAGGAAGCTG AGGATTGGGA CAAGGAGGCC	600
	AAGGATTAGA TGGGGGAGG AAGCTCATGT ACCTGCAGGA GCTGCCAGG AGGGACCAYT	660
25	ACATCTTTTA CTGCAAGAC CAGCACCATG GGGGCSTGCT CCACATGGGA AAGCTTGTGG	720
	GTAGGAATTC TGATACCAAC CGGGAGGCC TGAAGAATT TAAGAAATTG GTGCAGCGCA	780
30	AGGGACTCTC GGAGGAGGAC ATTTTCACGC CCTGCAGAC GGAAGCTGC GTTCCCGAAC	840
	ACTAGGCAGC CCGGGGTCT GCACCTCCAG AGCCACCCCT ACCACCAGAC ACAGAGCCCG	900
	GACCACCTGG ACCTACCCTC CAGCCATGAC CCTTCCCTGC TCCCACCCAC CTGACTCCAA	960
35	ATAAAGTCCT TCTCCCCAA AAAAAAAAAA AAAAAAATC GA	1002

40 (2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH: 2581 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

50	TGCAAAACCA CTGGACACTG GACAAGTACG GGATCCTGGS CGACGCACGC CTCTTCTTTG	60
	GGCCCCAGCA CCGGSCGTC ATCCTTCGGT TGTCCAACCG CCGGCACTG CGCCTCGTG	120
55	CCAGCTTCTC CCAGCCCTC TTCCAGGCTG TGGSTGCCAT CTGCCGCTC CTCAGCATCC	180
	GGCACCCCGA GGAGCTGTCC CTGCTCCGGG CTCTGAGAA GAAGGAGAAG AAGAAGAAAG	240
	AGAAGGAGCC AGAGGAAGAG CTCTATGACT TGAGCAAGGT TGTCTTGGCT GGGGGCGTGG	300
60	CACCTGCACT GTTCCGGGG ATGCCAGCTC ACTTCTCGGA CAGCGCCAG ACTGAGGCCT	360

	GCTACCACAT GCTGAGCCCG CCCAGCCGC CACCCGACCC CCTCCTGCTC CAGCGTCTGC	420
5	CACGGCCAG CTCCCTGTCA GACAAGACCC AGCTCCACAG CAGGTGGCTG GACTCGTCGC	480
	GGTGTCTCAT GCAGCAGGGC ATCAAGGCCG GGGACGCACT CTGGCTGCGC TTCAAGTACT	540
	ACAGCTTCTT CGATTGGAT CCCAAGACAG ACCCGTGGC GCTGACACAG CTGTATGAGC	600
10	AGGCCCCGTG GGACCTGCTG CTGGAGGAGA TTGACTGCAC CGAGGAGGAG ATGATGGTGT	660
	TTGCCGCCCT GCAGTACCAC ATCAACAAGC TGTCCAGAG CGGGGAGGTG GGGGAGCCCG	720
15	CTGGCACAGA CCCAGGGCTG GACGACCTGG ATGTGGCCCT GAGCAACCTG GAGGTGAAGC	780
	TGGAGGGGTC GGCGCCACA GATGTGCTGG ACAGCCTCAC CACCATCCCA GAGCTCAAGG	840
	ACCATCTCCG AATCTTTCGG CCCCAGAAC TGACCTGAA GGGCTACCGC CAACACTGGG	900
20	TGGTGTCAA GGAGACCACA CTGTCTACT ACAAGAGCCA GGACGAGGCC CTGGGGACC	960
	CCATTACAGA GCTCAACCTC AAGGGCTGTG AGGTGGTTCC CGATGTTAAC GTCTCCGGCC	1020
25	AGAAGTCTG CATTAACCTC CTAGTGCCCT CCCCTGAGGC ATGAGTGAGA TCTACCTGCG	1080
	GTGCCAGGAT GAGCAGCAGT ATGCCCGCTG GATGGCTGGC TGCCGCCTGG CCTCCAAAGG	1140
	CCGCACCATG GCCACAGCA GCTACACCAG CGAGGTGCAG GCCATCCTGG CYTTCCTCAG	1200
30	CCTGCAGCGC ACGGCGAGTG GGGGCCCGGG CAACCACCCC CACGGCCCTG ATGCCTCTGC	1260
	CGAGGGCCTC AACCCCTAGC GCCTCGTTGC CCCCCGTTTC CAGCGAAAGT TCAAGGCCAA	1320
35	GCAGCTCACC CCACGGATCC TGAAGCCCA CCAGAATGTG GCCAGTTGT CGCTGGCAGA	1380
	GGCCAGCTG CGCTTCATCC AGGCCTGGCA GTCCCTGCCC GACTTCGGCA TCTCCTATGT	1440
	CATGGTCAGG TTCAAGGGCA GCAGGAAAGA CGAGATCCTG GGCATCGCCA ACAACCGACT	1500
40	GATCCGCATC GACTTGGCCG TGGGCGACGT GGTCAAGACC TGGCGTTTCA GCAACATGCG	1560
	CCAGTGAAT GTCAACTGGG ACATCCGGCA NGTGGCCATC GAGTTTGATG AACACATCAA	1620
45	TGTGGCCTTC AGCTGCGTGT CTGCCAGCTG CCGAATTGTA CACGAGTATA TCGGGGCTA	1680
	CATTTTCCTG TCGACGCGG AGNNGGCCCG TGGGGAGGAG CTGGATGAAG ACCTCTTCTT	1740
	GCAGCTCACC GGGGGCCATG AGGCCTTCTG AGGGCTGTCT GATTGCCCTT GCCCTGCTCA	1800
50	CCACCTGTC ACAGCCACTC CCAAGCCAC ACCCAGAGG GCTCACTGCC CCACACCCGC	1860
	TCCAGGCAGG CACCCAGCTG GGCATTTTAC CTGCTGTAC TGACTTTGTG CAGGCCAAGG	1920
55	ACCTGGCAGG GCCAGACGCT GTACCATCAC CCAGGCCAGG GATGGGGTG GGGGTCCCTG	1980
	AGCTCATGTG GTGCCCCCTT TCCTTGTCTG AGTGGCTGAG GCTGATACCC CTGACCTATC	2040
	TGCAGTCCCC CAGCACAAA GGAAGACCAG ATGTAGCTAC AGGATGATGA AACATGGTTT	2100
60	CAAACGAGTT CTTCTTGTG ACTTTTAAA ATTCTTTTTT TATAAATTAA TATTTTATTG	2160

TTGGATCCTC CTCCTTCTC TGGAGCTGTG CTTGGGGCTA CTCTGACACT CTGTCTCTTC 2220
5 ATCACCAGCC AAGGAAAGGG GCTTTCCTGA TAAAGACAAG AGTTGGTTAG AGAAAGGGAC 2280
ACCTAAGTCA GTCTAGGGTT GGAAGCTAGG AGAGAGGTGA GGGCAGAAGG GCACAGCTTT 2340
CAGGAACAAG GAATAGGGGC TGGGGTKGTK GTTCTCACGG GTAGGCGGTA CCTGCAGGGC 2400
10 CTCCTTGAAG TACTTGGGAA GGAGGAAGCC ATCAGTATTC CCTGGAGTCA GAATCACCCC 2460
ATTGGCAGAG CGAAGAAGG GTATTCATC TGCTGACAGA GCCAGAGATG TGAATCATGC 2520
15 CCTCCCCGAA GGCAAAGTCA GCTCCTGCTT TGTCCAGACT CACCTGCCAG AGCCAGGGGT 2580
C 2581

20

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:
25 (A) LENGTH: 1764 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

30 GAATTCGGCA CGAGGATGAT ATTCTACTA TTCCTCACC CACTCTGGCT GCAAAAAGGA 60
AGTGCAGGGA AAATGAGTGG GGAGTTCCTG TATGCCAGTC TGTTCATG GAACTATTTT 120
35 TGGAGGAATA AAAAAGTATG CTAGATTATA TTGGTACGAT AGGCATTTTC TTACATTGCA 180
TATAGTCTGC TTTGGCTTTT ACCTGTTGAG GGAAGAATG AGGAGAGGAT AAAAATCATT 240
40 GTATCCCCTA GAGAAGGAAT ATCAAAATCC ATTTAATAAA AAAACTCATA CTAAGAATAA 300
AATTGCATAG TGTTTTATTC TCCITTGTTC ATAATTAAAC ACAAGATATT TTAAATTGTC 360
AAATCAGTTT CTTTATGAAA AAATATGACC TGTATGCCTT TATTCTCTCC TTTCTTCTTT 420
45 CCCACCCGTC GCTTCTTTTC TTCTCTTCTT TTTTCTTTT CCTGTCTCTC TGAATAAATG 480
AAGAACAAC ATTTGATAAA AGCCACTGCC AATTCATGAT AAAAATTCAC AGCAAAGTTG 540
50 GTACAGAAAA GAACTTTCTC TGGGTGTAA AGGGTGCCTC TCCCATGCTC TCAGCAAATA 600
TTTAATGATG AAATCTTATT AATAATCACT GTAGAACCAA GAATTAAACT AGTATACCCA 660
CTGTCTGGC TTGTAATCAA CAATATACAG GTGGTTCTAG CCAGTGCAAT AAGACAAGAG 720
55 AAACAAAAAT GTTATAAGGC CTGGAAGA TGAAACAAAC TGTATTTCAC AAAATACTGT 780
CTATACAGAA TGCTCAGTGT CTTTTTTTCT TTTCTTTTTT TTAAACTTTA GTGAGATACC 840
CTTCTGCCCT ATCTTAAAT CACGTGGTGG GGGGTGGTGT CTGCACTTGA AACAGGACAC 900
60

	TTGGTTCTCTG GGTTPAGCAT TGACCTTGCC AGCTTGGTYT GGCAGCTGAG TTGTTGGACT	960
	AGGAAGCGTC CYTGCAGGTT GTGKTCTGKT ACCTCTCTGT AAAGCCTGAA AGCATCCTAC	1020
5	SATTGCATTT GCTAGKTCTC AGTAGAGCTA TTTAACAAGA ATCTGGAAAC ATTTTYCCTG	1080
	AGGGCTCTCT TTAGACAGCA GTAAAATGTA GCTGGAGACA TATTGAGTAA ATGGAAAAGA	1140
10	AAAATCTAAT GAGGCCAGGA ATTTTITTTAA TCTTCTATTTC TCACAGAAGG CCTCAAGGAG	1200
	AACACCATAA TTCATATTTT ACTCAKGTGG GTTAGGCATA AAGCCTCCCC CATAGATCCA	1260
	ATAACCTGTA RGTGTYCTGG TTTTGAAATT GCACCTGCTT ACATKGCTGG ATCNTAGCAC	1320
15	TAAWTCACAC RGCAACGGCT TCTGGTTCAA TKGTTTCATTA CTGGGAATG TCAGATTGCC	1380
	AGAGAGCAGC CTGATGTTTA CATCCAATCG GCAATGCCTT AGGAAATCAG TTTTAATTAC	1440
20	AATCTCACGT AGCAGCACTG CACTCAACCT TCAGAGAGGC TGGGATTTGT GTTGAACCTA	1500
	CATCTTATAG CTGTGCAGAA AATGCCCTGTC CGACTGGGTC ATGCAAAATG GACAGCAAAG	1560
	TCAGCAGAAC CTTAGAAAAG ATGACACAGC AAGTGAACA CAGCTGGATC ATCCCCCGTC	1620
25	CTGTCAAGCG TGCAGTGCTC TCTGGCCCCT TTTTAAAACA AGGGAACCCA GTTGGCGTTT	1680
	GCCTTTCAGC TTCCCCATTC TGATATAAAA ATCTGTGACC CAGCAGCTTT AACCATAAAA	1740
30	AAAAAAAAA AAAAAAAAAAC TCGA	1764

35 (2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 796 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

45	ACCTTCTTCC ATGTTTAGTC CCTTGGGCTC TGCTACCTC CTGCTGGAGG TGAGAGCATC	60
	CTGTGTGCAA CCAGAGATGC CCTCTGGCTT TCAGACCTGC CTGCTTTTCA CCTCAGCCC	120
	TTTCTCACTC AGCAAAATG TGGGGGTCCC TAGTCAGCAG CTCCCTGGGC AGCTCTCTGA	180
50	GCAAGTGGT CTCTGTGGTC ATGAAGGAGA GCCGGCTAGG ACAGTGCCGG AAACCTCAGCT	240
	GCCTCTCCCC TTCAACTCAG CTGGCCCCCC GCACCTGAAG TGCACAGGAG CCGGGAAGAG	300
55	AGTCTGGAGC CCACCCCGA GGCAGCACA GGAGGTGTCT YTGAGCTGG TGTCTGCM	360
	CCCYTGCAGG CAGMACAGT CCCGGGCATT YTCYTTAGCC ACAGACAGAA CAGCCAGTGC	420
	CAGAGTCTGC TGTGCTTCC CCTTTAAGCA CACTCATTC AACCACCCGA GGAGGCCAGA	480
60	GGTGCAGGGA GCATGGGCTG TCGTTCCCCT TTAAGCACAC TCATTCACCA CACCCGAGGA	540

5 GGCCAGAAGT GCAGGGAGCA TGGGCTGGGT GCACCTCCGC AGGAGAGAAG GCTGAGCCAC 600
 CGCCGTCCCG GGAGCCCGGC TCCCAGGCCT CTCGTTTTCC CCTACCTCCC TAAGACTTTT 660
 CTGTCACTCT CTGGCCATG AAAGGCTTCT GTTCCTTAAA GTGCTGTTAC ACTCTCCTTT 720
 CCCAGGATGC AGCAAGCCAA AACAGTACCA CTGCACGTCA GCCTGGGTGA CAGAGTGAGA 780
 10 CCTATCTTA AAAAAA 796

15 (2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1705 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

25 TGGCCATGGA AGCGCTAGAA GGTTTAGATT TTGAAACAGC AAAGAAGGAT TTCCTTGGAT 60
 CTGGAGACCC CAAAGAAACA AAGATGCTAA TCACCAAACA GGCTGACTGG GCCAGAAATA 120
 TCAAGGAGCC CAAAGCCGCC GTGGAGATGT ACATCTCAGC AGGAGAGCAC GTCAAGGCCA 180
 30 TCGAGATCTG TGGTGACCAT GGCTGGGTTG ACATGTTGAT CGACATCGCC CGCAAACCTGG 240
 ACAAGGCTGA GCGCGAGCCC CTGCTGCTGT GCGCTACCTA CCTCAAGAAG CTGGACAGCC 300
 35 CTGGCTATGC TGCTGAGACC TACCTGAAGA TGGGTGACCT CAAGTCCCTG GTGCAGCTGC 360
 AGTGGAGACC CAGCGCTGGG ATGAGGCCTT TGCTTTGGGT GAGAAGCATC CTGAGTTTAA 420
 GGATGACATC TACATGCCGT ATGCTCAGTG GCTAGCAGAG AACGATCGCT TTGAGGAAGC 480
 40 CCAGAAAGCG TTCCACAAGG CTGGGCGACA GAGAGAAGCG GTCCAGGTGC TGGAGCAGCT 540
 CACAAACAAT GCCGTGGCGG AGAGCAGGTT TAATGATGCT GCCTATTATT ACTGGATGCT 600
 45 GTCCATGCAG TGCTCGATA TAGCTCAAGA TCCTGCCCAG AAGGACACAA TGCTTGCCAA 660
 GTTCTACCAC TTCCAGCGTT TGGCAGAGCT GTACCATGGT TACCATGCCA TCCATCGCCA 720
 CACGGAAGAT CCGTTCAGTG TCCATCGTCC TGAAACTCTT TTCAACATCT CCAGGTTCTT 780
 50 GCTGCACAGC CTGCCCCAAG ACACCCCTC GGGCATCTCT AAAGTGAAAA TACTCTTCAC 840
 CTTGGCCAAG CAGAGCAAGG CCCTCGGTGC CTACAGGCTG GCCCGGCACG CCTATGACAA 900
 55 GCTGCGTGGC CTGTACATCC CTGCCAGATT CCAAAAGTCC ATTGAGCTGG GTACCCTGAC 960
 CATCCCGGCC AAGCCCTTCC ACGACAGTGA GGAGTTGGTG CCCTTGCTGT ACCGCTGCTC 1020
 60 CACCAACAAC CCGCTGCTCA ACAACCTGGG CAACGTCTGC ATCAACTGCC GCCAGCCCTT 1080

CATCTTCTCC GCGCTCTCCT ACGACGTGCT ACACCTGGTT GAGTTCTACC TGGAGGAAGG 1140
GATCACTGAT GAAGAAGCCA TCTCCCTCAT CGACCTGGAG GTGCTGAGAC CCAAGCGGGA 1200
5 TGACAGACAG CTAGAGATTT GCAAACAACA GCTCCCAGAT TCTTGCGGCT AGTGGGAGAC 1260
CAAGGGACTC CATCGGAGAT NAGGACCCGT TCACAGCTAA GCTRAGCTTT GAGCAAGGTG 1320
10 GCTCARAGTT CGTGCCAGTG GTGGTGAGCC GGCTGGTGCT GCGCTCCATG AGCCGCCGGG 1380
ATGTCTCAT CAAGCGATGG CCCCCACCC TGAGGTGGCA ATACTTCCGC TCACTGCTGC 1440
CTGACGCCTC CATTACCATG TGCCCTCCT GCTTCCAGAT GTTCCATTCT GAGGACTATG 1500
15 AGTTGCTGGT GCTTCAGCAT GGCTGCTGCC CCTACTGCCG CAGGTGCAAG GATGACCTG 1560
GCCCATGACC AGCATCCTGG GGAAGGCTG CACCTCTGC CCGCCTTGGG GTCTGCTGGG 1620
CTGTGAAGGA GAATAAAGAG TTAAACTGTC AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1680
20 AAAAAAAAAA AAAAAAAAAA AAANA 1705

25

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:
30 (A) LENGTH: 981 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

TCGGCAGCAC AGAGCTCTGG AGATGAAGAC CCTGTTCTTG GGTGTCACGC TCGGCCTGGC 60
GCTGCCCTGT CTTTCAACCT GGRGGAGGAG GATATCACAG GGACCTGGTA CGTGAAGGCC 120
40 ATGGTGGTGC ATAAGACTTT CCGGAGACAG GAGGCCAGA AGGTGTCCCC AGTGAAGGTG 180
ACAGCCCTGG GCGGTGGGAA GTTGAAGCC ACGTTACCT TCATGAGGGA GGATCGGTGC 240
ATCCAGAAGA AAATCCTGRT GCGGAAGACG GAGGAGCCTG GCAAATACAG CGCCTGTGAG 300
45 CCCCCTCCCC AYTCCACCC CCACCTCCC CCACCGCCAA CCCCAGTGCA CCAGCCTCCA 360
CAGGTAGAGA GTGCCCAGGC TGCCCTTTTG CCAGGGCCCC AGCTCTGCCC ACCTCCAAGG 420
50 AGGGGCTGGC CTCTCCTTCC TGGGGGGCTG GTGGCCCTGA CATCAGACAC CGGGTGTGAC 480
AGGCTTGTC GCAGTCGAGA TGGACCAGAT CACGCCTGCC CTCTGGGAGG CCCTAGCCAT 540
TGACACATG AGGAAGCTGA GGATTGGGAC AAGGAGGCCA AGGATTAGAT GGGGGCAGGA 600
55 AGCTCATGTA CCTGCAGGAG CTGCCCAGGA GGGACCAYTA CATCTTTTAC TGCAAAGACC 660
AGCACCATGG GGGCSTGCTC CACATGGGAA AGCTTGTTGG TAGGAATTCT GATACCAACC 720
60 GGGAGGCCCT GGAAGAATTT AAGAAATTGG TGCAGCGCAA GGGACTCTCG GAGGAGGACA 780

145

5 TTTTCACGCC CCTGCAGACG GGAAGCTGCR TTCCCGAACA CTAGGCAGCC CCCGGGTCTG 840
 CACCTCCAGA GCCCACCTA CCACCAGACA CAGAGCCCGG ACCACCTGGA CCTACCCTCC 900
 AGCCATGACC CTTCCTGCT CCCACCCACC TGA CTCCAAA TAAAGTCCTT CTCCCCCAA 960
 AAAAAAAAAA AAAAACTCG A 981

10

(2) INFORMATION FOR SEQ ID NO: 48:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 146 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

20

Met His Tyr Gln Met Ser Val Thr Leu Lys Tyr Glu Ile Lys Lys Leu
 1 5 10 15

25

Ile Tyr Val His Leu Val Ile Trp Leu Leu Leu Val Ala Lys Met Ser
 20 25 30

Val Gly His Leu Arg Leu Leu Ser His Asp Gln Val Ala Met Pro Tyr
 35 40 45

30

Gln Trp Glu Tyr Pro Tyr Leu Leu Ser Ile Leu Pro Ser Leu Leu Gly
 50 55 60

35

Leu Leu Ser Phe Pro Arg Asn Asn Ile Ser Tyr Leu Val Leu Ser Met
 65 70 75 80

Ile Ser Met Gly Leu Phe Ser Ile Ala Pro Leu Ile Tyr Gly Ser Met
 85 90 95

40

Glu Met Phe Pro Ala Ala Gln Pro Ser Thr Ala Met Ala Arg Pro Thr
 100 105 110

Val Ser Ser Leu Val Phe Leu Pro Phe Pro Ser Cys Thr Trp Cys Trp
 115 120 125

45

Cys Trp Gln Cys Lys Cys Met Pro Gly Ser Cys Thr Thr Ala Arg Ser
 130 135 140

Ser Xaa
 145

50

(2) INFORMATION FOR SEQ ID NO: 49:

55

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 312 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

60

Met Asn Ser Val Val Ser Leu Leu Leu Ile Leu Glu Pro Asp Lys Gln
 1 5 10 15
 5 Glu Ala Leu Ile Glu Ser Leu Cys Glu Lys Leu Val Lys Phe Arg Glu
 20 25 30
 Gly Glu Arg Pro Ser Leu Arg Leu Gln Leu Leu Ser Asn Leu Phe His
 35 40 45
 10 Gly Met Asp Lys Asn Thr Pro Val Arg Tyr Thr Val Tyr Cys Ser Leu
 50 55 60
 Ile Lys Val Ala Ala Ser Cys Gly Ala Ile Gln Tyr Ile Pro Thr Glu
 65 70 75 80
 15 Leu Asp Gln Val Arg Lys Trp Ile Ser Asp Trp Asn Leu Thr Thr Glu
 85 90 95
 Lys Lys His Thr Leu Leu Arg Leu Leu Tyr Glu Ala Leu Val Asp Cys
 100 105 110
 Lys Lys Ser Asp Ala Ala Ser Lys Val Met Val Glu Leu Leu Gly Ser
 115 120 125
 25 Tyr Thr Glu Asp Asn Ala Ser Gln Ala Arg Val Asp Ala His Arg Cys
 130 135 140
 Ile Val Arg Ala Leu Lys Asp Pro Asn Ala Phe Leu Phe Asp His Leu
 145 150 155 160
 30 Leu Thr Leu Lys Pro Val Lys Phe Leu Glu Gly Glu Leu Ile His Asp
 165 170 175
 Leu Leu Thr Ile Phe Val Ser Ala Lys Leu Ala Ser Tyr Val Lys Phe
 180 185 190
 Tyr Gln Asn Asn Lys Asp Phe Ile Asp Ser Leu Gly Leu Leu His Glu
 195 200 205
 40 Gln Asn Met Ala Lys Met Arg Leu Leu Thr Phe Met Gly Met Ala Val
 210 215 220
 Glu Asn Lys Glu Ile Ser Phe Asp Thr Met Gln Gln Glu Leu Gln Ile
 225 230 235 240
 45 Gly Ala Asp Asp Val Glu Ala Phe Val Ile Asp Ala Val Arg Thr Lys
 245 250 255
 Met Val Tyr Cys Lys Ile Asp Gln Thr Gln Arg Lys Val Val Val Ser
 260 265 270
 His Ser Thr His Arg Thr Phe Gly Lys Gln Gln Trp Gln Gln Leu Tyr
 275 280 285
 55 Asp Thr Leu Asn Ala Trp Lys Gln Asn Leu Asn Lys Val Lys Asn Ser
 290 295 300
 Leu Leu Ser Leu Ser Asp Thr Xaa
 305 310
 60

(2) INFORMATION FOR SEQ ID NO: 50:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 47 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

Gly Gly Cys Pro Arg Arg Arg Leu Val Leu Tyr Cys Leu Phe Gly Ser
 1 5 10 15

15

Ala Gly Gly Gly Arg Ile His Ser Glu Ala Trp Phe Pro Lys Ala Trp
 20 25 30

Pro Glu Ala Glu Lys Trp Leu Phe Ala Glu Leu Leu Arg Gly Xaa
 35 40 45

20

(2) INFORMATION FOR SEQ ID NO: 51:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 467 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

30

Met Leu Ser Arg Pro Gln Pro Pro Pro Asp Pro Leu Leu Leu Gln Arg
 1 5 10 15

Leu Pro Arg Pro Ser Ser Leu Ser Asp Lys Thr Gln Leu His Ser Arg
 20 25 30

35

Trp Leu Asp Ser Ser Arg Cys Leu Met Gln Gln Gly Ile Lys Ala Gly
 35 40 45

40

Asp Ala Leu Trp Leu Arg Phe Lys Tyr Tyr Ser Phe Phe Asp Leu Asp
 50 55 60

Pro Lys Thr Asp Pro Val Arg Leu Thr Gln Leu Tyr Glu Gln Ala Arg
 65 70 75 80

45

Trp Asp Leu Leu Leu Glu Glu Ile Asp Cys Thr Glu Glu Glu Met Met
 85 90 95

Val Phe Ala Ala Leu Gln Tyr His Ile Asn Lys Leu Ser Gln Ser Gly
 100 105 110

50

Glu Val Gly Glu Pro Ala Gly Thr Asp Pro Gly Leu Asp Asp Leu Asp
 115 120 125

55

Val Ala Leu Ser Asn Leu Glu Val Lys Leu Glu Gly Ser Ala Pro Thr
 130 135 140

Asp Val Leu Asp Ser Leu Thr Thr Ile Pro Glu Leu Lys Asp His Leu
 145 150 155 160

60

Arg Ile Phe Arg Pro Arg Lys Leu Thr Leu Lys Gly Tyr Arg Gln His

					165					170						175
					Trp Val Val Phe Lys Glu Thr Thr Leu Ser Tyr Tyr Lys Ser Gln Asp											
					180					185						190
5					Glu Ala Pro Gly Asp Pro Ile Gln Gln Leu Asn Leu Lys Gly Cys Glu											
					195					200					205	
					Val Val Pro Asp Val Asn Val Ser Gly Gln Lys Phe Cys Ile Lys Leu											
10					210					215					220	
					Leu Val Pro Ser Pro Glu Gly Met Ser Glu Ile Tyr Leu Arg Cys Gln											
					225									235		240
					Asp Glu Gln Gln Tyr Ala Arg Trp Met Ala Gly Cys Arg Leu Ala Ser											
15					245					250						255
					Lys Gly Arg Thr Met Ala Asp Ser Ser Tyr Thr Ser Glu Val Gln Ala											
20					260					265					270	
					Ile Leu Ala Phe Leu Ser Leu Gln Arg Thr Gly Ser Gly Gly Pro Gly											
					275					280					285	
					Asn His Pro His Gly Pro Asp Ala Ser Ala Glu Gly Leu Asn Pro Tyr											
25					290					295					300	
					Gly Leu Val Ala Pro Arg Phe Gln Arg Lys Phe Lys Ala Lys Gln Leu											
					305									315		320
					Thr Pro Arg Ile Leu Glu Ala His Gln Asn Val Ala Gln Leu Ser Leu											
30					325					330						335
					Ala Glu Ala Gln Leu Arg Phe Ile Gln Ala Trp Gln Ser Leu Pro Asp											
					340					345					350	
35					Phe Gly Ile Ser Tyr Val Met Val Arg Phe Lys Gly Ser Arg Lys Asp											
					355					360					365	
					Glu Ile Leu Gly Ile Ala Asn Asn Arg Leu Ile Arg Ile Asp Leu Ala											
40					370					375					380	
					Val Gly Asp Val Val Lys Thr Trp Arg Phe Ser Asn Met Arg Gln Trp											
					385									395		400
					Asn Val Asn Trp Asp Ile Arg Gln Val Ala Ile Glu Phe Asp Glu His											
					405					410						415
					Ile Asn Val Ala Phe Ser Cys Val Ser Ala Ser Cys Arg Ile Val His											
50					420					425					430	
					Glu Tyr Ile Gly Gly Tyr Ile Phe Leu Ser Thr Arg Glu Arg Ala Arg											
					435					440					445	
					Gly Glu Glu Leu Asp Glu Asp Leu Phe Leu Gln Leu Thr Gly Gly His											
55					450					455					460	
		</														

(2) INFORMATION FOR SEQ ID NO: 52:

5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 83 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

10 Met Arg Pro Gly Arg Gly Ala Gly Thr Pro Gly Arg Pro Gly Arg Gly
 1 5 10 15

Arg Gly Leu Ala Ala Thr Cys Ser Leu Ser Ser Pro Ser His Leu Leu
 20 25 30

15 Pro Thr Leu Leu His Thr Phe Ser Phe Ser Leu Pro Pro Pro Ser Pro
 35 40 45

20 Ala Ala Pro Arg Gln Pro Ser Pro Pro Ala Leu Leu Leu Pro Gly Pro
 50 55 60

Gln Lys Pro Arg Pro Gly Asp Pro Thr Tyr Thr Gly Ala Leu Thr Asp
 65 70 75 80

25 Trp Ser Xaa

30 (2) INFORMATION FOR SEQ ID NO: 53:

35 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 63 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

40 Met Phe Leu Val Phe Phe Leu Ser Phe Phe Ser His Ser Ile Ser Ala
 1 5 10 15

Leu Thr Leu Val Cys Ser Gln Gly Gly Lys Ala Asp Met Asn Leu Leu
 20 25 30

45 Ser Trp Asp Phe Arg Pro His Trp Leu Glu Gly Ile Arg Phe Leu Leu
 35 40 45

Gly Trp Gly Gln Ala Leu Met Ala Gly Leu Phe Pro Trp Leu Xaa
 50 55 60

50

(2) INFORMATION FOR SEQ ID NO: 54:

55 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 124 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

60 Met Arg Gly Ser Trp His Arg Ser Pro Leu Pro Ala Val Val Leu Pro

150

1 5 10 15
 Ser Val Leu Gln Thr Ala Leu Ser Pro Leu Ala Leu Cys Gln Ala Trp
 20 25 30
 5 Arg Arg Ala Val Pro His Gly Val Pro Ser Gln Arg Leu Arg Asn Gln
 35 40 45
 10 Glu Ala Ser Leu Val Pro Lys Gly Val Pro Arg Ala Trp Tyr Pro Gly
 50 55 60
 Pro Leu Gln Asn Gly Leu Trp Thr His Leu Glu Lys Gly Glu Leu Leu
 65 70 75 80
 15 Gly Leu Lys Pro Thr Pro Gly Gly Leu Leu Leu Arg Ser Phe Trp
 85 90 95
 Asp Pro His Pro Ser Arg Pro Phe Leu Cys Thr Leu Leu Pro Pro Pro
 100 105 110
 20 Leu Xaa Ile Phe Pro Pro Leu Arg Cys Ser Ala Xaa
 115 120

25

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 180 amino acids
 30 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

35 Met Thr Ser Ala Gly Pro Val Xaa Leu Phe Leu Leu Val Ser Ile Ser
 1 5 10 15
 Thr Ser Val Ile Leu Met Gln His Leu Leu Xaa Ala Ser Tyr Cys Asp
 20 25 30
 40 Leu Leu His Lys Ala Ala Ala His Leu Gly Cys Trp Gln Lys Val Asp
 35 40 45
 Pro Ala Leu Cys Ser Asn Val Leu Gln His Pro Trp Thr Glu Glu Cys
 50 55 60
 45 Met Trp Pro Gln Gly Val Leu Val Lys His Ser Lys Asn Val Tyr Lys
 65 70 75 80
 50 Ala Val Gly Xaa Xaa Xaa Val Ala Ile Pro Ser Asp Val Ser His Phe
 85 90 95
 Arg Phe Xaa Phe Phe Phe Ser Lys Pro Leu Arg Ile Leu Asn Ile Leu
 100 105 110
 55 Leu Leu Leu Glu Gly Ala Val Ile Val Tyr Gln Leu Tyr Ser Leu Met
 115 120 125
 Ser Ser Glu Lys Trp His Gln Thr Ile Ser Leu Ala Leu Ile Leu Phe
 130 135 140
 60

151

Ser Asn Tyr Tyr Ala Phe Phe Lys Leu Leu Arg Asp Arg Leu Val Leu
145 150 155 160

5 Gly Lys Ala Tyr Ser Tyr Ser Ala Ser Pro Gln Arg Asp Leu Asp His
165 170 175

Arg Phe Ser Xaa
180

10

(2) INFORMATION FOR SEQ ID NO: 56:

15 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 287 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

20 Met Pro Leu Phe Lys Leu Tyr Met Val Met Ser Ala Cys Phe Leu Ala
1 5 10 15

Ala Gly Ile Phe Trp Val Ser Ile Leu Cys Arg Asn Thr Tyr Ser Val
20 25 30

25 Phe Lys Ile His Trp Leu Met Ala Ala Leu Ala Phe Thr Lys Ser Ile
35 40 45

30 Ser Leu Leu Phe His Ser Ile Asn Tyr Tyr Phe Ile Asn Ser Gln Gly
50 55 60

Pro Pro His Arg Arg Pro Cys Arg His Val Leu His Arg Thr Pro Ala
65 70 75 80

35 Glu Gly Arg Pro Pro Leu His His His Arg Pro Asp Trp Leu Arg Leu
85 90 95

Gly Phe Ile Lys Tyr Val Leu Ser Asp Lys Glu Lys Lys Val Phe Gly
100 105 110

40 Ile Val Ile Pro Met Gln Val Leu Ala Asn Val Ala Tyr Ile Ile Ile
115 120 125

45 Glu Ser Arg Glu Glu Gly Ala Thr Asn Tyr Val Leu Trp Lys Glu Ile
130 135 140

Leu Phe Leu Val Asp Leu Ile Cys Cys Gly Ala Ile Leu Phe Pro Val
145 150 155 160

50 Val Trp Ser Ile Arg His Leu Gln Asp Ala Ser Gly Thr Asp Gly Lys
165 170 175

Val Ala Val Asn Leu Ala Lys Leu Lys Leu Phe Arg His Tyr Tyr Val
180 185 190

55 Met Val Ile Cys Tyr Val Tyr Phe Thr Arg Ile Ile Ala Ile Leu Leu
195 200 205

60 Gln Val Ala Val Pro Phe Gln Trp Gln Trp Leu Tyr Xaa Leu Leu Val
210 215 220

152

Glu Gly Ser Thr Leu Ala Phe Phe Val Leu Thr Gly Tyr Lys Phe Gln
 225 230 235 240
 5 Pro Thr Gly Asn Asn Pro Tyr Leu Gln Leu Pro Gln Glu Asp Glu Glu
 245 250 255
 Asp Val Gln Met Glu Gln Val Met Thr Asp Ser Gly Phe Arg Glu Gly
 260 265 270
 10 Leu Ser Lys Val Asn Lys Thr Ala Ser Gly Arg Glu Leu Leu Xaa
 275 280 285

15

(2) INFORMATION FOR SEQ ID NO: 57:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

20 Met Pro Met Val Phe Leu Leu Leu Phe Asn Leu Met Ser Trp Leu Ile
 25 1 5 10 15

Arg Asn Ala Arg Val Ile Leu Arg Ser Leu Asn Leu Lys Arg Asp Gln
 20 25 30

30 Val, Xaa

35

(2) INFORMATION FOR SEQ ID NO: 58:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

40 Met Lys Ile Val Val Leu Leu Pro Leu Phe Leu Leu Ala Thr Phe Pro
 45 1 5 10 15

Arg Lys Leu Gln Thr Cys Leu Xaa
 20

50

(2) INFORMATION FOR SEQ ID NO: 59:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 47 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

55 Met Ser Gly Gly Glu Gly Ala Ala Leu Pro Ile Leu Leu Leu Leu
 60 1 5 10 15

Ala Leu Arg Gly Thr Phe His Gly Ala Arg Pro Gly Gly Gly Ala Ser
 20 25 30
 5 Gly Ile Trp Cys Leu Leu Leu Pro Glu Gln Glu Pro Pro Val Xaa
 35 40 45

10 (2) INFORMATION FOR SEQ ID NO: 60:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 114 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly
 1 5 10 15
 20 Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly
 20 25 30
 25 Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys
 35 40 45
 Cys Met Asp Cys Ala Ser Cys Arg Ala Arg Pro His Ser Asp Phe Cys
 50 55 60
 30 Leu Gly Cys Ala Ala Ala Pro Pro Ala Pro Phe Arg Leu Leu Trp Pro
 65 70 75 80
 Ile Leu Gly Gly Ala Leu Ser Leu Thr Phe Val Leu Gly Leu Leu Ser
 85 90 95
 35 Gly Phe Leu Val Trp Arg Arg Cys Arg Arg Glu Arg Ser Ser Pro Pro
 100 105 110
 40 Pro Xaa

45 (2) INFORMATION FOR SEQ ID NO: 61:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

Met Val Cys Ile Leu Val Leu Thr Leu Val Ser Tyr Ser Ser Leu Val
 1 5 10 15
 55 Asn Ser Pro Leu Pro Phe Val His Leu Xaa Val Gly Ile Ser Ala Xaa
 20 25 30
 60

(2) INFORMATION FOR SEQ ID NO: 62:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 81 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

Met Thr Gly Gly Phe Leu Ser Cys Ile Leu Gly Leu Val Leu Pro Leu
 1 5 10 15

15

Ala Tyr Xaa Ser Ser Leu Thr Trp Cys Trp Trp Arg Trp Gly Leu Pro
 20 25 30

Xaa Pro Ala Gly Pro Pro Arg Cys Thr Pro Gly Cys Asn Ala Ser Gly
 35 40 45

20

Ala Gly Arg Gly Pro Ser Pro Gly Pro Pro Gly Gly Glu Leu His Thr
 50 55 60

Pro Ala Ser Arg Asp Pro Gly Pro Gly Ala Glu Trp Arg Gly Thr Ser
 65 70 75 80

25

Xaa

30

(2) INFORMATION FOR SEQ ID NO: 63:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 104 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

Met Ala Ala Pro Val Asp Leu Glu Leu Lys Lys Ala Phe Thr Glu Leu
 1 5 10 15

Gln Ala Lys Val Ile Asp Thr Gln Gln Lys Val Lys Leu Ala Asp Ile
 20 25 30

45

Gln Ile Glu Gln Leu Asn Arg Thr Lys Lys His Ala His Leu Thr Asp
 35 40 45

Thr Glu Ile Met Thr Leu Val Asp Glu Thr Asn Met Tyr Glu Gly Val
 50 55 60

50

Gly Arg Met Phe Ile Leu Gln Ser Lys Glu Ala Ile His Ser Gln Leu
 65 70 75 80

Leu Glu Lys Gln Lys Ile Ala Glu Glu Lys Ile Lys Glu Leu Glu Gln
 85 90 95

55

Lys Lys Ser Tyr Leu Glu Arg Arg
 100

60

(2) INFORMATION FOR SEQ ID NO: 64:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 146 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

10 Met Pro Ser Gly Phe Gln Thr Cys Leu Leu Phe Thr Leu Ser Pro Phe
 1 5 10 15

Ser Leu Ser Lys Ile Val Gly Val Pro Ser Gln Gln Leu Pro Gly Gln
 20 25 30

15 Leu Ser Glu Gln Gly Gly Leu Cys Gly His Glu Gly Glu Pro Ala Arg
 35 40 45

20 Thr Val Pro Glu Thr Gln Leu Pro Leu Pro Phe Asn Ser Ala Gly Pro
 50 55 60

Pro His Leu Lys Cys Thr Gly Ala Gly Lys Arg Val Trp Ser Pro Pro
 65 70 75 80

25 Arg Arg Ala Ala Gln Glu Val Ser Leu Gln Leu Val Ser Cys His Pro
 85 90 95

Cys Arg Gln His Thr Ser Arg Ala Phe Ser Leu Ala Thr Asp Arg Thr
 100 105 110

30 Ala Ser Ala Arg Val Cys Cys Arg Ser Pro Leu Ser Thr Leu Ile His
 115 120 125

35 His Thr Arg Gly Gly Gln Arg Cys Arg Glu His Gly Leu Ser Leu Pro
 130 135 140

Leu Xaa
 145

40

(2) INFORMATION FOR SEQ ID NO: 65:

45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 31 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

50 Met Ala Ile Leu Met Leu Leu Ala Gly Ser Pro Cys Thr Leu Ser Phe
 1 5 10 15

Ser Thr Asp Thr Gly Ser Ser Ala Pro Gly Pro Lys Ile Pro Xaa
 20 25 30

55

(2) INFORMATION FOR SEQ ID NO: 66:

60 (i) SEQUENCE CHARACTERISTICS:

156

(A) LENGTH: 260 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

5

Met Asp Pro Gln Gly Gln Thr Leu Leu Leu Phe Leu Phe Val Asp Phe
 1 5 10 15

10

His Ser Ala Phe Pro Val Gln Gln Met Glu Ile Trp Gly Val Tyr Thr
 20 25 30

Leu Leu Thr Thr His Leu Asn Ala Ile Leu Val Glu Ser His Ser Val
 35 40 45

15

Val Gln Gly Ser Ile Gln Phe Thr Val Asp Lys Val Leu Glu Gln His
 50 55 60

20

His Gln Ala Ala Lys Ala Gln Gln Lys Leu Gln Ala Ser Leu Ser Val
 65 70 75 80

Ala Val Asn Ser Ile Met Ser Ile Leu Thr Gly Ser Thr Arg Ser Ser
 85 90 95

25

Phe Arg Lys Met Cys Leu Gln Thr Leu Gln Ala Ala Asp Thr Gln Glu
 100 105 110

Phe Arg Thr Lys Leu His Lys Val Phe Arg Glu Ile Thr Gln His Gln
 115 120 125

30

Phe Leu His His Cys Ser Cys Glu Val Lys Gln Leu Thr Leu Glu Lys
 130 135 140

35

Lys Asp Ser Ala Gln Gly Thr Glu Asp Ala Pro Asp Asn Ser Ser Leu
 145 150 155 160

Glu Leu Leu Ala Asp Thr Ser Gly Gln Ala Glu Asn Lys Arg Leu Lys
 165 170 175

40

Arg Gly Ser Pro Arg Ile Glu Glu Met Arg Ala Leu Arg Ser Ala Arg
 180 185 190

Ala Pro Ser Pro Ser Glu Ala Ala Pro Arg Arg Pro Glu Ala Thr Ala
 195 200 205

45

Ala Pro Leu Thr Pro Arg Gly Arg Glu His Arg Glu Ala His Gly Arg
 210 215 220

50

Ala Leu Ala Pro Gly Arg Ala Ser Leu Gly Ser Arg Leu Glu Asp Val
 225 230 235 240

Leu Trp Leu Gln Glu Val Ser Asn Leu Ser Glu Trp Leu Ser Pro Ser
 245 250 255

55

Pro Gly Pro Xaa
 260

60

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

Met Ala Ala Ala Cys Gly Pro Gly Ala Ala Gly Thr Ala Cys Ser Ser
 1 5 10 15

10 Ala Cys Ile Cys Phe Cys Xaa
 20

15 (2) INFORMATION FOR SEQ ID NO: 68:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

Met His Ala Leu Ile Leu Gln Phe Ile Phe Ser Leu Cys Met Tyr Ile
 1 5 10 15

25 Ser Leu Phe Ser Ala Ala Arg Phe Leu Phe Xaa
 20 25

30 (2) INFORMATION FOR SEQ ID NO: 69:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

Leu Leu Leu Leu Cys Phe Cys Cys His Pro Thr His Leu Gln Gly Xaa
 1 5 10 15

Trp Ala Leu Asp Leu Gly Leu Phe Pro Phe Asn Cys Xaa
 20 25

45 (2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 216 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

55 Met Tyr Leu Ser Ile Ile Phe Leu Ala Phe Val Ser Ile Asp Arg Cys
 1 5 10 15

Leu Gln Leu Thr His Ser Cys Lys Ile Tyr Arg Ile Gln Glu Pro Gly
 20 25 30

60

	Phe	Ala	Lys	Met	Ile	Ser	Thr	Val	Val	Trp	Leu	Met	Val	Leu	Leu	Ile
	35						40			45						
5	Met	Val	Pro	Asn	Met	Met	Ile	Pro	Ile	Lys	Asp	Ile	Lys	Glu	Lys	Ser
	50						55			60						
	Asn	Val	Gly	Cys	Met	Glu	Phe	Lys	Lys	Glu	Phe	Gly	Arg	Asn	Trp	His
	65			70						75			80			
10	Leu	Leu	Thr	Asn	Phe	Ile	Cys	Val	Ala	Ile	Phe	Leu	Asn	Phe	Ser	Ala
				85						90			95			
	Ile	Ile	Leu	Ile	Ser	Asn	Cys	Leu	Val	Ile	Arg	Gln	Leu	Tyr	Arg	Asn
15	100						105						110			
	Lys	Asp	Asn	Glu	Asn	Tyr	Pro	Asn	Val	Lys	Lys	Ala	Leu	Ile	Asn	Ile
	115						120						125			
20	Leu	Leu	Val	Thr	Thr	Gly	Tyr	Ile	Ile	Cys	Phe	Val	Pro	Tyr	His	Ile
	130			135						140						
	Val	Arg	Ile	Pro	Tyr	Thr	Leu	Ser	Gln	Thr	Glu	Val	Ile	Thr	Asp	Cys
	145			150						155			160			
25	Ser	Thr	Arg	Ile	Ser	Leu	Phe	Lys	Ala	Lys	Glu	Ala	Thr	Leu	Leu	Leu
				165						170			175			
	Ala	Val	Ser	Asn	Leu	Cys	Phe	Asp	Pro	Ile	Leu	Tyr	Tyr	His	Leu	Ser
30	180						185						190			
	Lys	Ala	Phe	Arg	Ser	Lys	Val	Thr	Glu	Thr	Phe	Ala	Ser	Pro	Lys	Glu
	195						200						205			
35	Thr	Lys	Val	Arg	Lys	Lys	Asn	Xaa								
	210			215												

40 (2) INFORMATION FOR SEQ ID NO: 71:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 407 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

	Met	His	Pro	Ala	Val	Phe	Leu	Ser	Leu	Pro	Asp	Leu	Arg	Cys	Ser	Leu	
	1				5					10					15		
50	Leu	Leu	Leu	Val	Thr	Trp	Val	Phe	Thr	Pro	Val	Thr	Thr	Glu	Ile	Thr	
				20					25					30			
	Ser	Leu	Asp	Thr	Glu	Asn	Ile	Asp	Glu	Ile	Leu	Asn	Asn	Ala	Asp	Val	
			35					40					45				
55	Ala	Leu	Val	Asn	Phe	Tyr	Ala	Asp	Trp	Cys	Arg	Phe	Ser	Gln	Met	Leu	
		50					55					60					
60	His	Pro	Ile	Phe	Glu	Glu	Ala	Ser	Asp	Val	Ile	Lys	Glu	Glu	Phe	Pro	
	65				70						75				80		

	Asn	Glu	Asn	Gln	Val	Val	Phe	Ala	Arg	Val	Asp	Cys	Asp	Gln	His	Ser		
	85																90	95
5	Asp	Ile	Ala	Gln	Arg	Tyr	Arg	Ile	Ser	Lys	Tyr	Pro	Thr	Leu	Lys	Leu		
	100						105				110							
10	Phe	Arg	Asn	Gly	Met	Met	Met	Lys	Arg	Glu	Tyr	Arg	Gly	Gln	Arg	Ser		
	115						120				125							
15	Val	Lys	Ala	Leu	Ala	Asp	Tyr	Ile	Arg	Gln	Gln	Lys	Ser	Asp	Pro	Ile		
	130						135				140							
20	Gln	Glu	Ile	Arg	Asp	Leu	Ala	Glu	Ile	Thr	Thr	Leu	Asp	Arg	Ser	Lys		
	145						150				155							
25	Arg	Asn	Ile	Ile	Gly	Tyr	Phe	Glu	Gln	Lys	Asp	Ser	Asp	Asn	Tyr	Arg		
	165						170				175							
30	Val	Phe	Glu	Arg	Val	Ala	Asn	Ile	Leu	His	Asp	Asp	Cys	Ala	Phe	Leu		
	180						185				190							
35	Ser	Ala	Phe	Gly	Asp	Val	Ser	Lys	Pro	Glu	Arg	Tyr	Ser	Gly	Asp	Asn		
	195						200				205							
40	Ile	Ile	Tyr	Lys	Pro	Pro	Gly	His	Ser	Ala	Pro	Asp	Met	Val	Tyr	Leu		
	210						215				220							
45	Gly	Ala	Met	Thr	Asn	Phe	Asp	Val	Thr	Tyr	Asn	Trp	Ile	Gln	Asp	Lys		
	225						230				235							
50	Cys	Val	Pro	Leu	Val	Arg	Glu	Ile	Thr	Phe	Glu	Asn	Gly	Glu	Glu	Leu		
	245						250				255							
55	Thr	Glu	Glu	Gly	Leu	Pro	Phe	Leu	Ile	Leu	Phe	His	Met	Lys	Glu	Asp		
	260						265				270							
60	Thr	Glu	Ser	Leu	Glu	Ile	Phe	Gln	Asn	Glu	Val	Ala	Arg	Gln	Leu	Ile		
	275						280				285							
65	Ser	Glu	Lys	Gly	Thr	Ile	Asn	Phe	Leu	His	Ala	Asp	Cys	Asp	Lys	Phe		
	290						295				300							
70	Arg	His	Pro	Leu	Leu	His	Ile	Gln	Lys	Thr	Pro	Ala	Asp	Cys	Pro	Val		
	305						310				315							
75	Ile	Ala	Ile	Asp	Ser	Phe	Arg	His	Met	Tyr	Val	Phe	Gly	Asp	Phe	Lys		
	325						330				335							
80	Asp	Val	Leu	Ile	Pro	Gly	Lys	Leu	Lys	Gln	Phe	Val	Phe	Asp	Leu	His		
	340						345				350							
85	Ser	Gly	Lys	Leu	His	Arg	Glu	Phe	His	His	Gly	Pro	Asp	Pro	Thr	Asp		
	355						360				365							
90	Thr	Ala	Pro	Gly	Glu	Gln	Ala	Gln	Asp	Val	Ala	Ser	Ser	Pro	Pro	Glu		
	370						375				380							
95	Ser	Ser	Phe	Gln	Lys	Leu	Ala	Pro	Ser	Glu	Tyr	Arg	Tyr	Thr	Leu	Leu		
	385						390				395							
100																	400	

Arg Asp Arg Asp Glu Leu Xaa
405

5

(2) INFORMATION FOR SEQ ID NO: 72:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

15 Tyr Leu Ile Ser Tyr Leu Cys Phe Xaa
1 5

20 (2) INFORMATION FOR SEQ ID NO: 73:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 34 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

Met Pro Leu Lys Ala Val Thr Trp Pro Thr Leu Asn Ser Lys Leu Val
1 5 10 15

30 Ala Ala Val Val Asn Leu Lys Ala Ser Gln Met Pro Ala Ser Ser Arg
20 25 30

35 Val Xaa

40 (2) INFORMATION FOR SEQ ID NO: 74:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 57 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

Gln Ser Pro Arg Ser Ser Ala Leu Gly Ala Gly Gln Lys Leu Ala Val
1 5 10 15

50 Cys Ser Pro Asp Ile Leu Cys Cys Pro Thr Asp Thr Leu Leu Ala Ser
20 25 30

His Pro His Ser Leu Leu Thr Gly Thr Gln Phe Ser Gly Gln Thr Gln
35 40 45

55

Ala Leu Ala Pro Ser Trp Cys Ala Xaa
50 55

60

(2) INFORMATION FOR SEQ ID NO: 75:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:

Met Ala Gly Ile His Arg Ala Phe Leu Val Phe Cys Leu Trp Gly Leu
 1 5 10 15
 Xaa Leu Cys Val Val Gly Gly Pro Trp Xaa
 20 25

15

(2) INFORMATION FOR SEQ ID NO: 76:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:

Met Ser Phe Ser Ser Pro Lys Ser Leu Leu Ser Leu Ile Ser Xaa
 1 5 10 15

30

(2) INFORMATION FOR SEQ ID NO: 77:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77:

Met Thr Ile Trp Gln Leu Phe Ala Val Leu Ile Val Leu Phe Ala Lys
 1 5 10 15
 Ser Arg Glu Ile Ser Thr Glu Gly Glu Pro Cys Val Leu Ser Lys Asn
 20 25 30

45

Xaa

(2) INFORMATION FOR SEQ ID NO: 78:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:

Met Leu Asn Pro Phe Xaa Gln Leu Leu Leu Val Leu Leu Phe Pro Glu
 1 5 10 15

60

Trp Pro Thr Pro Leu His Xaa

20

5 (2) INFORMATION FOR SEQ ID NO: 79:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 173 amino acids

(B) TYPE: amino acid

10 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:

Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
 1 5 10 15

Ser Xaa Thr Leu Xaa Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys
 20 25 30

Ala Met Val Val Asp Lys Thr Phe Arg Arg Gln Glu Ala Gln Lys Val
 35 40 45

Ser Pro Val Lys Val Thr Ala Leu Gly Gly Gly Lys Leu Glu Ala Thr
 50 55 60

Phe Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Xaa
 65 70 75 80

Arg Lys Thr Glu Glu Pro Gly Lys Tyr Ser Ala Cys Glu Pro Leu Pro
 85 90 95

His Ser His Pro His Xaa Pro Pro Pro Pro Thr Pro Val His Gln Pro
 100 105 110

Pro Gln Val Glu Ser Ala Gln Ala Ala Leu Leu Pro Gly Pro Gln Leu
 115 120 125

Cys Pro Pro Pro Arg Arg Gly Trp Pro Leu Leu Pro Gly Gly Leu Val
 130 135 140

Ala Leu Thr Ser Asp Thr Gly Cys Asp Arg Leu Val Arg Ser Arg Asp
 145 150 155 160

Gly Pro Asp His Ala Cys Pro Leu Gly Gly Pro Ser His
 165 170

45

(2) INFORMATION FOR SEQ ID NO: 80:

50 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 208 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80:

Met Ala Asp Ser Ser Tyr Thr Ser Glu Val Gln Ala Ile Leu Ala Phe
 1 5 10 15

Leu Ser Leu Gln Arg Thr Gly Ser Gly Gly Pro Gly Asn His Pro His
 20 25 30

60

163

Gly Pro Asp Ala Ser Ala Glu Gly Leu Asn Pro Tyr Gly Leu Val Ala
 35 40 45
 5 Pro Arg Phe Gln Arg Lys Phe Lys Ala Lys Gln Leu Thr Pro Arg Ile
 50 55 60
 Leu Glu Ala His Gln Asn Val Ala Gln Leu Ser Leu Ala Glu Ala Gln
 65 70 75 80
 10 Leu Arg Phe Ile Gln Ala Trp Gln Ser Leu Pro Asp Phe Gly Ile Ser
 85 90 95
 Tyr Val Met Val Arg Phe Lys Gly Ser Arg Lys Asp Glu Ile Leu Gly
 100 105 110
 Ile Ala Asn Asn Arg Leu Ile Arg Ile Asp Leu Ala Val Gly Asp Val
 115 120 125
 20 Val Lys Thr Trp Arg Phe Ser Asn Met Arg Gln Trp Asn Val Asn Trp
 130 135 140
 Asp Ile Arg Xaa Val Ala Ile Glu Phe Asp Glu His Ile Asn Val Ala
 145 150 155 160
 25 Phe Ser Cys Val Ser Ala Ser Cys Arg Ile Val His Glu Tyr Ile Gly
 165 170 175
 Gly Tyr Ile Phe Leu Ser Thr Arg Glu Xaa Ala Arg Gly Glu Glu Leu
 180 185 190
 Asp Glu Asp Leu Phe Leu Gln Leu Thr Gly Gly His Glu Ala Phe Xaa
 195 200 205
 35

40 (2) INFORMATION FOR SEQ ID NO: 81:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:

Met Ile Phe Leu Leu Phe Leu Thr Pro Leu Trp Leu Gln Lys Gly Ser
 1 5 10 15
 50 Ala Gly Lys Met Ser Gly Glu Phe Leu Tyr Ala Ser Leu Phe Gln Trp
 20 25 30
 Asn Tyr Phe Trp Arg Asn Lys Lys Val Cys Xaa
 35 40
 55

60 (2) INFORMATION FOR SEQ ID NO: 82:

164

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 146 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:

Met Pro Ser Gly Phe Gln Thr Cys Leu Leu Phe Thr Leu Ser Pro Phe
 1 5 10 15

10 Ser Leu Ser Lys Ile Val Gly Val Pro Ser Gln Gln Leu Pro Gly Gln
 20 25 30

Leu Ser Glu Gln Gly Gly Leu Cys Gly His Glu Gly Glu Pro Ala Arg
 35 40 45

15 Thr Val Pro Glu Thr Gln Leu Pro Leu Pro Phe Asn Ser Ala Gly Pro
 50 55 60

20 Pro His Leu Lys Cys Thr Gly Ala Gly Lys Arg Val Trp Ser Pro Pro
 65 70 75 80

Arg Arg Ala Ala Gln Glu Val Ser Leu Gln Leu Val Ser Cys Xaa Pro
 85 90 95

25 Cys Arg Gln Xaa Thr Ser Arg Ala Phe Ser Leu Ala Thr Asp Arg Thr
 100 105 110

Ala Ser Ala Arg Val Cys Cys Arg Phe Pro Phe Lys His Thr His Ser
 115 120 125

30 Pro His Pro Arg Arg Pro Glu Val Gln Gly Ala Trp Ala Val Val Pro
 130 135 140

35 Leu Xaa
 145

40 (2) INFORMATION FOR SEQ ID NO: 83:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83:

Met Pro Trp Arg Arg Ala Gly Leu Met Met Leu Pro Ile Ile Thr Gly
 1 5 10 15

50 Cys Cys Pro Cys Ser Ala Ser Ile Xaa
 20 25

55 (2) INFORMATION FOR SEQ ID NO: 84:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84:

Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Leu Pro Cys
 1 5 10 15

Pro Ser Pro Trp Xaa Arg Arg Ile Ser Gln Gly Pro Gly Thr Xaa
 20 25 30

(2) INFORMATION FOR SEQ ID NO: 85:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 374 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85:

Met Ser Val Pro Ala Phe Ile Asp Ile Ser Glu Glu Asp Gln Ala Ala
 1 5 10 15

Glu Leu Arg Ala Tyr Leu Lys Ser Lys Gly Ala Glu Ile Ser Glu Glu
 20 25 30

Asn Ser Glu Gly Gly Leu His Val Asp Leu Ala Gln Ile Ile Glu Ala
 35 40 45

Cys Asp Val Cys Leu Lys Glu Asp Asp Lys Asp Val Glu Ser Val Met
 50 55 60

Asn Ser Val Val Ser Leu Leu Ile Leu Glu Pro Asp Lys Gln Glu
 65 70 75 80

Ala Leu Ile Glu Ser Leu Cys Glu Lys Leu Val Lys Phe Arg Glu Gly
 85 90 95

Glu Arg Pro Ser Leu Arg Leu Gln Leu Leu Ser Asn Leu Phe His Gly
 100 105 110

Met Asp Lys Asn Thr Pro Val Arg Tyr Thr Val Tyr Cys Ser Leu Ile
 115 120 125

Lys Val Ala Ala Ser Cys Gly Ala Ile Gln Tyr Ile Pro Thr Glu Leu
 130 135 140

Asp Gln Val Arg Lys Trp Ile Ser Asp Trp Asn Leu Thr Thr Glu Lys
 145 150 155 160

Lys His Thr Leu Leu Arg Leu Leu Tyr Glu Ala Leu Val Asp Cys Lys
 165 170 175

Lys Ser Asp Ala Ala Ser Lys Val Met Val Glu Leu Leu Gly Ser Tyr
 180 185 190

Thr Glu Asp Asn Ala Ser Gln Ala Arg Val Asp Ala His Arg Cys Ile
 195 200 205

Val Arg Ala Leu Lys Asp Pro Asn Ala Phe Leu Phe Asp His Leu Leu
 210 215 220

166

Thr Leu Lys Pro Val Lys Phe Leu Glu Gly Glu Leu Ile His Asp Leu
 225 230 235 240
 5 Leu Thr Ile Phe Val Ser Ala Lys Leu Ala Ser Tyr Val Lys Phe Tyr
 245 250 255
 Gln Asn Asn Lys Asp Phe Ile Asp Ser Leu Gly Leu Leu His Glu Gln
 260 265 270
 10 Asn Met Ala Lys Met Arg Leu Leu Thr Phe Met Gly Met Ala Val Glu
 275 280 285
 Asn Lys Glu Ile Ser Phe Asp Thr Met Gln Gln Glu Leu Gln Ile Gly
 290 295 300
 15 Ala Asp Asp Val Glu Ala Phe Val Ile Asp Ala Val Arg Thr Lys Met
 305 310 315 320
 Val Tyr Cys Lys Ile Asp Gln Thr Gln Arg Lys Val Val Val Ser His
 325 330 335
 20 Ser Thr His Arg Thr Phe Gly Lys Gln Gln Trp Gln Gln Leu Tyr Asp
 340 345 350
 25 Thr Leu Asn Ala Trp Lys Gln Asn Leu Asn Lys Val Lys Asn Ser Leu
 355 360 365
 Leu Ser Leu Ser Asp Thr
 370
 30

(2) INFORMATION FOR SEQ ID NO: 86:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 13 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86:

Met Ser Val Pro Ala Phe Ile Asp Ile Ser Glu Glu Asp
 1 5 10

45

(2) INFORMATION FOR SEQ ID NO: 87:

50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87:

55 Gln Ala Ala Glu Leu Arg Ala Tyr Leu Lys Ser Lys Gly Ala Glu
 1 5 10 15

60 (2) INFORMATION FOR SEQ ID NO: 88:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88:
- Ile Ser Glu Glu Asn Ser Glu Gly Gly Leu His Val Asp Leu Ala Gln
 1 5 10 15
- 10 Ile
- 15 (2) INFORMATION FOR SEQ ID NO: 89:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89:
- Ile Glu Ala Cys Asp Val Cys Leu Lys Glu Asp Asp Lys Asp Val Glu
 1 5 10 15
- 25 Ser Val
- 30 (2) INFORMATION FOR SEQ ID NO: 90:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 16 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90:
- Val Ala Arg Pro Ser Ser Leu Phe Arg Ser Ala Trp Ser Cys Glu Trp
 1 5 10 15
- 40
- 45 (2) INFORMATION FOR SEQ ID NO: 91:
- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 12 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
- 50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91:
- 55 Leu Arg Leu Gln Leu Leu Ser Asn Leu Phe His Gly
 1 5 10
- 60 (2) INFORMATION FOR SEQ ID NO: 92:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92:

Lys Asp Val Glu Ser Val Met Asn Ser Val Val Ser Leu Leu Ile
 1 5 10 15
 Leu

(2) INFORMATION FOR SEQ ID NO: 93:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93:

Asp Ala Ala Ser Lys Val Met Val Glu Leu Leu Gly Ser Tyr Thr Glu
 1 5 10 15
 Asp Asn Ala Ser Gln Ala Arg Val Asp Ala
 20 25

(2) INFORMATION FOR SEQ ID NO: 94:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94:

Val Glu Ala Phe Val Ile Asp Ala Val Arg
 1 5 10

(2) INFORMATION FOR SEQ ID NO: 95:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95:

Met Ser Glu Ile Tyr Leu Arg Cys Gln Asp Glu Gln Gln Tyr Ala Arg
 1 5 10 15
 Trp Met Ala Gly Cys Arg Leu Ala Ser Lys Gly Arg Thr Met Ala Asp
 20 25 30

Ser Ser Tyr
 35

5 (2) INFORMATION FOR SEQ ID NO: 96:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96:

Leu Val Ala Pro Arg Phe Gln Arg Lys Phe Lys Ala Lys Gln Leu Thr
 1 5 10 15

15 Pro Arg Ile Leu Glu Ala His Gln Asn Val Ala Gln Leu Ser Leu Ala
 20 25 30

Glu Ala Gln Leu Arg Phe Ile Gln Ala Trp Gln Ser Leu
 35 40 45

(2) INFORMATION FOR SEQ ID NO: 97:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 97:

30 Val Gly Asp Val Val Lys Thr Trp Arg Phe Ser Asn Met Arg Gln Trp
 1 5 10 15

35 Asn Val Asn Trp Asp Ile Arg
 20

(2) INFORMATION FOR SEQ ID NO: 98:

40 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98:

Glu Glu Ile Asp Cys Thr Glu Glu Glu Met Met Val Phe Ala Ala Leu
 1 5 10 15

50 Gln Tyr His Ile Asn Lys Leu Ser Gln Ser
 20 25

55 (2) INFORMATION FOR SEQ ID NO: 99:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 amino acids

(B) TYPE: amino acid

60 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99:

Glu Glu Ile Asp Cys Thr Glu Glu Glu Met Met Val Phe Ala Ala Leu
1 5 10 15
Gln Tyr His Ile Asn Lys Leu Ser Gln Ser
20 25

(2) INFORMATION FOR SEQ ID NO: 100:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100:

Lys Glu Leu Ser Phe Ala Arg Ile Lys Ala Val Glu Cys Val Glu Ser
1 5 10 15
Thr Gly Arg His Ile Tyr Phe Thr Leu Val
20 25

(2) INFORMATION FOR SEQ ID NO: 101:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 101:

Gly Trp Asn Ala Gln Ile Thr Leu Gly Leu Val Lys Phe Lys Asn Gln
1 5 10 15
Gln

(2) INFORMATION FOR SEQ ID NO: 102:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102:

Leu Val Leu Gly Leu Ser Xaa Leu Asn Asn Ser Tyr Asn Phe Ser Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 103:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103:

His Val Val Ile Gly Ser Gln Ala Glu Glu Gly Gln Tyr Ser Leu Asn
1 5 10 15

10 Phe

15 (2) INFORMATION FOR SEQ ID NO: 104:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104:

His Asn Cys Asn Asn Ser Val Pro Gly Lys Glu His Pro Phe Asp Ile
1 5 10 15

25 Thr Val Met

30 (2) INFORMATION FOR SEQ ID NO: 105:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105:

Phe Ile Lys Tyr Val Leu Ser Asp Lys Glu Lys Lys Val Phe Gly Ile
1 5 10 15

40 Val

45 (2) INFORMATION FOR SEQ ID NO: 106:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106:

Ile Pro Met Gln Val Leu Ala Asn Val Ala Tyr Ile Ile
1 5 10

60 (2) INFORMATION FOR SEQ ID NO: 107:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107:
- Ile Pro Met Gln Val Leu Ala Asn Val Ala Tyr Ile Ile
1 5 10
- 10 (2) INFORMATION FOR SEQ ID NO: 108:
- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108:
- 20 Asp Gly Lys Val Ala Val Asn Leu Ala Lys Leu Lys Leu Phe Arg
1 5 10 15
- 25 (2) INFORMATION FOR SEQ ID NO: 109:
- 30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109:
- 35 Ile Arg Glu Lys Asn Pro Asp Gly Phe Leu Ser Ala Ala
1 5 10
- 40 (2) INFORMATION FOR SEQ ID NO: 110:
- 45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 110:
- Met Met Phe Gly Gly Tyr Glu Thr Ile
1 5
- 50 (2) INFORMATION FOR SEQ ID NO: 111:
- 55 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111:
- 60 Tyr Arg Asp Glu Ser Ser Ser Glu Leu Ser Val Asp Ser Glu Val Glu

173

1 5 10 15
 Phe Gln Leu Tyr Ser Gln Ile His
 20

5

(2) INFORMATION FOR SEQ ID NO: 112:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 136 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 112:

15

Tyr Ala Gln Asp Leu Asp Asp Val Ile Arg Glu Glu Glu His Glu Glu
 1 5 10 15

20

Lys Asn Ser Gly Asn Ser Glu Ser Ser Ser Ser Lys Pro Asn Gln Lys
 20 25 30

Lys Leu Ile Val Leu Ser Asp Ser Glu Val Ile Gln Leu Ser Asp Gly
 35 40 45

25

Ser Glu Val Ile Thr Leu Ser Asp Glu Asp Ser Ile Tyr Arg Cys Lys
 50 55 60

30

Gly Lys Asn Val Arg Val Gln Ala Gln Glu Asn Ala His Gly Leu Ser
 65 70 75 80

Ser Ser Leu Gln Ser Asn Glu Leu Val Asp Lys Lys Cys Lys Ser Asp
 85 90 95

35

Ile Glu Lys Pro Lys Ser Glu Glu Arg Ser Gly Val Ile Arg Glu Val
 100 105 110

Met Ile Ile Glu Val Ser Ser Ser Glu Glu Glu Glu Ser Thr Ile Ser
 115 120 125

40

Glu Gly Asp Asn Val Glu Ser Trp
 130 135

45

(2) INFORMATION FOR SEQ ID NO: 113:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 113:

Met Leu Leu Gly Cys Glu Val Asp Asp Lys Asp Asp Asp Ile Leu Leu
 1 5 10 15

55

Asn Leu Val Gly Cys Glu Asn Ser Val Thr Glu Gly Glu Asp Gly Ile
 20 25 30

60

Asn Trp Ser Ile Ser
 35

5 (2) INFORMATION FOR SEQ ID NO: 114:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 114:

Asp Lys Asp Ile Glu Ala Gln Ile Ala Asn Asn Arg Thr Pro Gly Arg
1 5 10 15

15 Trp Thr

20 (2) INFORMATION FOR SEQ ID NO: 115:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 115:

Gln Arg Tyr Tyr Ser Ala Asn Lys Asn Ile Ile Cys Arg Asn Cys Asp
1 5 10 15

30 Lys Arg Gly His Leu Ser Lys Asn Cys Pro Leu Pro Arg Lys Val
20 25 30

35 (2) INFORMATION FOR SEQ ID NO: 116:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 179 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 116:

45 Arg Arg Cys Phe Leu Cys Ser Arg Arg Gly His Leu Leu Tyr Ser Cys
1 5 10 15

Pro Ala Pro Leu Cys Glu Tyr Cys Pro Val Pro Lys Met Leu Asp His
20 25 30

50 Ser Cys Leu Phe Arg His Ser Trp Asp Lys Gln Cys Asp Arg Cys His
35 40 45

Met Leu Gly His Tyr Thr Asp Ala Cys Thr Glu Ile Trp Arg Gln Tyr
50 55 60

55 His Leu Thr Thr Lys Pro Gly Pro Pro Lys Lys Pro Lys Thr Pro Ser
65 70 75 80

60 Arg Pro Ser Ala Leu Ala Tyr Cys Tyr His Cys Ala Gln Lys Gly His
85 90 95

175

Tyr Gly His Glu Cys Pro Glu Arg Glu Val Tyr Asp Pro Ser Pro Val
 100 105 110
 5 Ser Pro Phe Ile Cys Tyr Tyr Xaa Asp Lys Tyr Glu Ile Gln Glu Arg
 115 120 125
 Glu Lys Arg Leu Lys Gln Lys Ile Lys Val Xaa Lys Lys Asn Gly Val
 130 135 140
 10 Ile Pro Glu Pro Ser Lys Leu Pro Tyr Ile Lys Ala Ala Asn Glu Asn
 145 150 155 160
 15 Pro His His Asp Ile Arg Lys Gly Arg Ala Ser Trp Lys Ser Asn Arg
 165 170 175
 Trp Pro Gln

20

(2) INFORMATION FOR SEQ ID NO: 117:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 117:

30 Leu Ser Ile Ile Phe Leu Ala Phe Val Ser Ile Asp Arg Cys Leu Gln
 1 5 10 15
 Leu

35

(2) INFORMATION FOR SEQ ID NO: 118:

40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 67 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118:

Gly Ser Cys Phe Ala Thr Trp Ala Phe Ile Gln Lys Asn Thr Asn His
 1 5 10 15
 50 Arg Cys Val Ser Ile Tyr Leu Ile Asn Leu Leu Thr Ala Asp Phe Leu
 20 25 30
 Leu Thr Leu Ala Leu Pro Val Lys Ile Val Val Asp Leu Gly Val Ala
 35 40 45
 55 Pro Trp Lys Leu Lys Ile Phe His Cys Gln Val Thr Ala Cys Leu Ile
 50 55 60

Tyr Ile Asn
 65

60

(2) INFORMATION FOR SEQ ID NO: 119:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 60 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 119:

5 Ala Pro Leu Glu Thr Met Gln Asn Lys Pro Arg Ala Pro Gln Lys Arg
 1 5 10 15
 10 Ala Leu Pro Phe Pro Glu Leu Glu Leu Arg Asp Tyr Ala Ser Val Leu
 20 25 30
 15 Thr Arg Tyr Ser Leu Gly Leu Arg Asn Lys Glu Pro Ser Leu Gly His
 35 40 45
 Arg Trp Gly Thr Gln Lys Leu Gly Arg Ser Pro Cys
 50 55 60

(2) INFORMATION FOR SEQ ID NO: 120:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 166 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120:

30 Asn Arg Glu Arg Gly Gly Ala Gly Ala Thr Phe Glu Cys Asn Ile Cys
 1 5 10 15
 Leu Glu Thr Ala Arg Glu Ala Val Val Ser Val Cys Gly His Leu Tyr
 20 25 30
 35 Cys Trp Pro Cys Leu His Gln Trp Leu Glu Thr Arg Pro Glu Arg Gln
 35 40 45
 Glu Cys Pro Val Cys Lys Ala Gly Ile Ser Arg Glu Lys Val Val Pro
 50 55 60
 40 Leu Tyr Gly Arg Gly Ser Gln Lys Pro Gln Asp Pro Arg Leu Lys Thr
 65 70 75 80
 45 Pro Pro Arg Pro Gln Gly Gln Arg Pro Ala Pro Glu Ser Arg Gly Gly
 85 90 95
 Phe Gln Pro Phe Gly Asp Thr Gly Gly Phe His Phe Ser Phe Gly Val
 100 105 110
 50 Gly Ala Phe Pro Phe Gly Phe Phe Thr Thr Val Phe Asn Ala His Glu
 115 120 125
 Pro Phe Arg Arg Gly Thr Gly Val Asp Leu Gly Gln Gly His Pro Ala
 130 135 140
 55 Ser Ser Trp Gln Asp Ser Leu Phe Leu Phe Leu Ala Ile Phe Phe Phe
 145 150 155 160
 60 Phe Trp Leu Leu Ser Ile
 165

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>29</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <p style="text-align: center;">American Type Culture Collection</p>	
Address of depositary institution (including postal code and country) <p>10801 University Boulevard Manassas, Virginia 20110-2209 United States of America</p>	
Date of deposit <u>May 22, 1997</u>	Accession Number <u>209075</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
EUROPE In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4)EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit") 	

For receiving Office use only	For International Bureau use only
<input checked="checked" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <p style="text-align: center;">JERYL McDOWELL 703-305-3639</p>	Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>30</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <p style="text-align: center;">American Type Culture Collection</p>	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit May 8, 1997	Accession Number 209022
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
EUROPE In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4)EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications, e.g., "Accession Number of Deposit")	

<p style="text-align: center;">For receiving Office use only</p> <div style="border: 1px solid black; padding: 5px;"> <input checked="" type="checkbox"/> This sheet was received with the international application </div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> Authorized officer <p style="text-align: center;">JERYL McDOWELL 703-305-3639</p> </div>	<p style="text-align: center;">For International Bureau use only</p> <div style="border: 1px solid black; padding: 5px;"> <input type="checkbox"/> This sheet was received by the International Bureau on: </div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> Authorized officer </div>
---	--

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
 - (f) a polynucleotide which is a variant of SEQ ID NO:X;
 - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
 - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
 - (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

5

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

10

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

15

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

20

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

25

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

30

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

35

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

- (g) a variant of SEQ ID NO:Y;
- (h) an allelic variant of SEQ ID NO:Y; or
- (i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the
5 full length protein comprises sequential amino acid deletions from either the C-terminus
or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of
claim 11.
10

14. A recombinant host cell that expresses the isolated polypeptide of claim
11.

15. A method of making an isolated polypeptide comprising:
15 (a) culturing the recombinant host cell of claim 14 under conditions such that
said polypeptide is expressed; and
(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.
20

17. A method for preventing, treating, or ameliorating a medical condition,
comprising administering to a mammalian subject a therapeutically effective amount of
the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a
pathological condition in a subject comprising:
(a) determining the presence or absence of a mutation in the polynucleotide of
claim 1; and
(b) diagnosing a pathological condition or a susceptibility to a pathological
30 condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a
pathological condition in a subject comprising:
(a) determining the presence or amount of expression of the polypeptide of
35 claim 11 in a biological sample; and
(b) diagnosing a pathological condition or a susceptibility to a pathological
condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

- 5 (a) contacting the polypeptide of claim 11 with a binding partner; and
(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

10 22. A method of identifying an activity in a biological assay, wherein the method comprises:

- (a) expressing SEQ ID NO:X in a cell;
(b) isolating the supernatant;
(c) detecting an activity in a biological assay; and
15 (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 22.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/10868

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07K 1/00; C07H 21/04

US CL :530/350; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MPSRCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	Database Genbank on MPSRCH, University of Edinburgh, (Edinburgh, UK), No. N20562, HILLIER et al. 'yx39a08.s1 Homo sapiens cDNA clone 264086 3'.' 18 December 1995, compare to SEQ ID No. 11.	1 ----- 2-10, 14, 15, 21
X -- Y	WO 95/31544 A1 (H WEINWURZEL, H.) 23 November 1995, compare Figure 1b to SEQ ID No. 12.	1 --- 2-10, 14, 15, 21
X -- Y	Database Genbank on MPSRCH, University of Edinburgh, (Edinburgh, UK), No. N23080, HILLIER et al. 'yw43d02.s1 Homo sapiens cDNA clone 254979 3'.' 28 December 1995, compare to SEQ ID No. 13.	1 ----- 2-10, 14, 15, 21

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

02 OCTOBER 1998

Date of mailing of the international search report

28 OCT 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BRUCE CAMPELL

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/10868

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	Database Genbank on MPSRCH, University of Edinburgh, (Edinburgh, UK), No. G23170, HUDSON, T. 'human STS WI-16915', 31 May 1996, compare with SEQ ID No. 14.	1 ----- 2-10, 14, 15, 21
X -- Y	Database Genbank on MPSRCH, University of Edinburgh, (Edinburgh, UK), No. H18098, HILLIER et al. 'yn47d01.s1 Homo sapiens cDNA clone 171553 3'' 29 June 1995, compare with SEQ ID No. 15.	1 ----- 2-10, 14, 15, 21
X -- Y	Database Genbank on MPSRCH, University of Edinburgh, (Edinburgh, UK), No. N46256, HILLIER et al. 'yy72g09.s1 Homo sapiens cDNA clone 279136 3'' 14 February 1996, compare with SEQ ID No. 16.	1 ----- 2-10, 14, 15, 21
X -- Y	Database Genbank on MPSRCH, University of Edinburgh, (Edinburgh, UK), No. N28611, HILLIER et al. 'yx38f03.r1 Homo sapiens cDNA clone 264029 5'' 04 January 1996, compare with SEQ ID No. 17.	1 ----- 2-10, 14, 15, 21
X -- Y	Database Genbank on MPSRCH, University of Edinburgh, (Edinburgh, UK), No. R70283, HILLIER et al. 'yj81c08.r1 Homo sapiens cDNA clone 155150 5'' 01 June 1995, compare with SEQ ID No. 18.	1 --- 2-10, 14, 15, 21
X -- Y	Database Genbank on MPSRCH, University of Edinburgh, (Edinburgh, UK), No. T98012, HILLIER et al. 'ye56e07.s1 Homo sapiens cDNA clone 121764 3'' 29 March 1995, compare with SEQ ID No. 19.	1 ----- 2-10, 14, 15, 21
X -- Y	Database Genbank on MPSRCH, University of Edinburgh, (Edinburgh, UK), No. Z44692, GENEXPRESS. 'H. sapiens partial cDNA sequence; clone 27b07, mRNA sequence.' 21 September 1995, compare with SEQ ID No. 20.	1 ----- 2-10, 14, 15, 21
X -- Y	Database Genbank on MPSRCH, University of Edinburgh, (Edinburgh, UK), No. W83277, MARRA et al. 'mf25e5.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 406112 5', mRNA sequence.' 12 September 1996, compare with SEQ ID No. 43.	1 ----- 2-10, 14, 15, 21

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/10868

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I:

Claims 1-10, 14, 15, and 21 drawn to a polynucleotide(s), vector(s) containing the polynucleotide, host cells containing the vector(s) which are SEQ ID NO: X or a polynucleotide encoding the polypeptide Y or a cDNA in the material deposited with American Type Culture Collection with accession number Z wherein the cDNA in Z hybridizes to X. Additionally Group I contains the first method making the cells (claim 14) containing the vector(s) containing the polynucleotide(s) and the first method of use of the cells (claim 15) to make a product. There appear to be a total of 46 polynucleotide sequences of which the first ten (10) are selected for examination and therefore, there are nine (9) remaining additional groups of four (4) polynucleotide sequences.

Group II:

Claims 11, 12, 16, and 23 drawn to polypeptides and/or fragments thereof with the amino acid sequence defined by SEQ ID NO: Y as found in the material deposited with the American Type Culture Collection with accession number Z. There appear to be a total of 74 polypeptide sequences and therefore 73 additional species of proteins.

Group III:

Claim 13, drawn to an antibody and/or fragments thereof that bind to a polypeptide with the amino acid sequence defined by SEQ ID NO: Y as found in the material deposited with the American Type Culture Collection with accession number Z. There appear to be a total of 74 antibodies that correspond to the SEQ ID NOs: for the "Y" and "Z" sequences and therefore 73 additional species of proteins.

Group IV:

Claim 17, drawn to a process of preventing, treating, or ameliorating a medical condition by administering a polypeptide or a polynucleotide which a second/alternative process of use of the second product and of an alternative process of use of the first claimed product in Group I.

In Group IV, and where additional fees are paid, the claims are searched only insofar as they are applicable to the selected polypeptide and its corresponding SEQ ID NO: as the first species as directed to a process practiced using a polypeptide. The second species is the practice of the process using a polynucleotide. In each instance, the same selected polypeptide as for the first species of Group II and for the first 10 polynucleotide sequences for Group I would be examined. Applicant may elect to pay additional fees for each additional one of the 73 different polypeptide species beyond the first one (1) polypeptide and/or the first 10 polynucleotides as set forth in the above paragraphs directed to Group I and II.

Group V:

Claim 18, drawn to a method of diagnosis of a pathological condition and another alternative process of use of the first claimed product in Group I. Additionally Group V contains indications that there are a total of 46 polynucleotide sequences and therefore, nine(9) additional groups of four (4) polynucleotide sequences beyond the first ten (10) sequences.

Group VI:

Claim 19, drawn to a method of diagnosis of a pathological condition and another alternative process of use of the polypeptide. There appear to be a total of 74 polypeptide sequences and therefore 73 additional species of proteins.

Group VII:

Claim 20, drawn to a method of identification of a binding partner for a polypeptide. There appear to be a total of 74 polypeptide sequences and therefore 73 additional species of proteins.

Group VIII:

Claim 22, drawn to a method of identification of function of a protein is another alternative process of use of the product in Group I. Additionally Group V contains indications that there are a total of 46 polynucleotide sequences and therefore, nine(9) additional groups of four (4) polynucleotide sequences beyond the first ten (10) sequences.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/10868

The inventions listed as Groups I through VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons.

Claims of Group I are drawn to nucleotides, nucleotide constructs, and/or methods requiring the use of nucleotides or nucleotide constructs that contain more than ten individual, independent, and distinct nucleotide sequences in alternative form. Accordingly, these claims are subject to lack of unity as outlined in 1192 O.G. 68 (19 November 1996).

For Group I, the first ten (10) of the individual polynucleotide sequences designated as "X" by SEQ ID NO: as set forth in the application (see for example page 29+ and/or the SEQUENCE LISTING) are included for search. The corresponding SEQ ID NO: for "Y" and "Z" for each selected "X" should also be noted. The search of the no more than ten sequences may include the complements of the selected sequences and, where appropriate, may include subsequences within the selected sequences (e.g., oligomeric probes and/or primers).

In Group IV (as directed to the species which are polynucleotides) should applicant pay the additional fee for the second appearing species in Group IV which are polynucleotides, first ten (10) of the individual polynucleotide sequences designated as "X" by SEQ ID NO: as set forth in the application (see for example page 29+ and/or the SEQUENCE LISTING) are included for search of Group IV should the fees for Group IV be paid. This is also applied to Groups V and VIII. The corresponding SEQ ID NO: for "Y" and "Z" for each selected "X" should also be noted. The search of the no more than ten sequences may include the complements of the selected sequences and, where appropriate, may include subsequences within the selected sequences (e.g., oligomeric probes and/or primers).

Where Applicant may elect to pay additional fees for a search of sequences beyond the initial ten (10) polynucleotide sequences, and in accordance with 1192 O.G. 68 (19 November 1996), applicant may select additional groups of polynucleotides consisting of four (4) sequences beyond the initial ten (10) sequences for Group I which would then be searched with Group I upon payment of the requisite fees for the requisite Groups beyond Group I.

As to the polypeptides of Groups II, III, IV (as directed to a species which is a polypeptide), VI, and VII each is a distinct and different protein. Should additional fees for the above indicated Groups be paid, the first amino acid sequence identified from the SEQUENCE LISTING by applicant would be searched with the additional group for which the additional search fees were paid.

Applicant may select additional proteins and or antibodies to be searched by specifying the appropriate SEQ ID NOs and payment of the requisite additional fees for each single additional particular species that are selected beyond the one (1) protein identified by SEQ ID NO:.

The SEQ ID NOs in Group I define, absent evidence to the contrary, structurally distinct and different proteins. Note the present application written description (page 5+) refers to the protein encoded by gene 1 as likely to be involved in promotion of a variety of cancers whereas gene 2 (pages 6-7) is directed to apparently a variety but not correlated immune system disorder(s) whereas gene 3 (pages 7-8) is asserted at page 7 to be a mediator of ligand dependent AF-2. Each of which and absent factual evidence to the contrary, are directed to genes encoding distinct and different proteins and are therefore distinct and different genes and appear to map to different chromosomes.

As to the protein of Group II and the antibody of Group III, each is distinct and different for the reasons indicated in the preceding paragraph and because the proteins have distinct and different chemical, physical, and biological properties from that of DNA/polynucleotides/vectors and cells containing same.

Groups IV through VIII are directed to alternative processes of use of the Group I and II compositions where Group I contains in claims 14 and 15, the first claimed method of making the polynucleotide and the first claimed process of use of the cells containing the vector which contains the polynucleotides.